AU3974001A - Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme - Google Patents

Description

WO 01/57206 PCT/USO1/03504 1 DESCRIPTION METHOD AND REAGENT FOR THE INHIBITION OF CHECKPOINT KINASE-1 (CHK1) ENZYME Background Of The Invention The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of conditions and diseases related to the expression of kinases which phosphorylate Cdc25 S216, such as Chk1 (checkpoint kinase 1) enzyme. The following is a brief description of the current understanding of Chkl. The discussion is not meant to be complete and is provided only for understanding the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention. Mammalian cells treated with agents that inhibit DNA replication or cause DNA damage undergo cell cycle arrest due to the presence of multiple checkpoint response mechanisms. Cancer cells frequently lack the p53-induced G1 DNA damage checkpoint response and instead arrest in G2 due to a checkpoint pathway directed towards preventing Cdc2 kinase activation. Inhibition of Cdc2 kinase activity is mediated by Weel-like kinases, which phosphorylate key residues within the ATP-binding pocket of Cdc2 (accession No. X05360). Maintenance of this arrest also involves repressing Cdc25 function, the phosphatase that removes the Cdc2 inhibitory phosphorylations, by a mechanism involving the binding of 14-3-3 proteins to a phosphorylated seine residue (S216) in Cdc25. Multiple kinases, including Chkl (accession No. AF016582), Chk2 (Cdsl) (accession No. NM_007194), and C-TAK1 (accession No. AL050393), can phosphorylate Cdc25 S216 (accession No. M34065) in-vitro. These kinases may function in the DNA replication and/or DNA damage checkpoint response in vivo. Hoekstra et al., International PCT publication No. WO/9955844, describe, in general terms, a method for promoting differentiation of a differentiation-inhibited cell by introducing into a cell a first polynucleotide encoding an antisense polynucleotide that hybridizes to a second polynucleotide encoding a cell cycle checkpoint protein.

WO 01/57206 PCT/USO1/03504 2 Summary Of The Invention The invention features novel nucleic acid-based techniques [e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups] and methods for their use to modulate the expression of kinases which phosphorylate Cdc25 S216, such as Chk1 (checkpoint kinase 1) enzyme, Chk2 (Cdsl) and C-TAK1. The description below of the various aspects and embodiments is provided with reference to the exemplary gene Chkl. However, the various aspects and embodiments are also directed to each of the other genes which phosphorylate Cdc25S216. Those additional genes can be analyzed for target sites as described for Chkl. Further, the nucleic acid-based techniques, molecules, and compositions targeted to those genes can be performed as for Chkl. Thus, the inhibition and the effects of such inhibition of the other genes can be performed as described herein. In a preferred embodiment, the invention features the use of one or more of the nucleic acid-based techniques independently or in combination to inhibit the expression of the genes encoding Chkl. Specifically, the invention features the use of nucleic acid-based techniques to specifically inhibit the expression of Chk1 gene. In another preferred embodiment, the invention features the use of an enzymatic nucleic acid molecule, preferably in the hammerhead, NCH, G-cleaver, amberzyme, zinzyme and/or DNAzyme motif, to inhibit the expression of Chk1 gene. By "inhibit" it is meant that the activity of Chk1 or level of RNAs or equivalent RNAs encoding one or more protein subunits of Chkl is reduced below that observed in the absence of the nucleic acid molecules of the invention. In one embodiment, inhibition with enzymatic nucleic acid molecule preferably is below that level observed in the presence of an enzymatically inactive or attenuated molecule that is able to bind to the same site on the target RNA, but is unable to cleave that RNA. In another embodiment, inhibition with antisense oligonucleotides is preferably below that level observed in the presence of, for example, an oligonucleotide with scrambled sequence or with mismatches. In another embodiment, inhibition of Chkl genes with the nucleic acid molecule of the instant invention is greater than in the presence of the nucleic acid molecule than in its absence. By "enzymatic nucleic acid molecule" it is meant a nucleic acid molecule which has complementarity in a substrate-binding region to a specified gene target, and also has an enzymatic activity which is active to specifically cleave target RNA. That is, the enzymatic WO 01/57206 PCT/USO1/03504 3 nucleic acid molecule is able to intermolecularly cleave RNA and thereby inactivate a target RNA molecule. These complementary regions allow sufficient hybridization of the enzymatic nucleic acid molecule to the target RNA and thus permit cleavage. One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention (see for example Werner and Uhlenbeck, 1995, Nucleic Acids Research, 23, 2092 2096; Hammann et al., 1999, Antisense and Nucleic Acid Drug Dev., 9, 25-31). The nucleic acids may be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, aptazyme or aptamer-binding ribozyme, regulatable ribozyme, catalytic oligonucleotides, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity. The specific enzymatic nucleic acid molecules described in the instant application are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving and/or ligation activity to the molecule (Cech et al., U.S. Patent No. 4,987,071; Cech et al., 1988, 260 JAMA 3030). By "nucleic acid molecule" as used herein is meant a molecule having nucleotides. The nucleic acid can be single, double, or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof. By "enzymatic portion" or "catalytic domain" is meant that portion/region of the enzymatic nucleic acid molecule essential for cleavage of a nucleic acid substrate (for example, see Figures 1-5). By "substrate binding arm" or "substrate binding domain" is meant that portion/region of a enzymatic nucleic acid which is able to interact, for example via complementarity (i.e., able to base-pair with), with a portion of its substrate. Preferably, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 can be base-paired (see for example Werner and Uhlenbeck, 1995, Nucleic Acids Research, 23, 2092-2096; Hammann et al., 1999, Antisense and Nucleic Acid Drug Dev., 9, 25-31). Examples of such arms are shown generally in Figures 1-5. That is, these arms contain sequences within a enzymatic nucleic acid which are intended to bring enzymatic nucleic acid and target RNA together through complementary base-pairing interactions. The enzymatic nucleic acid of the invention may have binding arms that are contiguous or non-contiguous and may be of varying lengths. The length of the binding arm(s) are preferably greater than or equal to four nucleotides and of sufficient WO 01/57206 PCT/USO1/03504 4 length to stably interact with the target RNA; preferably 12-100 nucleotides; more preferably 14 24 nucleotides long (see for example Werner and Uhlenbeck, supra; Hamman et al., supra; Hampel et al., EP0360257; Berzal-Herrance et al, 1993, EMBO J., 12, 2567-73). If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (i.e., each of the binding arms is of the same length; e.g., five and five nucleotides, or six and six nucleotides, or seven and seven nucleotides long) or asymmetrical (i.e., the binding arms are of different length; e.g., six and three nucleotides; three and six. nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like). By "Inozyme" or "NCH" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described as NCH Rz in Figure 2. Inozymes possess endonuclease activity to cleave RNA substrates having a cleavage triplet NCH/, where N is a nucleotide, C is cytidine and H is adenosine, uridine or cytidine, and / represents the cleavage site. H is used interchangeably with X. Inozymes can also possess endonuclease activity to cleave RNA substrates having a cleavage triplet NCN/, where N is a nucleotide, C is cytidine, and / represents the cleavage site. "I" in Figure 2 represents an Inosine nucleotide, preferably a ribo-Inosine or xylo-Inosine nucleoside. By "G-cleaver" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described as G-cleaver in Figure 2. G-cleavers possess endonuclease activity to cleave RNA substrates having a cleavage triplet NYN/, where N is a nucleotide, Y is uridine or cytidine and / represents the cleavage site. G-cleavers may be chemically modified as is generally shown in Figure 2. By "amberzyme" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described in Figure 3. Amberzymes possess endonuclease activity to cleave RNA substrates having a cleavage triplet NGIN, where N is a nucleotide, G is guanosine, and / represents the cleavage site. Amberzymes may be chemically modified to increase nuclease stability through substitutions as are generally shown in Figure 3. In addition, differing nucleoside and/or non-nucleoside linkers can be used to substitute the 5'-gaaa-3' loops shown in the figure. Amberzymes represent a non-limiting example of an enzymatic nucleic acid molecule that does not require a ribonucleotide (2'-OH) group within its own nucleic acid sequence for activity. By "zinzyme" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described in Figure 4. Zinzymes possess endonuclease activity to cleave RNA substrates having a cleavage triplet including but not limited to YG/Y, where Y is uridine or cytidine, and G is guanosine and / represents the cleavage site. Zinzymes may be chemically WO 01/57206 PCT/USO1/03504 5 modified to increase nuclease stability through substitutions as are generally shown in Figure 4, including substituting 2'-O-methyl guanosine nucleotides for guanosine nucleotides. In addition, differing nucleotide and/or non-nucleotide linkers can be used to substitute the 5'-gaaa-2' loop shown in the figure. Zinzymes represent a non-limiting example of an enzymatic nucleic acid molecule that does not require a ribonucleotide (2'-OH) group within its own nucleic acid sequence for activity. By 'DNAzyme' is meant, an enzymatic nucleic acid molecule that does not require the presence of a 2'-OH group for its activity. In particular embodiments the enzymatic nucleic acid molecule may have an attached linker(s) or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups. DNAzymes can be synthesized chemically or expressed endogenously in vivo, by means of a single stranded DNA vector or equivalent thereof. An example of a DNAzyme is shown in Figure 5 and is generally reviewed in Usman et al., International PCT Publication No. WO 95/11304; Chartrand et al., 1995, NAR 23, 4092; Breaker et al., 1995, Chem. Bio. 2, 655; Santoro et al., 1997, PNAS 94, 4262; Breaker, 1999, Nature Biotechnology, 17, 422-423; and Santoro et. al., 2000, J. Am. Chem. Soc., 122, 2433-39. Additional DNAzyme motifs can be selected for using techniques similar to those described in these references, and hence, are within the scope of the present invention. By "sufficient length" is meant an oligonucleotide of greater than or equal to 3 nucleotides that is of a length great enough to provide the intended function under the expected condition. For example, for binding anns of enzymatic nucleic acid "sufficient length" means that the binding arm sequence is long enough to provide stable binding to a target site under the expected binding conditions. Preferably, the binding arms are not so long as to prevent useful turnover. By "stably interact" is meant interaction of the oligonucleotides with target nucleic acid (e.g., by forming hydrogen bonds with complementary nucleotides in the target under physiological conditions) that is sufficient to the intended purpose (e.g., cleavage of target RNA by an enzyme). By "equivalent" RNA to Chkl is meant to include those naturally occurring RNA molecules having homology (partial or complete) to Chk1 proteins or encoding for proteins with similar function as Chk1 in various organisms, including human, rodent, primate, rabbit, pig, protozoans, fungi, plants, and other microorganisms and parasites. The equivalent RNA sequence also includes in addition to the coding region, regions such as 5'-untranslated region, 3'--untranslated region, introns, intron-exon junction and the like. By "homology" is meant the nucleotide sequence of two or more nucleic acid molecules is partially or completely identical.

WO 01/57206 PCT/USO1/03504 6 By "antisense nucleic acid", it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993 Nature 365, 566) interactions and alters the activity of the target RNA (for a review, see Stein and Cheng, 1993 Science 261, 1004 and Woolf et al., US patent No. 5,849,902). Typically, antisense molecules are complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule may bind such that the antisense molecule forms a loop. Thus, the antisense molecule may be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both. For a review of current antisense strategies, see Schmajuk et al., 1999, J. Biol. Chem., 274, 21783-21789, Delihas et al., 1997, Nature, 15, 751 753, Stein et al., 1997, Antisense N. A. Drug Dev., 7, 151, Crooke, 2000, Methods Enzymol., 313, 3-45; Crooke, 1998, Biotech. Genet. Eng. Rev., 15, 121-157, Crooke, 1997, Ad. Pharmacol., 40, 1-49. In addition, antisense DNA can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. The antisense oligonucleotides can comprise one or more RNAse H activating region, which is capable of activating RNAse H cleavage of a target RNA. Antisense DNA can be synthesized chemically or expressed via the use of a single stranded DNA expression vector or equivalent thereof. By "RNase H activating region" is meant a region (generally greater than or equal to 4-25 nucleotides in length, preferably from 5-11 nucleotides in length) of a nucleic acid molecule capable of binding to a target RNA to form a non-covalent complex that is recognized by cellular RNase H enzyme (see for example Arrow et al., US 5,849,902; Arrow et al., US 5,989,912). The RNase H enzyme binds to the nucleic acid molecule-target RNA complex and cleaves the target RNA sequence. The RNase H activating region comprises, for example, phosphodiester, phosphorothioate (preferably at least four of the nucleotides are phosphorothiote substitutions; more specifically, 4-11 of the nucleotides are phosphorothiote substitutions); phosphorodithioate, 5'-thiophosphate, or methylphosphonate backbone chemistry or a combination thereof. In addition to one or more backbone chemistries described above, the RNase H activating region can also comprise a variety of sugar chemistries. For example, the RNase H activating region can comprise deoxyribose, arabino, fluoroarabino or a combination thereof, nucleotide sugar chemistry. Those skilled in the art will recognize that the foregoing are non-limiting examples and that any combination of phosphate, sugar and base chemistry of a nucleic acid that supports the activity of RNase H enzyme is within the scope of the definition of the RNase H activating region and the instant invention.

WO 01/57206 PCT/USO1/03504 7 By "2-5A antisense chimera" is meant an antisense oligonucleotide containing a 5' phosphorylated 2'-5'-linked adenylate residue. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence et aL, 1993 Proc. Nat!. Acad. Sci. USA 90, 1300; Silverman et al., 2000, Methods Enzymol., 313, 522-533; Player and Torrence, 1998, Pharmacol. Other , 78, 55-113). By "triplex forming oligonucleotides" is meant an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval Valentin et al., 1992 Proc. Nat!. Acad. Sci. USA 89, 504; Fox, 2000, Curr. Med. Chem., 7, 17-37; Praseuth et. al., 2000, Biochim. Biophys. Acta, 1489, 181-206). By "gene" it is meant a nucleic acid that encodes an RNA, for example, nucleic acid sequences including but not limited to structural genes encoding a polypeptide. "Complementarity" refers to the ability of a nucleic acid to form hydrogen bond(s) with another RNA sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its target or complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., enzymatic nucleic acid cleavage, antisense or triple helix inhibition. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol. LII pp.123-133; Frier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377; Turner et al., 1987, J. Am. Chem. Soc. 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. By "RNA" is meant a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" or "2'-OH" is meant a nucleotide with a hydroxyl group at the 2' position of a p-D-ribo-furanose moiety. By "decoy RNA" is meant a RNA molecule that mimics the natural binding domain for a ligand. The decoy RNA therefore competes with natural binding target for the binding of a specific ligand. For example, it has been shown that over-expression of HIV trans-activation WO 01/57206 PCT/USO1/03504 8 response (TAR) RNA can act as a "decoy" and efficiently binds HIV tat protein, thereby preventing it from binding to TAR sequences encoded in the HIV RNA (Sullenger et al., 1990, Cell, 63, 601-608). This is but a specific example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art. Several varieties of naturally occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. Table I summarizes some of the characteristics of these ribozymes. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor of gene expression, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. The enzymatic nucleic acid molecule that cleave the specified sites in Chkl-specific RNAs represent a novel therapeutic approach to treat a variety of pathologic indications, including cancer. In one of the preferred embodiments of the inventions described herein, the enzymatic nucleic acid molecule is formed in a hammerhead or hairpin motif, but may also be formed in the motif of a hepatitis delta virus, group I intron, group II intron or RNase P RNA (in association with an RNA guide sequence), Neurospora VS RNA, DNAzymes, NCH cleaving motifs, or G cleavers. Examples of such hammerhead motifs are described by Dreyfus, supra, Rossi et al., 1992, AIDS Research and Human Retroviruses 8, 183. Examples of hairpin motifs are described by Hampel et al., EP0360257, Hampel and Tritz, 1989 Biochemistry 28, 4929, Feldstein et al., 1989, Gene 82, 53, Haseloff and Gerlach, 1989, Gene, 82, 43, Hampel et al., 1990 Nucleic Acids Res. 18, 299; and Chowrira & McSwiggen, US. Patent No. 5,631,359. The hepatitis delta virus motif is described by Perrotta and Been, 1992 Biochemistry 31, 16. The RNase P motif is described by Guerrier-Takada et al., 1983 Cell 35, 849; Forster and Altman, 1990, Science 249, 783; and Li and Altman, 1996, Nucleic Acids Res. 24, 835. The Neurospora VS RNA ribozyme WO 01/57206 PCT/USO1/03504 9 motif is described by Collins (Saville and Collins, 1990 Cell 61, 685-696; Saville and Collins, 1991 Proc. Natl. Acad. Sci. USA 88, 8826-8830; Collins and Olive, 1993 Biochemistry 32, 2795 2799; and Guo and Collins, 1995, EMBO. J. 14, 363). Group II introns are described by Griffin et al., 1995, Chem. Biol. 2, 761; Michels and Pyle, 1995, Biochemistry 34, 2965; and Pyle et al., International PCT Publication No. WO 96/22689. The Group I intron is described by Cech et al., U.S. Patent 4,987,071. DNAzymes are described by Usman et al., International PCT Publication No. WO 95/11304; Chartrand et al., 1995, NAR 23, 4092; Breaker et al., 1995, Chem. Bio. 2, 655; and Santoro et al., 1997, PNAS 94, 4262. NCH cleaving motifs are described in Ludwig & Sproat, International PCT Publication No. WO 98/58058; and G-cleavers are described in Kore et al., 1998, Nucleic Acids Research 26, 4116-4120 and Eckstein et al., International PCT Publication No. WO 99/16871. Additional motifs include the Aptazyme (Breaker et al., WO 98/43993), Amberzyme (Class I motif; Figure 3; Beigelman et al., International PCT publication No. WO 99/55857) and Zinzyme (Beigelman et al., International PCT publication No. WO 99/55857), all these references are incorporated by reference herein in their totalities, including drawings and can also be used in the present invention. These specific motifs are not limiting in the invention. and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule (Cech et al., U.S. Patent No. 4,987,071). In preferred embodiments of the present invention, a nucleic acid molecule of the instant invention can be between 13 and 100 nucleotides in length. Exemplary enzymatic nucleic acid molecules of the invention are shown in Tables III-XIII. For example, enzymatic nucleic acid molecules of the invention are preferably between 15 and 50 nucleotides in length, more preferably between 25 and 40 nucleotides in length, e.g., 34, 36, or 38 nucleotides in length (for example see Jarvis et al., 1996, J. Biol. Chem., 271, 29107-29112). Exemplary DNAzymes of the invention are preferably between 15 and 40 nucleotides in length, more preferably between 25 and 35 nucleotides in length, e.g., 29, 30, 31, or 32 nucleotides in length (see for example Santoro et al., 1998, Biochemistry, 37, 13330-13342; Chartrand et al., 1995, Nucleic Acids Research, 23, 4092-4096). Exemplary antisense molecules of the invention are preferably between 15 and 75 nucleotides in length, more preferably between 20 and 35 nucleotides in 'length, e.g., 25, 26, 27, or 28 nucleotides in length (see for example Woolf et al., 1992, PNAS., 89, 7305-7309; Milner et al., 1997, Nature Biotechnology, 15, 537-541). Exemplary triplex forming oligonucleotide molecules of the invention are preferably between 10 and 40 nucleotides in length, more preferably between 12 and 25 nucleotides in length, e.g., 18, 19, 20, or 21 nucleotides in length (see for example Maher et al., 1990, Biochemistry, 29, 8820-8826; Strobel WO 01/57206 PCT/USO1/03504 10 and Dervan, 1990, Science, 249, 73-75). Those skilled in the art will recognize that all that is required is for the nucleic acid molecule are of length and conformation sufficient and suitable for the nucleic acid molecule to catalyze a reaction contemplated herein. The length of the nucleic acid molecules of the instant invention are not limiting within the general limits stated. Preferably, a nucleic acid molecule that down regulates the replication of Chk1 comprises between 12 and 100 bases complementary to a RNA molecule of Chkl. Even more preferably, a nucleic acid molecule that down regulates the replication of Chk1 comprises between 14 and 24 bases complementary to a RNA molecule of Chkl. In a preferred embodiment, the invention provides a method for producing a class of nucleic acid-based gene inhibiting agents which exhibit a high degree of specificity for the RNA of a desired target. For example, the enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of target RNAs encoding kinases which phosphorylate Cdc25 S216, such as Chk1 proteins (specifically Chk1 gene) such that specific treatment of a disease or condition can be provided with either one or several nucleic acid molecules of the invention. Such nucleic acid molecules can be delivered exogenously to specific tissue or cellular targets as required. Alternatively, the nucleic acid molecules (e.g., ribozymes and antisense) can be expressed from DNA and/or RNA vectors that are delivered to specific cells. In a preferred embodiment, the invention features the use of nucleic acid-based inhibitors of the invention to specifically target genes that share homology with the Chk1 gene. As used in herein "cell" is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell may be present in an organism which may be a human but is preferably a non-human multicellular organism, e.g., birds, plants and mammals such as cows, sheep, apes, monkeys, swine, dogs, and cats. The cell may be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). By "Chk1 proteins" is meant, a protein or a mutant protein derivative thereof, comprising phosphorylation activity, preferably to seine residue (S216), or its equivalent, in Cdc25 phosphatase. By "highly conserved sequence region" is meant, a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other. The nucleic acid-based inhibitors of Chkl expression are useful for the prevention and/or treatment of diseases and conditions such as cancer, including cancer of the colon, rectum, lung, WO 01/57206 PCT/US01/03504 11 breast, prostate and any other diseases or conditions that are related to or will respond to the levels of Chk1 in a cell or tissue, alone or in combination with other therapies. In addition, Chk1 inhibition may be used as a therapeutic target for abrogating the G2 DNA damage checkpoint arrest; a situation that may selectively sensitize p53-deficient tumor cells to radiation or chemotherapy treatment. By "related" is meant that the reduction of Chk1 expression (specifically Chkl gene) RNA levels and thus reduction in the level of the respective protein will relieve, to some extent, the symptoms of the disease or condition. The nucleic acid-based inhibitors of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their incorporation in biopolymers. In preferred embodiments, the enzymatic nucleic acid inhibitors comprise sequences, which are complementary to the substrate sequences in Tables III to VIII. Examples of such enzymatic nucleic acid molecules also are shown in Tables III to VIII. Examples of such enzymatic nucleic acid molecules consist essentially of sequences defined in these Tables. In yet another embodiment, the invention features antisense nucleic acid molecules and 2 5A chimera including sequences complementary to the substrate sequences shown in Tables III to IX. Such nucleic acid molecules can include sequences as shown for the binding arms of the enzymatic nucleic acid molecules in Tables III to VIII and sequences shown as GeneBlocTM sequences in Table IX. Similarly, triplex molecules can be provided targeted to the corresponding DNA target regions, and containing the DNA equivalent of a target sequence or a sequence complementary to the specified target (substrate) sequence. Typically, antisense molecules will be complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule may bind such that the antisense molecule forms a loop. Thus, the antisense molecule may be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both. By "consists essentially of' is meant that the active nucleic acid molecule of the invention, for example an enzymatic nucleic acid molecule, contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind RNA such that cleavage at the target site occurs. Other sequences may be present which do not interfere with such cleavage. Thus, a core WO 01/57206 PCT/USO1/03504 12 region may, for example, include one or more loop, stem-loop structure or linker, which does not prevent enzymatic activity. Thus, the underlined regions in the sequences in Tables III and IV can be such a loop, stem-loop, nucleotide linker, and/or non-nucleotide linker and can be represented generally as sequence "X". For example, a core sequence for a hammerhead enzymatic nucleic acid can comprise a conserved sequence, such as 5'-CUGAUGAG-3' and 5' CGAA-3' connected by a sequence X, where X is 5'-GCCGUJAGGC-3' (SEQ ID NO 3173) or any other stein II region known in the art or a nucleotide and/or non-nucleotide linker. Similarly, for other nucleic acid molecules of the instant invention, such as Inozyme, G-cleaver, amberzyme, zinzyme, DNAzyme, antisense, 2-5A antisense, triplex forming nucleic acid, and decoy nucleic acids, other sequences or non-nucleotide linkers may be present that do not interfere with the function of the nucleic acid molecule. Sequence X may be a linker of 2 nucleotides in length, preferably 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 26, 30, where the nucleotides may preferably be internally base-paired to form a stem of preferably 2 base pairs. Alternatively or in addition, sequence X may be a non-nucleotide linker. In yet another embodiment, the nucleotide linker X can be a nucleic acid aptamer, such as an ATP aptamer, HIV Rev aptamer (RRE), HIV Tat aptamer (TAR) and others (for a review see Gold et al., 1995, Annu. Rev. Biochem., 64, 763; and Szostak & Ellington, 1993, in The RNA World, ed. Gesteland and Atkins, pp. 511, CSH Laboratory Press). A "nucleic acid aptamer" as used herein is meant to indicate a nucleic acid sequence capable of interacting with a ligand. The ligand can be any natural or a synthetic molecule, including but not limited to a resin, metabolites, nucleosides, nucleotides, drugs, toxins, transition state analogs, peptides, lipids, proteins, amino acids, nucleic acid molecules, hormones, carbohydrates, receptors, cells, viruses, bacteria and others. In yet another embodiment, the non-nucleotide linker X is as defined herein. The term "non-nucleotide" as used herein include either abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, or polyhydrocarbon compounds. Specific examples include those described by Seela and Kaiser, Nucleic Acids Res. 1990, 18:6353 and Nucleic Acids Res. 1987, 15:3113; Cload and Schepartz, J. Am. Chem. Soc. 1991, 113:6324; Richardson and Schepartz, J Am. Chem. Soc. 1991, 113:5109; Ma et al., Nucleic Acids Res. 1993, 21:2585 and Biochemistry 1993, 32:1751; Durand et al., Nucleic Acids Res. 1990, 18:6353; McCurdy et al., Nucleosides & Nucleotides 1991, 10:287; Jschke et al., Tetrahedron Lett. 1993, 34:301; Ono et al., Biochemistry 1991, 30:9914; Arnold et al., International Publication No. WO 89/02439; Usman et al., International Publication No. WO 95/06731; Dudycz et al., International Publication No. WO 95/11910 and Ferentz and Verdine, J. Am. Chem. Soc. 1991, 113:4000, all hereby incorporated by reference herein. A "non-nucleotide" further means any group or WO 01/57206 PCT/USO1/03504 13 compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine. Thus, in a preferred embodiment, the invention features an enzymatic nucleic acid molecule having one or more non-nucleotide moieties, and having enzymatic activity to cleave an RNA or DNA molecule. In another aspect of the invention, ribozymes or antisense molecules that cleave target RNA molecules and inhibit Chk1 (specifically Chk1 gene) activity are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme or antisense expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the ribozymes or antisense are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of ribozymes or antisense. Such vectors can be repeatedly administered as necessary. Once expressed, the ribozymes or antisense bind to the target RNA and inhibit its function or expression. Delivery of ribozyme or antisense expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell. By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid. By "patient" is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. "Patient" also refers to an organism to which the nucleic acid molecules of the invention can be administered. Preferably, a patient is a mammal or mammalian cells. More preferably, a patient is a human or human cells. By "enhanced enzymatic activity" is meant to include activity measured in cells and/or in vivo where the activity is a reflection of both the catalytic activity and the stability of the nucleic acid molecules of the invention. In this invention, the product of these properties can beincreased in vivo compared to an all RNA enzymatic nucleic acid or all DNA enzyme. In some cases, the activity or stability of the nucleic acid molecule can bedecreased (i.e., less than ten fold), but the overall activity of the nucleic acid molecule is enhanced, in vivo.

WO 01/57206 PCT/US01/03504 14 The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed above. For example, to treat a disease or condition associated with the levels of Chkl, the patient may be treated, or other appropriate cells may be treated, as is evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment. In a further embodiment, the described molecules, such as antisense or ribozymes, can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules could be used in combination with one or more known therapeutic agents to treat cancer, including but not limited to cancer of the colon, rectum, lung, breast and prostate. In another preferred embodiment, the invention features nucleic acid-based inhibitors (e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups) and methods for their use to down regulate or inhibit the expression of genes (e.g., Chkl) capable of progression and/or maintenance of cancer. In another aspect, the invention provides mammalian cells containing one or more nucleic acid molecules and/or expression vectors of this invention. The one or more nucleic acid molecules may independently be targeted to the same or different sites. By "comprising" is meant including, but not limited to, whatever follows the word "comprising". Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of' is meant including, and limited to, whatever follows the phrase "consisting of'. Thus, the phrase "consisting of' indicates that the listed elements are required or mandatory, and that no other elements may be present. Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Description Of The Preferred Embodiments First the drawings will be described briefly.

WO 01/57206 PCT/USO1/03504 15 Drawings Figure 1 shows the secondary structure model for seven different classes of enzymatic nucleic acid molecules. Arrow indicates the site of cleavage. --------- indicate the target sequence. Lines interspersed with dots are meant to indicate tertiary interactions. - is meant to indicate base-paired interaction. Group I Intron: P1-P9.0 represent various stem-loop structures (Cech et al., 1994, Nature Struc. Bio., 1, 273). RNase P (M1RNA): EGS represents external guide sequence (Forster et al., 1990, Science, 249, 783; Pace et al., 1990, J. Biol. Chem., 265, 3587). Group II Intron: 5'SS means 5' splice site; 3'SS means 3'-splice site; IBS means intron binding site; EBS means exon binding site (Pyle et al., 1994, Biochemistry, 33, 2716). VS RNA: I-VI are meant to indicate six stem-loop structures; shaded regions are meant to indicate tertiary interaction (Collins, International PCT Publication No. WO 96/19577). HDV Ribozyme: : I-IV are meant to indicate four stem-loop structures (Been et al., US Patent No. 5,625,047). Hammerhead Ribozyme: : I-III are meant to indicate three stem-loop structures; stems I-III can be of any length and may be symmetrical or asymmetrical (Usman et al., 1996, Curr. Op. Struct. Bio., 1, 527). Hairpin Ribozyme: Helix 1, 4 and 5 can be of any length; Helix 2 is between 3 and 8 base-pairs long; Y is a pyrimidine; Helix 2 (H2) is provided with a least 4 base pairs (i.e., n is 1, 2, 3 or 4) and helix 5 can be optionally provided of length 2 or more bases (preferably 3 20 bases, i.e., m is from 1 - 20 or more). Helix 2 and helix 5 may be covalently linked by one or more bases (i.e., r is > 1 base). Helix 1, 4 or 5 may also be extended by 2 or more base pairs (e.g., 4 - 20 base pairs) to stabilize the ribozyme structure, and preferably is a protein binding site. In each instance, each N and N' independently is any normal or modified base and each dash represents a potential base-pairing interaction. These nucleotides may be modified at the sugar, base or phosphate. Complete base-pairing is not required in the helices, but is preferred. Helix 1 and 4 can be of any size (i.e., o and p is each independently from 0 to any number, e.g., 20) as long as some base-pairing is maintained. Essential bases are shown as specific bases in the structure, but those in the art will recognize that one or more may be modified chemically (abasic, base, sugar and/or phosphate modifications) or replaced with another base without significant effect. Helix 4 can be formed from two separate molecules, i.e., without a connecting loop. The connecting loop when present may be a ribonucleotide with or without modifications to its base, sugar or phosphate. "q" is 2 bases. The connecting loop can also be replaced with a non-nucleotide linker molecule. H refers to bases A, U, or C. Y refers to pyrimidine bases. "t " refers to a covalent bond. (Burke et al., 1996, Nucleic Acids & Mol. Biol., 10, 129; Chowrira et al., US Patent No. 5,631,359). Figure 2 shows examples of chemically stabilized ribozyme motifs. HH Rz, represents hammerhead ribozyme motif (Usman et al., 1996, Curr. Op. Struct. Bio., 1, 527); NCH Rz represents the NCH ribozyme motif (Ludwig & Sproat, International PCT Publication No. WO WO 01/57206 PCT/USO1/03504 16 98/58058); G-Cleaver, represents G-cleaver ribozyme motif (Kore et al., 1998, Nucleic Acids Research 26, 4116-4120). N or n, represent independently a nucleotide which may be same or different and have complementarity to each other; rI, represents ribo-Inosine nucleotide; arrow indicates the site of cleavage within the target. Position 4 of the HH Rz and the NCH Rz is shown as having 2'-C-allyl modification, but those skilled in the art will recognize that this position can be modified with other modifications well known in the art, so long as such modifications do not significantly inhibit the activity of the ribozyme. Figure 3 shows an example of the Amberzyme ribozyme motif that is chemically stabilized (see, for example, Beigelman et al., International PCT publication No. WO 99/55857, incorporated by reference herein; also referred to as Class I Motif). The Amberzyme motif is a class of enzymatic nucleic molecules that do not require the presence of a ribonucleotide (2'-OH) group for its activity. Figure 4 shows an example of the Zinzyme A ribozyme motif that is chemically stabilized (Beigelman et al., International PCT publication No. WO 99/55857, incorporated by reference herein; also referred to as Class A or Class II Motif). The Zinzyme motif is a class of enzymatic nucleic molecules that do not require the presence of a ribonucleotide (2'-OH) group for its activity. Figure 5 shows an example of a DNAzyme motif described by Santoro et al., 1997, PNAS, 94, 4262. Figure 6 shows a bar graph of a nucleic acid inhibitor (50 to 200 nM GeneBlocTM screen against Chkl RNA in HeLa cells using 1.25 ptg/ml GSV lipid with 24 hour sustained delivery in a 96-well format. Relative amounts of target RNA were measured normalized to actin using real-time PCR monitoring of amplification compared to mismatch nucleic acid and untreated controls. The sequences of GeneBlocTM reagents used in this experiment are shown in Table IX. Figure 7 shows a bar graph of a lipid optimization study utilizing lead nucleic acid inhibitors (GeneBlocs T M ) targeting Chkl RNA in HeLa cells; 96-well plate format, 5000 cells/well, GSV lipid. Six different lipid concentrations are shown in conjunction with two different concentrations of the nucleic acid inhibitors. Figure 8 shows a bar graph displaying a time-course inhibition study of a lead nucleic acid inhibitor (GeneBloc

TM

) targeting Chk1 RNA compared to a scrambled nucleic acid control, both at 5 and 100 nM concentrations; 96-well plate format, 5000 cells/well, 1.0 ptg/ml GSV lipid.

WO 01/57206 PCT/USO1/03504 17 Figure 9 shows a bar graph representing inhibition of Chk1 RNA via primary lead (GeneBlocTM) inhibition as described in Figure 6, however utilizing a 6-well plate format with a cell density of 150,000 cells per well. Figure 10 shows a bar graph representing inhibition of Chk1 RNA via primary lead (GeneBlocTM) inhibition in conjunction with +/- etoposide and nocodazole treatment; 50 nM GeneBloc T M , 1.25 gg/ml GSV lipid, HeLa cells, 6-well plate format, 100,000 cells/well. Figure 11 shows a bar graph of a lipid optimization study utilizing a lead nucleic acid inhibitor (GeneBloc

TM

) targeting Chk1 RNA in DLD-1 cells; 96-well plate format, 15,000 cells/well, GSV lipid. Four different lipid concentrations are shown in conjunction with two different concentrations of the nucleic acid inhibitor. Figure 12 shows a bar graph of a lipid optimization study utilizing a lead nucleic acid inhibitor (GeneBloc

TM

) targeting Chk1 RNA in MCF-7 cells; 96-well plate format, 10,000 cells/well, GSV lipid. Four different lipid concentrations are shown in conjunction with two different concentrations of the nucleic acid inhibitor. Figure 13 shows a dose curve of primary and secondary nucleic acid inhibitor (GeneBloc

TM

) leads targeting Chk1 RNA in HeLa cells using 1.25 pg/ml GSV lipid, 24 hr time point, 96-well plate format with a density of 5000 cells/well. Mechanism of action of Nucleic Acid Molecules of the Invention Antisense: Antisense molecules can be modified or unmodified RNA, DNA, or mixed polymer oligonucleotides which primarily function by specifically binding to matching sequences resulting in inhibition of peptide synthesis (Wu-Pong, Nov 1994, BioPharn, 20-33). The antisense oligonucleotide binds to target RNA by Watson Crick base-pairing and blocks gene expression by preventing ribosomal translation of the bound sequences either by steric blocking or by activating RNase H enzyme. Antisense molecules can also alter protein synthesis by interfering with RNA processing or transport from the nucleus into the cytoplasm (Mukhopadhyay & Roth, 1996, Crit. Rev. in Oncogenesis 7, 151-190). In addition, binding of single stranded DNA to RNA may result in nuclease degradation of the heteroduplex (Wu-Pong, supra; Crooke, supra). To date, the only backbone modified DNA chemistry which will act as substrates for RNase H are phosphorothioates, phosphorodithioates, and borontrifluoridates. Recently it has been reported that 2'-arabino and 2'-fluoro arabino containing oligos can also activate RNase H activity.

WO 01/57206 PCT/USO1/03504 18 A number of antisense molecules have been described that utilize novel configurations of chemically modified nucleotides, secondary structure, and/or RNase H substrate domains (Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., International PCT Publication No. WO 99/54459; Hartmann et al., USSN 60/101,174 which was filed on September 21, 1998) all of these are incorporated by reference herein in their entirety. In addition, antisense deoxyoligoribonucleotides can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. Antisense DNA can be expressed via the use of a single stranded DNA intracellular expression vector or equivalents and variations thereof. Triplex Forming Oligonucleotides (TFO): Single stranded DNA can be designed to bind to genomic DNA in a sequence specific manner. TFOs are comprised of pyrimidine-rich oligonucleotides which bind DNA helices through Hoogsteen Base-pairing (Wu-Pong, supra). The resulting triple helix composed of the DNA sense, DNA antisense, and TFO disrupts RNA synthesis by RNA polymerase. The TFO mechanism can result in gene expression or cell death since binding may be irreversible (Mukhopadhyay & Roth, supra). 2-5A Antisense Chimera: The 2-5A system is an interferon mediated mechanism for RNA degradation found in higher vertebrates (Mitra et al., 1996, Proc Nat Acad Sci USA 93, 6780 6785). Two types of enzymes, 2-5A synthetase and RNase L, are required for RNA cleavage. The 2-5A synthetases require double stranded RNA to form 2'-5' oligoadenylates (2-5A). 2-5A then acts as an allosteric effector for utilizing RNase L which has the ability to cleave single stranded RNA. The ability to form 2-5A structures with double stranded RNA makes this system particularly useful for inhibition of viral replication. (2'-5') oligoadenylate structures can be covalently linked to antisense molecules to form chimeric oligonucleotides capable of RNA cleavage (Torrence, supra). These molecules putatively bind and activate a 2-5A dependent RNase, the oligonucleotide/enzyme complex then binds to a target RNA molecule which can then be cleaved by the RNase enzyme. Enzymatic Nucleic Acid: Seven basic varieties of naturally occurring enzymatic RNAs are presently known. In addition, several in vitro selection (evolution) strategies (Orgel, 1979, Proc. R. Soc. London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing cleavage and ligation of phosphodiester linkages (Joyce, 1989, Gene, 82, 83-87; Beaudry et al., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al., 1994, TIBTECH 12, 268; Bartel et al.,1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al., 1995, FASEB J, 9, 1183; Breaker, 1996, Curr. Op. Biotech., 7, 442; Santoro et al., 1997, Proc. Natl. Acad. Sci., 94, 4262; Tang et al., 1997, RNA 3, 914; WO 01/57206 PCT/USO1/03504 19 Nakamaye & Eckstein, 1994, supra; Long & Uhlenbeck, 1994, supra; Ishizaka et al., 1995, supra; Vaish et al., 1997, Biochemistry 36, 6495; all of these are incorporated by reference herein). Each can catalyze a series of reactions including the hydrolysis of phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. Nucleic acid molecules of this invention will block to some extent Chkl protein expression and can be used to treat disease or diagnose disease associated with the levels of Chkl. The enzymatic nature of a ribozyme has significant advantages, such as the concentration of ribozyme necessary to affect a therapeutic treatment is lower. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base substitutions, near the site of cleavage can be chosen to completely eliminate catalytic activity of a ribozyme. Nucleic acid molecules having an endonuclease enzymatic activity are able to repeatedly cleave other separate RNA molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be targeted to virtually any RNA transcript, and achieve efficient cleavage in vitro (Zaug et al., 324, Nature 429 1986 ; Uhlenbeck, 1987 Nature 328, 596; Kim et al., 84 Proc. Natd. Acad. Sci. USA 8788, 1987; Dreyfus, 1988, Einstein Quart. J Bio. Med., 6, 92; Haseloff and Gerlach, 334 Nature 585, 1988; Cech, 260 JAMA 3030, 1988; and Jefferies et al., 17 Nucleic Acids Research 1371, 1989; Santoro et al., 1997 supra). Because of their sequence specificity, trans-cleaving ribozymes can be used as therapeutic agents for human disease (Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037). Ribozymes can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited (Warashina et al., 1999, Chemistry and Biology, 6, 237-250). The nucleic acid molecules of the instant invention are also referred to as GeneBlocTM reagents, which are essentially nucleic acid molecules (e.g.; ribozymes, antisense) capable of down-regulating gene expression. GeneBlocs are modified oligonucleotides including ribozymes and modified antisense oligonucleotides that bind to and target specific mRNA molecules. Because GeneBlocs can be WO 01/57206 PCT/USO1/03504 20 designed to target any specific mRNA, their potential applications are quite broad. Traditional antisense approaches have often relied heavily on the use of phosphorothioate modifications to enhance stability in biological samples, leading to a myriad of specificity problems stemming from non-specific protein binding and general cytotoxicity (Stein, 1995, Nature Medicine, 1, 1119). In contrast, GeneBlocs contain a number of modifications that confer nuclease resistance while making minimal use of phosphorothioate linkages, which reduces toxicity, increases binding affinity and minimizes non-specific effects compared with traditional antisense oligonucleotides. Similar reagents have recently been utilized successfully in various cell culture systems (Vassar, et al., 1999, Science, 286, 735) and in vivo (Jarvis et al., manuscript in preparation). In addition, novel cationic lipids can be utilized to enhance cellular uptake in the presence of serum. Since ribozymes and antisense oligonucleotides regulate gene expression at the RNA level, the ability to maintain a steady-state dose of GeneBloc over several days was important for target protein and phenotypic analysis. The advances in resistance to nuclease degradation and prolonged activity in vitro have supported the use of GeneBlocs in target validation applications. Target sites Targets for useful ribozymes and antisense nucleic acids can be determined as disclosed in Draper et al., WO 93/23569; Sullivan et al., WO 93/23057; Thompson et al., WO 94/02595; Draper et al., WO 95/04818; McSwiggen et al., US Patent No. 5,525,468. All of these publications are hereby incorporated by reference herein in their totality. Other examples include the following PCT applications, which concern inactivation of expression of disease-related genes: WO 95/23225, WO 95/13380, WO 94/02595, all of which are incorporated by reference herein. Rather than repeat the guidance provided in those documents here, specific examples of such methods are provided herein, not limiting to those in the art. Ribozymes and antisense to such targets are designed as described in those applications and synthesized to be tested in vitro and in vivo, as also described. The sequences of human Chk1 RNAs were screened for optimal enzymatic nucleic acid and antisense target sites using a computer-folding algorithm. Antisense, hammerhead, DNAzyme, NCH, amberzyme, zinzyme, or G-Cleaver ribozyme binding/cleavage sites were identified. These sites are shown in Tables III to VIII (all sequences are 5' to 3' in the tables; underlined regions can be any sequence or linker X, the actual sequence is not relevant here). The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of enzymatic nucleic acid molecule. While human sequences can be screened and enzymatic nucleic acid molecule and/or antisense thereafter designed, as discussed in Stinchcomb et al., WO 95/23225, mouse targeted ribozymes may be useful to test efficacy of action of the enzymatic nucleic acid molecule and/or antisense prior to testing in humans.

WO 01/57206 PCT/USO1/03504 21 Antisense, hammerhead, DNAzyme, NCH, amberzyme, zinzyme or G-Cleaver ribozyme binding/cleavage sites were identified. The nucleic acid molecules are individually analyzed by computer folding (Jaeger et al., 1989 Proc. Natl. Acad. Sci. USA, 86, 7706) to assess whether the sequences fold into the appropriate secondary structure. Those nucleic acid molecules with unfavorable intramolecular interactions such as between the binding arms and the catalytic core are eliminated from consideration. Varying binding ann lengths can be chosen to optimize activity. Antisense, hammerhead, DNAzyme, NCH, amberzyme, zinzyme or G-Cleaver ribozyme binding/cleavage sites were identified and were designed to anneal to various sites in the RNA target. The binding arms are complementary to the target site sequences described above. The nucleic acid molecules were chemically synthesized. The method of synthesis used follows the procedure for normal DNA/RNA synthesis as described below and in Usman et al., 1987 J Am. Chem. Soc., 109, 7845; Scaringe et al., 1990 Nucleic Acids Res., 18, 5433; Wincott et al., 1995 Nucleic Acids Res. 23, 2677-2684; and Caruthers et al., 1992, Methods in Enzymology 211,3-19. Synthesis of Nucleic acid Molecules Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., antisense oligonucleotides, hammerhead or the NCH ribozymes) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized. Oligonucleotides (e.g.; antisense GeneBlocsTM) are synthesized using protocols known in the art as described in Caruthers et al., 1992, Methods in Enzymology 211, 3-19, Thompson et al., International PCT Publication No. WO 99/54459, Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684, Wincott et al., 1997, Methods Mol. Bio., 74, 59, Brennan et al., 1998, Biotechnol Bioeng., 61, 33-45, and Brennan, US patent No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 gmol scale protocol with a 2.5 min coupling step for 2'-O-methylated nucleotides and a 45 sec coupling step for 2'-deoxy nucleotides. Table II outlines the amounts and the contact times of the reagents used in the WO 01/57206 PCT/USO1/03504 22 synthesis cycle. Alternatively, syntheses at the 0.2 pmol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60 pL of 0.11 M = 6.6 ptmol) of 2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 gL of 0.25 M = 15 pmol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 22-fold excess (40 gL of 0.11 M = 4.4 jimol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 gL of 0.25 M = 10 pmol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include; detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6 lutidine in THF (ABI); and oxidation solution is 16.9 mM 12, 49 mM pyridine, 9% water in THF

(PERSEPTIVE

TM

). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H- 1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used. Deprotection of the antisense oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 *C for 10 min. After cooling to -20 *C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H20/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The method of synthesis used for normal RNA including certain enzymatic nucleic acid molecules follows the procedure as described in Usman et al., 1987, J. Am. Chem. Soc., 109, 7845; Scaringe et al., 1990, Nucleic Acids Res., 18, 5433; Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684 and Wincott et al., 1997, Methods Mol. Bio., 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 tmol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2'-0 methylated nucleotides. Table H outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 gmol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal WO 01/57206 PCT/USO1/03504 23 modification to the cycle. A 33-fold excess (60 ptL of 0.11 M = 6.6 pmol) of 2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 ptL of 0.25 M = 15 ttmol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 66-fold excess (120 pL of 0.11 M = 13.2 gmol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 pL of 0.25 M = 30 pmol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include; detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM 12, 49 mM pyridine, 9% water in THF (PERSEPTIVE

TM

). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1 dioxide0.05 M in acetonitrile) is used. Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 'C for 10 min. After cooling to -20 'C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H20/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 pL of a solution of 1.5 mL N-methylpyrrolidinone, 750 [tL TEA and 1 mL TEA-3HF to provide a 1.4 M HF concentration) and heated to 65 'C. After 1.5 h, the oligomer is quenched with 1.5 M NH 4

HCO

3 Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65 'C for 15 min. The vial is brought to r.t. TEA-3HF (0.1 mL) is added and the vial is heated at 65 'C for 15 min. The sample is cooled at -20 'C and then quenched with 1.5 M NH 4

HCO

3 . For purification of the trityl-on oligomers, the quenched NH 4

HCO

3 solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA WO 01/57206 PCT/USO1/03504 24 for 13 min. The cartridge is then washed again with water, salt exchanged with 1 M NaC1 and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile. Inactive hammerhead ribozymes or binding attenuated control (BAC) oligonucleotides) are synthesized by substituting a U for G5 and a U for A14 (numbering from Hertel, K. J., et al., 1992, Nucleic Acids Res., 20, 3252). Similarly, one or more nucleotide substitutions can be introduced in other enzymatic nucleic acid molecules to inactivate the molecule and such molecules can serve as a negative control. The average stepwise coupling yields are typically >98% (Wincott et al., 1995 Nucleic Acids Res. 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the examples described above including but not limited to 96-well format, all that is important is the ratio of chemicals used in the reaction. Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example by ligation (Moore et al., 1992, Science 256, 9923; Draper et al., International PCT publication No. WO 93/23569; Shabarova et al., 1991, Nucleic Acids Research 19, 4247; Bellon et al., 1997, Nucleosides & Nucleotides, 16, 951; Bellon et al., 1997, Bioconjugate Chem. 8, 204). The nucleic acid molecules of the present invention are modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2' flouro, 2'-0-methyl, 2'-H (for a review see Usman and Cedergren, 1992, TIBS 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163). Ribozymes are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; See Wincott et al., supra, the totality of which is hereby incorporated herein by reference) and are re-suspended in water. The sequences of the ribozymes and antisense constructs that are chemically synthesized, useful in this study, are shown in Tables III to IX. Those in the art will recognize that these sequences are representative only of many more such sequences where the enzymatic portion of the ribozyme (all but the binding arms) is altered to affect activity. The ribozyme and antisense construct sequences listed in Tables III to IX may be formed of ribonucleotides or other nucleotides or non-nucleotides. Such ribozymes with enzymatic activity are equivalent to the ribozymes described specifically in the Tables. Optimizing Activity of the nucleic acid molecule of the invention. Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases can increase their potency (see WO 01/57206 PCT/USO1/03504 25 e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990 Nature 344, 565; Pieken et al., 1991, Science 253, 314; Usman and Cedergren, 1992, Trends in Biochem. Sci. 17, 334; Usman et al., International Publication No. WO 93/15187; Rossi et al., International Publication No. WO 91/03162; Sproat, US Patent No. 5,334,711; and Burgin et al., supra); all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. All these references are incorporated by reference herein. Modifications which enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired. There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2' amino, 2'-C-allyl, 2'-flouro, 2'-O-methyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, TIBS. 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163; Burgin et al., 1996, Biochemistry , 35, 14090). Sugar modifications of nucleic acid molecules have been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al. Nature, 1990, 344, 565-568; Pieken et al. Science, 1991, 253, 314-317; Usman and Cedergren, Trends in Biochem. Sci. , 1992, 17, 334 339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, US Patent No. 5,334,711 and Beigelman et al., 1995, J Biol. Chem., 270, 25702; Beigelman et al., International PCT publication No. WO 97/26270; Beigelman et al., US Patent No. 5,716,824; Usman et al., US patent No. 5,627,053; Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., USSN 60/082,404 which was filed on April 20, 1998; Karpeisky et al., 1998, Tetrahedron Lett., 39, 1131; Earnshaw and Gait, 1998, Biopolymers (Nucleic acid Sciences), 48, 39-55; Verma and Eckstein, 1998, Annu. Rev. Biochem., 67, 99-134; and Burlina et al., 1997, Bioorg. Med. Chem., 5, 1999-2010; all of the references are hereby incorporated by reference herein in their totalities). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into ribozymes without inhibiting catalysis. In view of such teachings, similar modifications can be used as described herein to modify the nucleic acid molecules of the instant invention. While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorothioate, and/or 5'-methylphosphonate linkages improves stability, too many of these modifications may cause some toxicity. Therefore when designing nucleic acid molecules the amount of these internucleotide linkages should be minimized. The reduction WO 01/57206 PCT/USO1/03504 26 in the concentration of these linkages should lower toxicity resulting in increased efficacy and higher specificity of these molecules. Nucleic acid molecules having chemical modifications which maintain or enhance activity are provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or in vivo the activity may not be significantly lowered. Therapeutic nucleic acid molecules delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA and DNA (Wincott et al., 1995 Nucleic Acids Res. 23, 2677; Caruthers et al., 1992, Methods in Enzymology 211,3-19 (incorporated by reference herein) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above. Use of the nucleic acid-based molecules of the present invention will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple antisense or enzymatic nucleic acid molecules targeted to different genes, nucleic acid molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations of molecules (including different motifs) and/or other chemical or biological molecules). The treatment of patients with nucleic acid molecules can also include combinations of different types of nucleic acid molecules. Therapeutic nucleic acid molecules (e.g., enzymatic nucleic acid molecules and antisense nucleic acid molecules) delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, these nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above. In yet another preferred embodiment, nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity are provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or in vivo the activity may not be significantly lowered. As exemplified herein such ribozymes are useful in a WO 01/57206 PCT/USO1/03504 27 cell and/or in vivo even if activity over all is reduced 10 fold (Burgin et al., 1996, Biochiemistry, 35, 14090). Such ribozymes herein are said to "maintain" the enzymatic activity of an all RNA ribozyme. In another aspect the nucleic acid molecules comprise a 5' and/or a 3'- cap structure. By "cap structure" is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Wincott et al., WO 97/26270, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5'-terminus (5'-cap) or at the 3'-terminus (3'-cap) or may be present on both termini. In non-limiting examples the 5'-cap is selected from the group comprising inverted abasic residue (moiety), 4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4' thio nucleotide, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5 dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2' inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3' phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety (for more details see Wincott et al., International PCT publication No. WO 97/26270, incorporated by reference herein). In yet another preferred embodiment, the 3'-cap is selected from a group comprising, 4',5' methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4 dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5' 5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details, see Beaucage and Iyer, 1993, Tetrahedron 49, 1925; incorporated by reference herein). By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar WO 01/57206 PCT/USO1/03504 28 and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine. An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =0, =S, N02 or N(CH3)2, amino, or SH. The term also includes alkenyl groups which are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =0, =S, N02, halogen, N(CH3)2, amino, or SH. The term "alkyl" also includes alkynyl groups which have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =0, =S, N02 or N(CH3)2, amino or SH. Such alkyl groups may also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and- ester groups. An "aryl" group refers to an aromatic group which has at least one ring having a conjugated 7c electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester" refers to an -C(O) OR', where R is either alkyl, aryl, alkylaryl or hydrogen.

WO 01/57206 PCT/USO1/03504 29 By "nucleotide" is meant a heterocyclic nitrogenous base in N-glycosidic linkage with a phosphorylated sugar. Nucleotides are recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhlman & Peyman, supra all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994, Nucleic Acids Res. 22, 2183. Some of the non-limiting examples of chemically modified and other natural nucleic acid bases that can be introduced into nucleic acids include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6 trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkyleytidines (e.g., 5-methyleytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, quesosine, 2-thiouridine, 4-thiouridine, wybutosine, wybutoxosine, 4-acetylcytidine, 5 (carboxyhydroxymethyl)uridine, 5'-carboxymethylaminomethyl-2-thiouridine, 5 carboxymethylaminomethyluridine, beta-D-galactosylqueosine, 1-methyladenosine, 1 methylinosine, 2,2-dimethylguanosine, 3-methyleytidine, 2-methyladenosine, 2 methylguanosine, N6-methyladenosine, 7-methylguanosine, 5-methoxyaminomethyl-2 thiouridine, 5-methylaminomethyluridine, 5-methylcarbonylmethyluridine, 5-methyloxyuridine, 5-methyl-2-thiouridine, 2-methylthio-N6-isopentenyladenosine, -D-mannosylqueosine, uridine 5-oxyacetic acid, 2-thiocytidine, threonine derivatives and others (Burgin et al., 1996, Biochemistry, 35, 14090; Uhlman & Peyman, supra). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases may be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule. By "nucleoside" is meant a heterocyclic nitrogenous base in N-glycosidic linkage with a sugar. Nucleosides are recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleoside sugar moiety. Nucleosides generally comprise a base and sugar group. The nucleosides can be umnodified or modified at the sugar, and/or base moiety, (also referred to interchangeably as nucleoside analogs, modified nucleosides, non-natural nucleosides, non-standard nucleosides and other; see for example, Usman and McSwiggen, supra; Eckstein et al., International PCT WO 01/57206 PCT/USO1/03504 30 Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhlman & Peyman, supra all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994, Nucleic Acids Res. 22, 2183. Some of the non-limiting examples of chemically modified and other natural nucleic acid bases that can be introduced into nucleic acids include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methyleytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, quesosine, 2-thiouridine, 4-thiouridine, wybutosine, wybutoxosine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 5' carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, -D galactosylqueosine, 1-methyladenosine, 1-methylinosine, 2,2-dimethylguanosine, 3 methylcytidine, 2-methyladenosine, 2-methylguanosine, N6-methyladenosine, 7 methylguanosine, 5-methoxyaminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5 methylcarbonylmethyluridine, 5-methyloxyuridine, 5-methyl-2-thiouridine, 2-methylthio-N6 isopentenyladenosine, beta-D-mannosylqueosine, uridine-5-oxyacetic acid, 2-thiocytidine, threonine derivatives and others (Burgin et al., 1996, Biochemistry, 35, 14090; Uhlman & Peyman, supra). By "modified bases" in this aspect is meant nucleoside bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases may be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule. In a preferred embodiment, the invention features modified ribozymes with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications see Hunziker and Leumann, 1995, Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331 417, and Mesmaeker et al., 1994, Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39. By "abasic" is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position, (for more details, see Wincott et al., International PCT publication No. WO 97/26270). By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, thymine, uracil joined to the 1' carbon of beta-D-ribo-furanose.

WO 01/57206 PCT/USO1/03504 31 By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. In connection with 2'-modified nucleotides as described for the present invention, by "amino" is meant 2'-NH 2 or 2'-0- NH 2 , which may be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Patent 5,672,695 and Matulic-Adamic et al., WO 98/28317, respectively, which are both incorporated by reference herein in their entireties. Various modifications to nucleic acid (e.g., antisense and ribozyme) structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells. Use of these molecules will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes (including different ribozyme motifs) and/or other chemical or biological molecules). The treatment of patients with nucleic acid molecules may also include combinations of different types of nucleic acid molecules. Therapies may be devised which include a mixture of ribozymes (including different ribozyme motifs), antisense and/or 2-5A chimera molecules to one or more targets to alleviate symptoms of a disease. Administration of Nucleic Acid Molecules Methods for the delivery of nucleic acid molecules are described in Akhtar et al., 1992, Trends Cell Bio., 2, 139; and Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar, 1995 which are both incorporated herein by reference. Sullivan et al., PCT WO 94/02595, further describes the general methods for delivery of enzymatic RNA molecules. These protocols may be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, nucleic acid molecules may be directly delivered ex vivo to cells or tissues with or without the aforementioned vehicles. Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or WO 01/57206 PCT/USO1/03504 32 pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of nucleic acid delivery and administration are provided in Sullivan et al., supra, Draper et al., PCT W093/23569, Beigelman et al., PCT W099/05094, and Klimuk et al., PCT W099/04819 all of which have been incorporated by reference herein. The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a patient. The negatively charged polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention may also be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions; suspensions for injectable administration; and other compositions known in the art. The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, including salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid. A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or patient, preferably a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect. By "systemic administration" is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the desired negatively charged polymers, e.g., nucleic acids, to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain WO 01/57206 PCT/USO1/03504 33 tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cancer cells. By pharmaceutically acceptable formulation is meant, a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P glycoprotein inhibitors (such as Pluronic P85) which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, 1999, Fundam. Clin. Pharmacol., 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, DF et al, 1999, Cell Transplant, 8, 47-58) Alkermes, Inc. Cambridge, MA; and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (Prog Neuropsychopharmacol Biol Psychiatry, 23, 941-949, 1999). Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado et al., 1998, J. Pharm. Sci., 87, 1308-1315; Tyler et al., 1999, FEBS Lett., 421, 280-284; Pardridge et al., 1995, PNAS USA., 92, 5592-5596; Boado, 1995, Adv. Drug Delivery Rev., 15, 73-107; Aldrian-Herrada et al., 1998, Nucleic Acids Res., 26, 4910-4916; and Tyler et al., 1999, PNAS USA., 96, 7053-7058. The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al. Chem. Rev. 1995, 95, 2601 2627; Ishiwata et al., Chem. Pharm. Bull. 1995, 43, 1005-1011). All incorporated by reference herein. Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al., Science 1995, 267, 1275-1276; Oku et al., 1995, Biochim. Biophys. Acta, 1238, 86-90). All incorporated by reference herein. The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al., J Biol. Chem. 1995, 42, 24864 24870; Choi et al., International PCT Publication No. WO 96/10391; Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO WO 01/57206 PCT/USO1/03504 34 96/10392; all of which are incorporated by reference herein). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen. The present invention also includes compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents may be provided. These include sodium benzoate, sorbic acid and esters ofp-hydroxybenzoic acid. In addition, antioxidants and suspending agents may be used. A phannaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer. The nucleic acid molecules of the present invention may also be administered to a patient in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication may increase the beneficial effects while reducing the presence of side effects. Alternatively, certain of the nucleic acid molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, Science, 229, 345; McGarry and Lindquist, 1986, Proc. Natl. Acad. Sci., USA 83, 399; Scanlon et al., 1991, Proc. Natl. Acad. Sci. USA, 88, 10591-5; Kashani-Sabet et al., 1992, Antisense Res. Dev., 2, 3 15; Dropulic et al., 1992, J Virol., 66, 1432-41; Weerasinghe et al., 1991, J Virol., 65, 5531-4; Ojwang et al., 1992, Proc. Natl. Acad. Sci. USA, 89, 10802-6; Chen et al., 1992, Nucleic Acids Res., 20, 4581-9; Sarver et al., 1990 Science, 247, 1222-1225; Thompson et al., 1995, Nucleic Acids Res., 23, 2259; Good et al., 1997, Gene Therapy, 4, 45; all of the references are hereby incorporated in their totality by reference herein). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of WO 01/57206 PCT/USO1/03504 35 such nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992, Nucleic Acids Symp. Ser., 27, 15-6; Taira et al., 1991, Nucleic Acids Res., 19, 5125-30; Ventura et al., 1993, Nucleic Acids Res., 21, 3249-55; Chowrira et al., 1994, J. Biol. Chem., 269, 25856; all of these references are hereby incorporated in their totalities by reference herein). In another aspect of the invention, RNA molecules of the present invention are preferably expressed from transcription units (see, for example, Couture et al., 1996, TIG., 12, 510) inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the nucleic acid molecules are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of nucleic acid molecules. Such vectors might be repeatedly administered as necessary. Once expressed, the nucleic acid molecule binds to the target mRNA. Delivery of nucleic acid molecule expressing vectors could be systemic, such as by intravenous or intra-muscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell (for a review, see Couture et al., 1996, TIG., 12, 510). In one aspect, the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the nucleic acid molecules disclosed in the instant invention. The nucleic acid sequence encoding the nucleic acid molecule of the instant invention is operable linked in a manner which allows expression of that nucleic acid molecule. In another aspect, the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a nucleic acid sequence encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. The vector may optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the sequence encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences). Transcription of the nucleic acid molecule sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the WO 01/57206 PCT/USO1/03504 36 levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, Proc. Nati. Acad. Sci. U S A, 87, 6743-7; Gao and Huang 1993, Nucleic Acids Res.., 21, 2867-72; Lieber et al., 1993, Methods Enzymol., 217, 47-66; Zhou et al., 1990, Mol. Cell. Biol., 10, 4529-37). All of these references are incorporated by reference herein. Several investigators have demonstrated that nucleic acid molecules, such as ribozymes expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992, Antisense Res. Dev., 2, 3-15; Ojwang et al., 1992, Proc. Natl. Acad. Sci. U SA, 89, 10802-6; Chen et al., 1992, Nucleic Acids Res., 20, 4581-9; Yu et al., 1993, Proc. Natd. Acad. Sci. U SA, 90, 6340-4; L'Huillier et al., 1992, EMBO J., 11, 4411-8; Lisziewicz et al., 1993, Proc. Natl. Acad. Sci. U. S. A, 90, 8000-4; Thompson et al., 1995, Nucleic Acids Res., 23, 2259; and Sullenger & Cech, 1993, Science, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as ribozymes in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994, Nucleic Acid Res., 22, 2830; Noonberg et al., US Patent No. 5,624,803; Good et al., 1997, Gene Ther., 4, 45; and Beigelman et al., International PCT Publication No. WO 96/18736; all of these publications are incorporated by reference herein. The above ribozyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review, see Couture and Stinchcomb, 1996, supra). In yet another aspect, the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the nucleic acid molecules of the invention, in a manner which allows expression of that nucleic acid molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another preferred embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3'-end of said open reading frame; and wherein said sequence is operably WO 01/57206 PCT/USO1/03504 37 linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In yet another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3'-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. Examples. The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention. The following examples demonstrate the selection and design of Antisense, hammerhead, DNAzyme, NCH, Amberzyme, Zinzyme, or G-Cleaver ribozyme molecules and binding/cleavage sites within Chk1 RNA. Nucleic acid inhibition of Chk1 target RNA Control of the cell cycle is one of the most highly orchestrated events in the cell. There is a great deal of interest in discovering the function of genes involved in mitotic checkpoint abrogation, since inhibition of these genes or activities of these gene products could sensitize cells to DNA damaging agents. In these studies, the cell cycle regulatory role of Chk1 (GeneBank Accession # AF016582 is investigated). In the fission yeast Schizosaccharonyces pombe, DNA damage by gamma irradiation or a chemical agent such as etoposide leads to activation of Chkl by phosphorylation. Chkl, also known as p56chkl, is a Wee 1-like protein kinase, which phosphorylates and inactivates Cdc25. Cdc25 is a phosphatase that acts directly on Cdc2. Chk1 is required for the DNA damage checkpoint, whereas the rad gene products are required for both S-M and DNA damage checkpoints. Wee 1 is also phosphorylated by Chk1 in vitro, also suggesting that Wee 1 is regulated by Chk1 in vivo and the resulting G2 delay is the result of maintaining Y15 WO 01/57206 PCT/USO1/03504 38 phosphorylation on Cdc2. In normal mammalian cells, DNA damage would lead to arrest at G1/S arrest via the p53 pathway, or G2/M arrest via the Cdc2/CyclinB pathway. Thus, p53- cells can remain viable following DNA damage because of the Cdc2/CyclinB arrest pathway. If the Cdc2/CyclinB mediated checkpoint is abrogated via inhibition of Weel and Myt1 by small molecule inhibitors in a p53- cell type, then viability is compromised. Chk1 has recently been cloned from mammalian cells. The Chkl protein is modified in response to DNA damage, and has been shown to bind and phosphorylate Cdc25A, Cdc25B and Cdc25C. The phosphorylation of Cdc25C prevents activation of the Cdc2/CyclinB complex and blocks entry into mitosis, thereby validating the inhibition of Chk1 as a target for nucleic acid based therapeutics. To address whether checkpoint kinases function redundantly during DNA replication and/or DNA damage checkpoint responses, applicant undertook an oligonucleotide-based approach to block Chkl gene function in a human cell line. HeLa cells lacking ChkI protein failed to maintain a G2 cell cycle arrest after etoposide or gamma radiation-induced DNA damaging treatments. Additionally, Chkl-defeicient cells failed to respond to the DNA replication inhibitor hydroxyurea. Based on these results, applicant concludes that the Chkl kinase plays an essential role in both the DNA replication and DNA damage checkpoint responses. These results also suggest the neither Chk2 nor C-TAK1 kinases function in these checkpoint responses to a significant level, at least in HeLa cells. Thus, Chkl is validated as an attractive therapeutic target for abrogating the G2 DNA damage checkpoint arrest; a situation that may selectively sensitize p53-deficient tumor cells to radiation or chemotherapy treatment. Example 1: Identification of Potential Target Sites in Human Chk1 RNA The sequence of human Chkl is screened for accessible sites using a computer-folding algorithm. Regions of the RNA are identified that do not form secondary folding structures. These regions contain potential ribozyme and/or antisense binding/cleavage sites. The sequences of these binding/cleavage sites are shown in Tables III-IX. Example 2: Selection of Enzymatic Nucleic Acid Cleavage Sites in Human Chk1 RNA Ribozyme target sites are chosen by analyzing sequences of Human Chk1 (Genbank accession number: AF016582) and prioritizing the sites on the basis of folding. Ribozymes are designed that could bind each target and are individually analyzed by computer folding (Christoffersen et al., 1994 J. Mol. Struck. Theochem, 311, 273; Jaeger et al., 1989, Proc. Natl. Acad. Sci. USA, 86, 7706) to assess whether the ribozyme sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular interactions between the binding arms and the catalytic core are eliminated from consideration. As noted below, varying WO 01/57206 PCT/USO1/03504 39 binding arm lengths can be chosen to optimize activity. Generally, at least 5 bases on each arm are able to bind to, or otherwise interact with, the target RNA. Example 3: Chemical Synthesis and Purification of Ribozymes and Antisense for Efficient Cleavage and/or blocking of Chk1 RNA Ribozymes and antisense constructs are designed to anneal to various sites in the RNA message. The binding arms of the ribozymes are complementary to the target site sequences described above, while the antisense constructs are fully complimentary to the target site sequences described above. The ribozymes and antisense constructs were chemically synthesized. The method of synthesis used followed the procedure for normal RNA synthesis as described above and in Usman et al., (1987 J Am. Chem. Soc., 109, 7845), Scaringe et al., (1990 Nucleic Acids Res., 18, 5433) and Wincott et al., supra, and made use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. The average stepwise coupling yields were typically >98%. Ribozymes and antisense constructs are also synthesized from DNA templates using bacteriophage T7 RNA polymerase (Milligan and Uhlenbeck, 1989, Methods Enzymol. 180, 51). Ribozymes and antisense constructs are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; see Wincott et al., supra; the totality of which is hereby incorporated herein by reference) and are resuspended in water. The sequences of the chemically synthesized ribozymes and antisense constructs used in this study are shown below in Table III-IX. Example 4: Ribozyme Cleavage of Chkl RNA Target in vitro Ribozymes targeted to the human Chk1 RNA are designed and synthesized as described above. These ribozymes can be tested for cleavage activity in vitro, for example, using the following procedure. The target sequences and the nucleotide location within the Chkl RNA are given in Tables III-IX. Cleavage Reactions: Full-length or partially full-length, internally-labeled target RNA for ribozyme cleavage assay is prepared by in vitro transcription in the presence of [a- 3 2 p] CTP, passed over a G 50 Sephadex@ column by spin chromatography and used as substrate RNA without further purification. Alternately, substrates are 5'- 3 2 P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed by pre-warming a 2X concentration of purified ribozyme in ribozyme cleavage buffer (50 mM Tris-HC1, pH 7.5 at 37*C, 10 mM MgCl2) and the cleavage reaction was initiated by adding the 2X ribozyme mix to an equal volume of substrate RNA (maximum of 1-5 nM) that was also pre-warmed in cleavage buffer.

WO 01/57206 PCT/USO1/03504 40 As an initial screen, assays are carried out for 1 hour at 370C using a final concentration of either 40 nM or 1 mM ribozyme, i.e., ribozyme excess. The reaction is quenched by the addition of an equal volume of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol after which the sample is heated to 95 0 C for 2 minutes, quick chilled and loaded onto a denaturing polyacrylamide gel. Substrate RNA and the specific RNA cleavage products generated by ribozyme cleavage are visualized on an autoradiograph of the gel. The percentage of cleavage is determined by Phosphor ImagerI quantitation of bands representing the intact substrate and the cleavage products. Example 5: Nucleic acid inhibition of Chkl target RNA in vivo Antisense nucleic acid molecules (GeneBlocsTM) targeted to the human Chkl RNA are designed and synthesized as described above. These nucleic acid molecules can be tested for cleavage activity in vivo, for example, using the following procedure. The target sequences and the nucleotide location within the Chkl RNA are given in Tables III-IX. Two formats were used to test the efficacy of nucleic acid reagents (GeneBlocsTM targeting Chkl. First, the reagents were tested on asynchronous HeLa cells, to determine the extent of RNA and protein inhibition. To demonstrate whether cells bypass the G2/M checkpoint, HeLa cells (p53-) are treated with etoposide to damage the DNA. Nocodazole and the potential checkpoint inhibitor are added 16 hours later, when all the cells should be arrested in G2. Nocodazole blocks cells from leaving mitosis, so if they have abrogated the checkpoint, the cells will be blocked in mitosis and appear "rounded" in shape. Other surrogate mitotic markers include decreased phosphorylation of cdc-2 at Thr14 and Tyrl5, phosphorylation of Myt-1, and phosphorylation of PP1. This study set out to determine whether inhibiting expression of the Chkl gene would allow the G2/M checkpoint to be bypassed after DNA damage, as well as determining if the presence of p53 influences the DNA-damage checkpoint response. Eight GeneBlocTM reagents (e.g.; see Table IX) were selected against the Chk1 cDNA target. RNA inhibition was measured after delivery of these reagents by GSV lipid (Glenn Research) to HeLa cells. Relative amounts of target RNA were measured versus actin using real time PCR monitoring of amplification (ABI 7700 Taqman@). The results are shown in Figure 6. The comparison is made to a mixture of 5 oligonucleotide sequences made to unrelated targets (GB-3) or to a randomized oligonucleotide control with the same overall length and chemistry, but randomly substituted at each position (GBC3.2). Primary and secondary lead reagents were chosen for the target and optimization performed. The optimal GSV lipid concentration was chosen after screening for RNA inhibition with oligonucleotides at 5 and 50 nM (Figure 7). After optimal lipid concentration was chosen, a RNA time-course of inhibition WO 01/57206 PCT/USO1/03504 41 was performed with the lead nucleic acid molecule (GeneBlocTM) (Figure 8). In addition, a cell plating format was tested for RNA inhibition. The use of a 96-well (5000 cells/well) versus six well (150,000 cells/well) plating density made no difference in the extent of RNA inhibition (Figure 9). The phenotypic assays require treatment with etoposide and nocodazole as described above, and RNA inhibition in this assay was also determined (Figure 10). The various treatments had essentially no effect on RNA levels. Optimization of delivery conditions were also performed in DLD-1 (p 5 3 -) (Figure 11) and MCF-7 (Figure 12) (p53+) cells. Similar levels of inhibition were observed when compared to HeLa cells at the optimal GSV concentration. Dose curves were also generated in HeLa cells with the two best lead nucleic acid molecules (Figure 13). IC50 values for both leads were in the 1-2 nM range. Similar IC50s were observed in DLD-1 and MCF-7 cells. Protein levels were assessed at 8, 24 and 32 hours after nucleic acid administration, as well as one to five days post delivery. The target protein was significantly reduced (80-90%) by 24 hours after nucleic acid administration and remained low (undetectable by western blot) until at least day 5. Application of nucleic acid inhibitors in the checkpoint abrogation assay resulted in the "rounding up" phenotype for the Chk1 target. Also, there is an increase in Myt 1 phosphorylation and a large increase in PP1 phosphorylation. There also appear to be decreases in phosphorylation of the Y15 and T14 residues on Cdc2, although this is not complete. Most importantly, this evidence demonstrates the role of Chkl in the G2/M checkpoint and suggests that inhibitors of Chk1 activity can be useful alone or in combination with DNA damaging agents in treatment of certain types of cancer. Indications Particular degenerative and disease states that can be associated with Chk1 expression modulation include but are not limited to cancers of the colon, rectum, lung, breast and prostate The present body of knowledge in Chk1 research indicates the need for methods to assay Chk1 activity and for compounds that can regulate Chk1 expression for research, diagnostic, and therapeutic use. Radiation and chemotherapeutic treatments are non-limiting examples of methods that can be combined with or used in conjunction with the nucleic acid molecules (e.g. ribozymes and antisense molecules) of the instant invention. Those skilled in the art will recognize that other drug compounds and therapies can be similarly be readily combined with the nucleic acid molecules of the instant invention (e.g. ribozymes and antisense molecules) are hence within the scope of the instant invention.

WO 01/57206 PCT/USO1/03504 42 Diagnostic uses The nucleic acid molecules of this invention (e.g., ribozymes) can be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of Chk1 RNA in a cell. The close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple ribozymes described in this invention, one can map nucleotide changes which are important to RNA structure and function in vitro, as well as in cells and tissues. Cleavage of target RNAs with ribozymes can be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combinational therapies (e.g., multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules). Other in vitro uses of ribozymes of this invention are well known in the art, and include detection of the presence of mRNAs associated with Chkl-related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a ribozyme using standard methodology. In a specific example, ribozymes which can cleave only wild-type or mutant forms of the target RNA are used for the assay. The first ribozyme is used to identify wild-type RNA present in the sample and the second ribozyme is used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA is cleaved by both ribozymes to demonstrate the relative ribozyme efficiencies in the reactions and the absence of cleavage of the "non-targeted" RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus, each analysis requires two ribozymes, two substrates and one unknown sample, which is combined into six reactions. The presence of cleavage products is determined using an RNAse protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (i.e., Chkl) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels will be adequate and will decrease the cost of the initial diagnosis. Higher mutant form to wild-type ratios are correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.

WO 01/57206 PCT/USO1/03504 43 Additional Uses Potential usefulness of sequence-specific enzymatic nucleic acid molecules of the instant invention might have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans et al., 1975 Ann. Rev. Biochem. 44:273). For example, the pattern of restriction fragments can be used to establish sequence relationships between two related RNAs, and large RNAs could be specifically cleaved to fragments of a size more useful for study. The ability to engineer sequence specificity of the enzymatic nucleic acid molecule is ideal for cleavage of RNAs of unknown sequence. Applicant has described the use of nucleic acid molecules to down-regulate gene expression of target genes in bacterial, microbial, fungal, viral, and eukaryotic systems including plant, or mammalian cells. All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually. One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims. It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of' and "consisting of' may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may WO 01/57206 PCT/US01/03504 44 be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims. In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group. Other embodiments are within the claims that follow.

WO 01/57206 PCT/USO1/03504 45 TABLE I Characteristics of naturally occurring ribozymes Group I Introns - Size: -150 to >1000 nucleotides. - Requires a U in the target sequence immediately 5' of the cleavage site. - Binds 4-6 nucleotides at the 5-side of the cleavage site. - Reaction mechanism: attack by the 3'-OH of guanosine to generate cleavage products with 3'-OH and 5'-guanosine. - Additional protein cofactors required in some cases to help folding and maintainance of the active structure. - Over 300 known members of this class. Found as an intervening sequence in Tetrahymena thermophila rRNA, fungal mitochondria, chloroplasts, phage T4, blue green algae, and others. - Major structural features largely established through phylogenetic comparisons, mutagenesis, and biochemical studies [ii]. - Complete kinetic framework established for one ribozyme [iiiv,v,vi]. - Studies of ribozyme folding and substrate docking underway [vii,vii,ix]. - Chemical modification investigation of important residues well established [x,xi]. - The small (4-6 nt) binding site may make this ribozyme too non-specific for targeted RNA cleavage, however, the Tetrahymena group I intron has been used to repair a "defective" beta-galactosidase message by the ligation of new beta galactosidase sequences onto the defective message [xii]. RNAse P RNA (M1 RNA) - Size: -290 to 400 nucleotides. e RNA portion of a ubiquitous ribonucleoprotein enzyme. - Cleaves tRNA precursors to form mature tRNA [xiii]. - Reaction mechanism: possible attack by M2+-OH to generate cleavage products with 3'-OH and 5'-phosphate.

WO 01/57206 PCT/US01/03504 46 - RNAse P is found throughout the prokaryotes and eukaryotes. The RNA subunit has been sequenced from bacteria, yeast, rodents, and primates. - Recruitment of endogenous RNAse P for therapeutic applications is possible through hybridization of an External Guide Sequence (EGS) to the target RNA [xivfxv] - Important phosphate and 2' OH contacts recently identified [xvixvii] Group II Introns - Size: >1000 nucleotides. e Trans cleavage of target RNAs recently demonstrated [xviiixix]. - Sequence requirements not fully determined. e Reaction mechanism: 2'-OH of an internal adenosine generates cleavage products with 3'-OH and a "lariat" RNA containing a 3'-5' and a 2'-5' branch point. - Only natural ribozyme with demonstrated participation in DNA cleavage [xx,xxi] in addition to RNA cleavage and ligation. - Major structural features largely established through phylogenetic comparisons [xxii]. - Important 2' OH contacts beginning to be identified [xxiii] - Kinetic framework under development [xxiv] Neurospora VS RNA - Size: -144 nucleotides. - Trans cleavage of hairpin target RNAs recently demonstrated [xxv]. - Sequence requirements not fully determined. - Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends. - Binding sites and structural requirements not fully determined. - Only 1 known member of this class. Found in Neurospora VS RNA. Hammerhead Ribozyme WO 01/57206 PCT/USO1/03504 47 (see text for references) * Size: ~13 to 40 nucleotides. e Requires the target sequence UH immediately 5' of the cleavage site. e Binds a variable number nucleotides on both sides of the cleavage site. - Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends. - 14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent. - Essential structural features largely defined, including 2 crystal structures [xxvi,xxvii] - Minimal ligation activity demonstrated (for engineering through in vitro selection) [xxviii] - Complete kinetic framework established for two or more ribozymes [xxix]. - Chemical modification investigation of important residues well established [xxx]. Hairpin Ribozyme - Size: -50 nucleotides. - Requires the target sequence GUC immediately 3' of the cleavage site. e Binds 4-6 nucleotides at the 5-side of the cleavage site and a variable number to the 3-side of the cleavage site. - Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends. - 3 known members of this class. Found in three plant pathogen (satellite RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory yellow mottle virus) which uses RNA as the infectious agent. - Essential structural features largely defined [xxxi,xxxii,xxxiii,xxxiv] - Ligation activity (in addition to cleavage activity) makes ribozyme amenable to engineering through in vitro selection [xxxv] - Complete kinetic framework established for one ribozyme [xxxvi]. - Chemical modification investigation of important residues begun [xxxvii,xxxviii].

WO 01/57206 PCT/USO1/03504 48 Hepatitis Delta Virus (HDV) Ribozyme e Size: -60 nucleotides. - Trans cleavage of target RNAs demonstrated [xxxix]. - Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required. Folded ribozyme contains a pseudoknot structure [xl]. - Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends. - Only 2 known members of this class. Found in human HDV. - Circular form of HDV is active and shows increased nuclease stability [x11] Michel, Francois; Westhof, Eric. Slippery substrates. Nat. Struct. Biol. (1994), 1(1), 5-7. Lisacek, Frederique; Diaz, Yolande; Michel, Francois. Automatic identification of group I intron cores in genomic DNA sequences. J. Mol. Biol. (1994), 235(4), 1206-17, iii. Herschlag, Daniel; Cech, Thomas R.. Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. 1. Kinetic description of the reaction of an RNA substrate complementary to the active site. Biochemistry (1990), 29(44), 10159-71. iv. Herschlag, Daniel; Cech, Thomas R.. Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. Biochemistry (1990), 29(44), 10172-80. v . Knitt, Deborah S.; Herschlag, Daniel. pH Dependencies of the Tetrahymena Ribozyme Reveal an Unconventional Origin of an Apparent pKa. Biochemistry (1996), 35(5), 1560-70. vi. Bevilacqua, Philip C.; Sugimoto, Naoki; Turner, Douglas H.. A mechanistic framework for the second step of splicing catalyzed by the Tetrahymena ribozyme. Biochemistry (1996), 35(2), 648-58. vii . Li, Yi; Bevilacqua, Philip C.; Mathews, David; Turner, Douglas H.. Thermodynamic and activation parameters for binding of a pyrene-labeled substrate by the Tetrahymena ribozyme: docking is not diffusion-controlled and is driven by a favorable entropy change. Biochemistry (1995), 34(44), 14394-9. viii . Banerjee, Aloke Raj; Turner, Douglas H.. The time dependence of chemical modification reveals slow steps in the folding of a group I ribozyme. Biochemistry (1995), 34(19), 6504-12. ix. Zarrinkar, Patrick P.; Williamson, James R.. The P9.1-P9.2 peripheral extension helps guide folding of the Tetrahymena ribozyme. Nucleic Acids Res. (1996), 24(5), 854-8. x . Strobel, Scott A.; Cech, Thomas R.. Minor groove recognition of the conserved G.cntdot.U pair at the Tetrahymena ribozyme reaction site. Science (Washington, D. C.) (1995), 267(5198), 675-9. xi. Strobel, Scott A.; Cech, Thomas R.. Exocycic Amine of the Conserved G.cntdot.U Pair at the Cleavage Site of the Tetrahymena Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization. Biochemistry (1996), 35(4), 1201-11. xii. Sullenger, Bruce A.; Cech, Thomas R.. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature (London) (1994), 371(6498), 619-22. xAfi. Robertson, H.D.; Altman, S.; Smith, J.D. J. Biol. Chem., 247 5243-5251 (1972). xiv. Forster, Anthony C.; Altman, Sidney. External guide sequences for an RNA enzyme. Science (Washington, D. C., 1883-) (1990), 249(4970), 783-6. xv. Yuan, Y.; Hwang, E. S.; Altman, S. Targeted cleavage of mRNA by human RNase P. Proc. Natl. Acad. Sci. USA (1992) 89, 8006-10.

WO 01/57206 PCT/US01/03504 49 xvi Harris, Michael E.; Pace, Norman R.. Identification of phosphates involved in catalysis by the ribozyme RNase P RNA. RNA (1995), 1(2), 210-18. xvii. Pan, Tao; Loria, Andrew; Zhong, Kun. Probing of tertiary interactions in RNA: 2'-hydroxyl-base contacts between the RNase P RNA and pre-tRNA. Proc. Natl. Acad. Sci. U. S. A. (1995), 92(26), 12510-14. xviii. Pyle, Anna Marie; Green, Justin B.. Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate. Biochemistry (1994), 33(9), 2716-25. xix. Michels, William J. Jr.; Pyle, Anna Marie. Conversion of a Group II Intron into a New Multiple Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships. Biochemistry (1995), 34(9), 2965-77. xx . Zimmerly, Steven; Guo, Huatao; Eskes, Robert; Yang, Jian; Perlman, Philip S.; Lambowitz, Alan M.. A group II intron RNA is a catalytic component of a DNA endonuclease involved in intron mobility. Cell (Cambridge, Mass.) (1995), 83(4), 529-38. xxi. Griffin, Edmund A., Jr.; Qin, Zhifeng; Michels, Williams J., Jr.; Pyle, Anna Marie. Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2' hydroxyl groups. Chem. Biol. (1995), 2(11), 761-70. xxii. Michel, Francois; Ferat, Jean Luc. Structure and activities of group II introns. Annu. Rev. Biochem. (1995), 64, 435-61. xxiii. Abramovitz, Dana L.; Friedman, Richard A.; Pyle, Anna Marie. Catalytic role of 2-hydroxyl groups within a group II intron active site. Science (Washington, D. C.) (1996), 271(5254), 1410-13. xxiv . Daniels, Danette L.; Michels, William J., Jr.; Pyle, Anna Marie. Two competing pathways for self splicing by group II introns: a quantitative analysis of in vitro reaction rates and products. J. Mol. Biol. (1996), 256(1), 31-49. xxv . Guo, Hans C. T.; Collins, Richard A.. Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme derived from Neurospora VS RNA. EMBO J. (1995), 14(2), 368-76. xxvi . Scott, W.G., Finch, J.T., AaronK. The crystal structure of an all RNA hammerhead ribozyme:Aproposed mechanism for RNA catalytic cleavage. Cell, (1995), 81, 991-1002. xxvii. McKay, Structure and function of the hammerhead ribozyme: an unfinished story. RNA, (1996), 2, 395-403. xxviii. Long, D., Uhlenbeck, 0., Hertel, K. Ligation with hammerhead ribozymes. US Patent No. 5,633,133. xxix Hertel, K.J., Herschlag, D., Uhlenbeck, 0. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry, (1994) 33, 3374-3385.Beigehnan, L., et al., Chemical modifications of hammerhead ribozymes. J. Biol. Chem., (1995) 270, 25702-25708. xxx . Beigelman, L., et al., Chemical modifications of hammerhead ribozymes. J. Biol. Chem., (1995) 270, 25702-25708. xxxi . Hampel, Arnold; Tritz, Richard; Hicks, Margaret; Cruz, Phillip. 'Hairpin' catalytic RNA model: evidence for helixes and sequence requirement for substrate RNA. Nucleic Acids Res. (1990), 18(2), 299 304. xxxii. Chowrira, Bharat M.; Berzal-Herranz, Alfredo; Burke, John M.. Novel guanosine requirement for catalysis by the hairpin ribozyme. Nature (London) (1991), 354(6351), 320-2. xxxiii . Berzal-Herranz, Alfredo; Joseph, Simpson; Chowrira, Bharat M.; Butcher, Samuel E.; Burke, John M.. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO J. (1993), 12(6), 2567-73. xxxiv . Joseph, Simpson; Berzal-Herranz, Alfredo; Chowrira, Bharat M.; Butcher, Samuel E.. Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates. Genes Dev. (1993), 7(1), 130-8. xxxv . Berzal-Herranz, Alfredo; Joseph, Simpson; Burke, John M.. In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions. Genes Dev. (1992), 6(1), 129-34. xxxvi . Hegg, Lisa A.; Fedor, Martha J.. Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes. Biochemistry (1995), 34(48), 15813-28. xxxvii. Grasby, Jane A.; Mersmann, Karin; Singh, Mohinder; Gait, Michael J.. Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA. Biochemistry WO 01/57206 PCT/USO1/03504 50 (1995), 34(12), 4068-76. Xxxvii. Schmidt, Sabine; Beigelman, Leonid; Karpeisky, Alexander; Usman, Nassim; Sorensen, Ulrik S.; Gait, Michael J.. Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure. Nucleic Acids Res. (1996), 24(4), 573-81. xxxix. Perrotta, Anne T.; Been, Michael D.. Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis .delta. virus RNA sequence. Biochemistry (1992), 31(1), 16-21. x1. Perrotta, Anne T.; Been, Michael D.. A pseudoknot-like structure required for efficient self cleavage of hepatitis delta virus RNA. Nature (London) (1991), 350(6317), 434-6. x . Puttaraju, M.; Perrotta, Anne T.; Been, Michael D.. A circular trans-acting hepatitis delta virus ribozyme. Nucleic Acids Res. (1993), 21(18), 4253-8.

WO 01/57206 PCT/USO1/03504 51 Table II: A. 2.5 pmol Synthesis Cycle ABI 394 i strument Reagent Equivalents Amount Wait Time* DNA Wait Time* 2'-0-methyl Wait Time*RNA Phosphoramidites 6.5 163 pL 45 sec 2.5 min 7.5 min S-Ethyl Tetrazole 23.8 238 pL 45 sec 2.5 min 7.5 min Acetic Anhydride 100 233 pL 5 sec 5 sec 5 sec N-Methyl 186 233 pL 5 sec 5 sec 5 sec Imidazole TCA 176 2.3 mL 21 sec 21 sec 21 sec Iodine 11.2 1.7 mL 45 sec 45sec 45 sec Beaucage 12.9 645 pL 100sec 300 sec 300 sec Acetonitrile NA 6.67 mL NA NA NA B. 0.2 pmol Synthesis Cycle ABI 394 Instrument Reagent Equivalents Amount Wait Time* DNA Wait Time* 2'-0-methyl Wait Time*RNA Phosphoramidites 15 31 pL 45 sec 233 sec 465 sec S-Ethyl Tetrazole 38.7 31 pL 45 sec 233 min 465 sec Acetic Anhydride 655 124 pL 5 sec 5 sec 5 sec N-Methyl 1245 124 pL 5 sec 5 sec 5 sec Imidazole TCA 700 732pL 10sec 10sec 10sec Iodine 20.6 244 pL 15 sec 15 sec 15 sec Beaucage 7.7 232 pL 100 sec 300 sec 300 sec Acetonitrile NA 2.64 mL NA NA NA C. 0.2 pmol Synthesis Cycle 96 well Instrument Reagent Equivalents:DNA/ Amount: DNA/2'-0- Wait Time* DNA Wait Time* 2'-0- Wait Time* Ribo 2'-O-methyl/Ribo methyl/Ribo methyl Phosphoramidites 22/33/66 40/60/120 pL 60 sec 180 sec 360sec S-Ethyl Tetrazole 70/105/210 40/60/120 pL 60 sec 180 min 360 sec Acetic Anhydride 265/265/265 50/50/50 pL 10 sec 10 sec 10 sec N-Methyl 502/502/502 50/50/50 pL 10 sec 10 sec 10 sec Imidazole TCA 238/475/475 250/500/500 pL 15 sec 15 sec 15 sec Iodine 6.8/6.8/6.8 80/80/80 pL 30 sec 30 sec 30 sec Beaucage 34/51/51 80/120/120 100 sec 200 sec 200 sec Acetonitrile NA 1150/1150/1150 pL NA NA NA 5 . Wait time does not include contact time during delivery.

WO 01/57206 PCT/USO1/03504 52 Table III: Human Chk1 Hammerhead Ribozyme and Substrate Sequence Pos Substrate Seq ID Ribozyme Rz Seq ID 12 CGGACAGU C CGCCGAGG 1 CCUCGGCG CUGAUGAG GCCGUUAGGC CGAA ACUGUCCG 1423 25 GAGGUGCU C GGUGGAGU 2 ACUCCACC CUGAUGAG GCCGUUAGGC CGAA AGCACCUC 1424 34 GGUGGAGU C AUGGCAGU 3 ACUGCCAU CUGAUGAG GCCGUUAGGC CGAA ACUCCACC 1425 48 AGUGCCCU U UGUGGAAG 4 CUUCCACA CUGAUGAG GCCGUUAGGC CGAA AGGGCACU 1426 49 GUGCCCUU U GUGGAAGA 5 UCUUCCAC CUGAUGAG GCCGUUAGGC CGAA AAGGGCAC 1427 66 CUGGGACU U GGUGCAAA 6 UUUGCACC CUGAUGAG GCCGUUAGGC CGAA AGUCCCAG 1428 93 AGGUGCCU A UGGAGAAG 7 CUUCUCCA CUGAUGAG GCCGUUAGGC CGAA AGGCACCU 1429 103 GGAGAAGU U CAACULUGC 8 GCAAGUUG CUGAUGAG GCCGUUAGGC CGAA ACUUCUCC 1430 104 GAGAAGUU C AACUUGCU 9 AGCAAGUU CUGAUGAG GCCGUUAGGC CGAA AACUUCUC 1431 109 GUUCAACU U GCUGUGAA 10 UUCACAGC CUGAUGAG GCCGUUAGGC CGAA AGUUGAAC 1432 119 CUGUGAAU A GAGUAACU 11 AGUUACUC CUGAUGAG GCCGUUAGGC CGAA AUUCACAG 1433 124 AAUAGAGU A ACUGAAGA 12 UCUUCAGU CUGAUGAG GCCGUUAGGC CGAA ACUCUAUU 1434 139 GAAGCAGU C GCAGUGAA 13 UUCACUGC CUGAUGAG GCCGUUAGGC CGAA ACUGCUUC 1435 151 GUGAAGAU U GUAGAUAU 14 AUAUCUAC CUGAUGAG GCCGUUAGGC CGAA AUCUUCAC 1436 154 AAGAUUGU A GAUAUGAA 15 UUCAUAUC CUGAUGAG GCCGUUAGGC CGAA ACAAUCUU 1437 158 UUGUAGAU A UGAAGCGU 16 ACGCUUCA CUGAUGAG GCCGUUAGGC CGAA AUCUACAA 1438 172 CGUGCCGU A GACUGUCC 17 GGACAGUC CUGAUGAG GCCGUUAGGC CGAA ACGGCACG 1439 179 UAGACUGU C CAGAAAAU 18 AUUUUCUG CUGAUGAG GCCGUUAGGC CGAA ACAGUCUA 1440 188 CAGAAAAU A UUAAGAAA 19 UUUCUUAA CUGAUGAG GCCGUUAGGC CGAA AUUUUCUG 1441 190 GAAAAUAU U AAGAAAGA 20 UCUUUCUU CUGAUGAG GCCGUUAGGC CGAA AUAUUUUC 1442 191 AAAAUAUU A AGAAAGAG 21 CUCUUUCU CUGAUGAG GCCGUUAGGC CGAA AAUAUUUU 1443 202 AAAGAGAU C UGUAUCAA 22 UUGAUACA CUGAUGAG GCCGUUAGGC CGAA AUCUCUUU 1444 206 AGAUCUGU A UCAAUAAA 23 UUUAUUTGA CUGAUGAG GCCGUUAGGC CGAA ACAGAUCU 1445 208 AUCUGUAU C AAUAAAAU 24 AUUUUAUU CUGAUGAG GCCGUUAGGC CGAA AUACAGAU 1446 212 GUAUCAAU A AAAUGCUA 25 UAGCAUUU CUGAUGAG GCCGUUAGGC CGAA AUUGAUAC 1447 220 AAAAUGCU A AAUCAUGA 26 UCAUGAUU CUGAUGAG GCCGUUAGGC CGAA AGCAUUUU 1448 224 UGCUAAAU C AUGAAAAU 27 AUUUUCAU CUGAUGAG GCCGUUAGGC CGAA AUUUAGCA 1449 235 GAAAAUGU A GUAAAAUU 28 AAUUUUAC CUGAUGAG GCCGUUAGGC CGAA ACAUUUUC 1450 238 AAUGUAGU A AAAUUCUA 29 UAGAAUUU CUGAUGAG GCCGUUAGGC CGAA ACUACAUU 1451 243 AGUAAAAU U CUAUGGUC 30 GACCAUAG CUGAUGAG GCCGUUAGGC CGAA AUUUUACU 1452 244 GUAAAAUU C UAUGGUCA 31 UGACCAUA CUGAUGAG GCCGUUAGGC CGAA AAUUUUAC 1453 246 AAAAUUCU A UGGUCACA 32 UGUGACCA CUGAUGAG GCCGUUAGGC CGAA AGAAUUUU 1454 251 UCUAUGGU C ACAGGAGA 33 UCUCCUGU CUGAUGAG GCCGUUAGGC CGAA ACCAUAGA 1455 269 AAGGCAAU A UCCAAUAU 34 AUAUUGGA CUGAUGAG GCCGUUAGGC CGAA AUUGCCUU 1456 271 GGCAAUAU C CAAUAUUU 35 AAAUAUUG CUGAUGAG GCCGUUAGGC CGAA AUAUUGCC 1457 276 UAUCCAAU A UUUAUUUC 36 GAAAUAAA CUGAUGAG GCCGUUAGGC CGAA AUUGGAUA 1458 278 UCCAAUAU U UAUUUCUG 37 CAGAAAUA CUGAUGAG GCCGUUAGGC CGAA AUAUUGGA 1459 279 CCAAUAUU U AUUUCUGG 38 CCAGAAAU CUGAUGAG GCCGUUAGGC CGAA AAUAUUGG 1460 280 CAAUAUUU A UUUCUGGA 39 UCCAGAAA CUGAUGAG GCCGUUAGGC CGAA AAAUAUUG 1461 282 AUAUUUAU U UCUGGAGU 40 ACUCCAGA CUGAUGAG GCCGUUAGGC CGAA AUAAAUAU 1462 283 UAUUUAUU U CUGGAGUA 41 UACUCCAG CUGAUGAG GCCGUUAGGC CGAA AAUAAAUA 1463 284 AUTUAUUU C UGGAGUAC 42 GUACUCCA CUGAUGAG GCCGUUAGGC CGAA AAAUAAAU 1464 291 UCUGGAGU A CUGUAGUG 43 CACUACAG CUGAUGAG GCCGUUAGGC CGAA ACUCCAGA 1465 296 AGUACUGU A GUGGAGGA 44 UCCUCCAC CUGAUGAG GCCGUUAGGC CGAA ACAGUACU 1466 310 GGAGAGCU U UUUGACAG 45 CUGUCAAA CUGAUGAG GCCGUUAGGC CGAA AGCUCUCC 1467 311 GAGAGCUU U UUGACAGA 46 UCUGUCAA CUGAUGAG GCCGUUAGGC CGAA AAGCUCUC 1468 WO 01/57206 PCT/USO1/03504 53 312 AGAGCUUU U UGACAGAA 47 UJCUGUCA CUGAUGAG GCCGUUAGGC CGAA AAAGCUCU 1469 313 GAGCUUUU U GACAGAAU 48 AUUCUGUC CUGAUGAG GCCGUUAGGC CGAA AAAAGCUC 1470 322 GACAGAAU A GAGCCAGA 49 UCUGGCUC CUGAUGAG GCCGUUAGGC CGAA AUUCUGUC 1471 334 CCAGACAU A GGCAUGCC 50 GGCAUGCC CUGAUGAG GCCGUUAGGC CGAA AUGUCUGG 1472 356 CAGAUGCU C AGAGAUUC 51 GAAUCUCU CUGAUGAG GCCGUUAGGC CGAA AGCAUCUG 1473 363 UCAGAGAU U CUUCCAUC 52 GAUGGAAG CUGAUGAG GCCGUUAGGC CGAA AUCUCUGA 1474 364 CAGAGAUU C UUCCAUCA 53 UGAUGGAA CUGAUGAG GCCGUUAGGC CGAA AAUCUCUG 1475 366 GAGAUUCU U CCAUCAAC 54 GUUGAUGG CUGAUGAG GCCGUUAGGC CGAA AGAAUCUC 1476 367 AGAUUCUU C CAUCAACU 55 AGUUGAUG CUGAUGAG GCCGUUAGGC CGAA AAGAAUCU 1477 371 UCUUCCAU C AACUCAUG 56 CAUGAGUU CUGAUGAG GCCGUUAGGC CGAA AUGGAAGA 1478 376 CAUCAACU C AUGGCAGG 57 CCUGCCAU CUGAUGAG GCCGUUAGGC CGAA AGUUGAUG 1479 391 GGGGUGGU U UAUCUGCA 58 UGCAGAUA CUGAUGAG GCCGUUAGGC CGAA ACCACCCC 1480 392 GGGUGGUU U AUCUGCAU 59 AUGCAGAU CUGAUGAG GCCGUUAGGC CGAA AACCACCC 1481 393 GGUGGUUU A UCUGCAUG 60 CAUGCAGA CUGAUGAG GCCGUUAGGC CGAA AAACCACC 1482 395 UGGUUUAU C UGCAUGGU 61 ACCAUGCA CUGAUGAG GCCGUUAGGC CGAA AUAAACCA 1483 404 UGCAUGGU A UUGGAAUA 62 UAUUCCAA CUGAUGAG GCCGUUAGGC CGAA ACCAUGCA 1484 406 CAUGGUAU U GGAAUAAC 63 GUUAUUCC CUGAUGAG GCCGUUAGGC CGAA AUACCAUG 1485 412 AUUGGAAU A ACUCACAG 64 CUGUGAGU CUGAUGAG GCCGUUAGGC CGAA AUUCCAAU 1486 416 GAAUAACU C ACAGGGAU 65 AUCCCUGU CUGAUGAG GCCGUUAGGC CGAA AGUUAUUC 1487 425 ACAGGGAU A UUAAACCA 66 UGGUUUAA CUGAUGAG GCCGUUAGGC CGAA AUCCCUGU 1488 427 AGGGAUAU U AAACCAGA 67 UCUGGUUU CUGAUGAG GCCGUUAGGC CGAA AUAUCCCU 1489 428 GGGAUAUU A AACCAGAA 68 UUCUGGUU CUGAUGAG GCCGUUAGGC CGAA AAUAUCCC 1490 440 CAGAAAAU C UUCUGUUG 69 CAACAGAA CUGAUGAG GCCGUUAGGC CGAA AUUUUCUG 1491 442 GAAAAUCU U CUGUUGGA 70 UCCAACAG CUGAUGAG GCCGUUAGGC CGAA AGAUUUUC 1492 443 AAAAUCUU C UGUUGGAU 71 AUCCAACA CUGAUGAG GCCGUUAGGC CGAA AAGAUUUU 1493 447 UCUUCUGU U GGAUGAAA 72 UUUCAUCC CUGAUGAG GCCGUUAGGC CGAA ACAGAAGA 1494 461 AAAGGGAU A ACCUCAAA 73 UUUGAGGU CUGAUGAG GCCGUUAGGC CGAA AUCCCUUU 1495 466 GAUAACCU C AAAAUCUC 74 GAGAUUUU CUGAUGAG GCCGUUAGGC CGAA AGGUUAUC 1496 472 CUCAAAAU C UCAGACUU 75 AAGUCUGA CUGAUGAG GCCGUUAGGC CGAA AUUUGAG 1497 474 CAAAAUCU C AGACUUUG 76 CAAAGUCU CUGAUGAG GCCGUUAGGC CGAA AGAUUUUG 1498 480 CUCAGACU U UGGCUUGG 77 CCAAGCCA CUGAUGAG GCCGUUAGGC CGAA AGUCUGAG 1499 481 UCAGACUU U GGCUUGGC 78 GCCAAGCC CUGAUGAG GCCGUUAGGC CGAA AAGUCUGA 1500 486 CUUUGGCU U GGCAACAG 79 CUGUUGCC CUGAUGAG GCCGUUAGGC CGAA AGCCAAAG 1501 496 GCAACAGU A UUUCGGUA 80 UACCGAAA CUGAUGAG GCCGUUAGGC CGAA ACUGUUGC 1502 498 AACAGUAU U UCGGUAUA 81 UAUACCGA CUGAUGAG GCCGUUAGGC CGAA AUACUGUU 1503 499 ACAGUAUU U CGGUAUAA 82 UUAUACCG CUGAUGAG GCCGUUAGGC CGAA AAUACUGU 1504 500 CAGUAUUU C GGUAUAAU 83 AUUAUACC CUGAUGAG GCCGUUAGGC CGAA AAAUACUG 1505 504 AUUUCGGU A UAAUAAUC 84 GAUUAUUA CUGAUGAG GCCGUUAGGC CGAA ACCGAAAU 1506 506 UUCGGUAU A AUAAUCGU 85 ACGAUUAU CUGAUGAG GCCGUUAGGC CGAA AUACCGAA 1507 509 GGUAUAAU A AUCGUGAG 86 CUCACGAU CUGAUGAG GCCGUUAGGC CGAA AUUAUACC 1508 512 AUAAUAAU C GUGAGCGU 87 ACGCUCAC CUGAUGAG GCCGUUAGGC CGAA AUUAUUAU 1509 521 GUGAGCGU U UGUUGAAC 88 GUUCAACA CUGAUGAG GCCGUUAGGC CGAA ACGCUCAC 1510 522 UGAGCGUU U GUUGAACA 89 UGUUCAAC CUGAUGAG GCCGUUAGGC CGAA AACGCUCA 1511 525 GCGUUUGU U GAACAAGA 90 UCUUGUUC CUGAUGAG GCCGUUAGGC CGAA ACAAACGC 1512 542 UGUGUGGU A CUUUACCA 91 UGGUAAAG CUGAUGAG GCCGUUAGGC CGAA ACCACACA 1513 545 GUGGUACU U UACCAUAU 92 AUAUGGUA CUGAUGAG GCCGUUAGGC CGAA AGUACCAC 1514 546 UGGUACUU U ACCAUAUG 93 CAUAUGGU CUGAUGAG GCCGUUAGGC CGAA AAGUACCA 1515 547 GGUACUUU A CCAUAUGU 94 ACAUAUGG CUGAUGAG GCCGUUAGGC CGAA AAAGUACC 1516 552 UUUACCAU A UGUUGCUC 95 GAGCAACA CUGAUGAG GCCGUUAGGC CGAA AUGGUAAA 1517 WO 01/57206 PCT/USO1/03504 54 556 CCAUAUGU U GCUCCAGA 96 UCUGGAGC CUGAUGAG GCCGUUAGGC CGAA ACAUAUGG 1518 560 AUGUUGCU C CAGAACUU 97 AAGUUCUG CUGAUGAG GCCGUUAGGC CGAA AGCAACAU 1519 568 CCAGAACU U CUGAAGAG 98 CUCUUCAG CUGAUGAG GCCGUUAGGC CGAA AGUUCUGG 1520 569 CAGAACUU C UGAAGAGA 99 UCUCUUCA CUGAUGAG GCCGUUAGGC CGAA AAGUUCUG 1521 585 AAGAGAAU U UCAUGCAG 100 CUGCAUGA CUGAUGAG GCCGUUAGGC CGAA AUUCUCUU 1522 586 AGAGAAUU U CAUGCAGA 101 UCUGCAUG CUGAUGAG GCCGUUAGGC CGAA AAUUCUCU 1523 587 GAGAAUUU C AUGCAGAA 102 UUCUGCAU CUGAUGAG GCCGUUAGGC CGAA AAAUTCUC 1524 601 GAACCAGU U GAUGUUUG 103 CAAACAUC CUGAUGAG GCCGUUAGGC CGAA ACUGGUUC 1525 607 GUUGAUGU U UGGUCCUG 104 CAGGACCA CUGAUGAG GCCGUUAGGC CGAA ACAUCAAC 1526 608 UUGAUGUU U GGUCCUGU 105 ACAGGACC CUGAUGAG GCCGUUAGGC CGAA AACAUCAA 1527 612 UGUUUGGU C CUGUGGAA 106 UUCCACAG CUGAUGAG GCCGUUAGGC CGAA ACCAAACA 1528 622 UGUGGAAU A GUACUJAC 107 GUAAGUAC CUGAUGAG GCCGUJAGGC CGAA AUJCCACA 1529 625 GGAAUAGU A CUUACUGC 108 GCAGUAAG CUGAUGAG GCCGUUAGGC CGAA ACUAUUCC 1530 628 AUAGUACU U ACUGCAAU 109 AUGCAGU CUGAUGAG GCCGUUAGGC CGAA AGUACUAU 1531 629 UAGUACUU A CUGCAAUG 110 CAUUGCAG CUGAUGAG GCCGUUAGGC CGAA AAGUACUA 1532 640 GCAAUGCU C GCUGGAGA 111 UCUCCAGC CUGAUGAG GCCGUUAGGC CGAA AGCAUUGC 1533 651 UGGAGAAU U GCCAUGGG 112 CCCAUGGC CUGAUGAG GCCGUTJAGGC CGAA AUUCUCCA 1534 680 ACAGCUGU C AGGAGUAU 113 AUACUCCU CUGAUGAG GCCGUUAGGC CGAA ACAGCUGU 1535 687 UCAGGAGU A UUCUGACU 114 AGUCAGAA CUGAUGAG GCCGUUAGGC CGAA ACUCCUGA 1536 689 AGGAGUAU U CUGACUGG 115 CCAGUCAG CUGAUGAG GCCGUUAGGC CGAA AUACUCCU 1537 690 GGAGUAUU C UGACUGGA 116 UCCAGUCA CUGAUGAG GCCGUUAGGC CGAA AAUACUCC 1538 714 AAAAACAU A CCUCAACC 117 GGUUGAGG CUGAUGAG GCCGUUAGGC CGAA AUGUUUUU 1539 718 ACAUACCU C AACCCUUG 118 CAAGGGUU CUGAUGAG GCCGUUAGGC CGAA AGGUAUGU 1540 725 UCAACCCU U GGAAAAAA 119 UUUUUCC CUGAUGAG GCCGUUAGGC CGAA AGGGUUGA 1541 736 AAAAAAAU C GAUUCUGC 120 GCAGAAUC CUGAUGAG GCCGUUAGGC CGAA AUUUUUUU 1542 740 AAAUCGAU U CUGCUCCU 121 AGGAGCAG CUGAUGAG GCCGUUAGGC CGAA AUCGAUUU 1543 741 AAUCGAUU C UGCUCCUC 122 GAGGAGCA CUGAUGAG GCCGUUAGGC CGAA AAUCGAUU 1544 746 AUUCUGCU C CUCUAGCU 123 AGCUAGAG CUGAUGAG GCCGUUAGGC CGAA AGCAGAAU 1545 749 CUGCUCCU C UAGCUCUG 124 CAGAGCUA CUGAUGAG GCCGUUAGGC CGAA AGGAGCAG 1546 751 GCUCCUCU A GCUCUGCU 125 AGCAGAGC CUGAUGAG GCCGUUAGGC CGAA AGAGGAGC 1547 755 CUCUAGCU C UGCUGCAU 126 AUGCAGCA CUGAUGAG GCCGUUAGGC CGAA AGCUAGAG 1548 764 UGCUGCAU A AAAUCUUA 127 UAAGAUUU CUGAUGAG GCCGUUAGGC CGAA AUGCAGCA 1549 769 CAUAAAAU C UUAGUUGA 128 UCAACUAA CUGAUGAG GCCGUUAGGC CGAA AUUUUAUG 1550 771 UAAAAUCU U AGUUGAGA 129 UCUCAACU CUGAUGAG GCCGUUAGGC CGAA AGAUUUUA 1551 772 AAAAUCUU A GUUGAGAA 130 UUCUCAAC CUGAUGAG GCCGUUAGGC CGAA AAGAUUUU 1552 775 AUCUUAGU U GAGAAUCC 131 GGAUUCUC CUGAUGAG GCCGUUAGGC CGAA ACUAAGAU 1553 782 UUGAGAAU C CAUCAGCA 132 UGCUGAUG CUGAUGAG GCCGUUAGGC CGAA AUUCUCAA 1554 786 GAAUCCAU C AGCAAGAA 133 UUCUUGCU CUGAUGAG GCCGUUAGGC CGAA AUGGAUUC 1555 796 GCAAGAAU U ACCAUUCC 134 GGAAUGGU CUGAUGAG GCCGUUAGGC CGAA AUUCUUGC 1556 797 CAAGAAUU A CCAUUCCA 135 UGGAAUGG CUGAUGAG GCCGUUAGGC CGAA AAUUCUUG 1557 802 AUUACCAU U CCAGACAU 136 AUGUCUGG CUGAUGAG GCCGUUAGGC CGAA AUGGUAAU 1558 803 UUACCAUU C CAGACAUC 137 GAUGUCUG CUGAUGAG GCCGUUAGGC CGAA AAUGGUAA 1559 811 CCAGACAU C AAAAAAGA 138 UCUUUUUU CUGAUGAG GCCGUUAGGC CGAA AUGUCUGG 1560 821 AAAAAGAU A GAUGGUAC 139 GUACCAUC CUGAUGAG GCCGUUAGGC CGAA AUCUUUUU 1561 828 UAGAUGGU A CAACAAAC 140 GUUUGUUG CUGAUGAG GCCGUUAGGC CGAA ACCAUCUA 1562 841 AAACCCCU C AAGAAAGG 141 CCUUUCUU CUGAUGAG GCCGUUAGGC CGAA AGGGGUUU 1563 868 CCCCGAGU C ACUUCAGG 142 CCUGAAGU CUGAUGAG GCCGUUAGGC CGAA ACUCGGGG 1564 872 GAGUCACU U CAGGUGGU 143 ACCACCUG CUGAUGAG GCCGUUAGGC CGAA AGUGACUC 1565 873 AGUCACUU C AGGUGGUG 144 CACCACCU CUGAUGAG GCCGUUAGGC CGAA AAGUGACU 1566 WO 01/57206 PCT/USO1/03504 55 885 UGGUGUGU C AGAGUCUC 145 GAGACUCU CUGAUGAG GCCGUUAGGC CGAA ACACACCA 1567 891 GUCAGAGU C UCCCAGUG 146 CACUGGGA CUGAUGAG GCCGUUAGGC CGAA ACUCUGAC 1568 893 CAGAGUCU C CCAGUGGA 147 UCCACUGG CUGAUGAG GCCGUUAGGC CGAA AGACUCUG 1569 903 CAGUGGAU U UUCUAAGC 148 GCUUAGAA CUGAUGAG GCCGUUAGGC CGAA AUCCACUG 1570 904 AGUGGAUU U UCUAAGCA 149 UGCUUAGA CUGAUGAG GCCGUUAGGC CGAA AAUCCACU 1571 905 GUGGAUUU U CUAAGCAC 150 GUGCUUAG CUGAUGAG GCCGUUAGGC CGAA AAAUCCAC 1572 906 UGGAUUUU C UAAGCACA 151 UGUGCUUA CUGAUGAG GCCGUUAGGC CGAA AAAAUCCA 1573 908 GAUUUUCU A AGCACAUU 152 AAUGUGCU CUGAUGAG GCCGUUAGGC CGAA AGAAAAUC 1574 916 AAGCACAU U CAAUCCAA 153 UUGGAUUG CUGAUGAG GCCGUUAGGC CGAA AUGUGCUU 1575 917 AGCACAUU C AAUCCAAU 154 AUUGGAUU CUGAUGAG GCCGUUAGGC CGAA AAUGUGCU 1576 921 CAUUCAAU C CAAUUUGG 155 CCAAAUUG CUGAUGAG GCCGUUAGGC CGAA AUUGAAUG 1577 926 AAUCCAAU U UGGACUUC 156 GAAGUCCA CUGAUGAG GCCGUUAGGC CGAA AUUGGAUU 1578 927 AUCCAAUU U GGACUUCU 157 AGAAGUCC CUGAUGAG GCCGUUAGGC CGAA AAUUGGAU 1579 933 UTUGGACU U CUCUCCAG 158 CUGGAGAG CUGAUGAG GCCGUUAGGC CGAA AGUCCAAA 1580 934 UUGGACUU C UCUCCAGU 159 ACUGGAGA CUGAUGAG GCCGUUAGGC CGAA AAGUCCAA 1581 936 GGACUUCU C UCCAGUAA 160 UUACUGGA CUGAUGAG GCCGUUAGGC CGAA AGAAGUCC 1582 938 ACUUCUCU C CAGUAAAC 161 GUUUACUG CUGAUGAG GCCGUUAGGC CGAA AGAGAAGU 1583 943 UCUCCAGU A AACAGUGC 162 GCACUGUU CUGAUGAG GCCGUUAGGC CGAA ACUGGAGA 1584 953 ACAGUGCU U CUAGUGAA 163 UUCACUAG CUGAUGAG GCCGUUAGGC CGAA AGCACUGU 1585 954 CAGUGCUU C UAGUGAAG 164 CUUCACUA CUGAUGAG GCCGUUAGGC CGAA AAGCACUG 1586 956 GUGCUUCU A GUGAAGAA 165 UUCUUCAC CUGAUGAG GCCGUUAGGC CGAA AGAAGCAC 1587 975 UGUGAAGU A CUCCAGUU 166 AACUGGAG CUGAUGAG GCCGUUAGGC CGAA ACUUCACA 1588 978 GAAGUACU C CAGUIUCUC 167 GAGAACUG CUGAUGAG GCCGUUAGGC CGAA AGUACUUC 1589 983 ACUCCAGU U CUCAGCCA 168 UGGCUGAG CUGAUGAG GCCGUUAGGC CGAA ACUGGAGU 1590 984 CUCCAGUU C UCAGCCAG 169 CUGGCUGA CUGAUGAG GCCGUUAGGC CGAA AACUGGAG 1591 986 CCAGUUCU C AGCCAGAA 170 UUCUGGCU CUGAUGAG GCCGUUAGGC CGAA AGAACUGG 1592 1007 GCACAGGU C UUUCCUUA 171 UAAGGAAA CUGAUGAG GCCGUUAGGC CGAA ACCUGUGC 1593 1009 ACAGGUCU U UCCUUAUG 172 CAUAAGGA CUGAUGAG GCCGUUAGGC CGAA AGACCUGU 1594 1010 CAGGUCUU U CCUUAUGG 173 CCAUAAGG CUGAUGAG GCCGUUAGGC CGAA AAGACCUG 1595 1011 AGGUCUUU C CUUAUGGG 174 CCCAUAAG CUGAUGAG GCCGUUAGGC CGAA AAAGACCU 1596 1014 UCUUUCCU U AUGGGAUA 175 UAUCCCAU CUGAUGAG GCCGUUAGGC CGAA AGGAAAGA 1597 1015 CUUUCCUU A UGGGAUAC 176 GUAUCCCA CUGAUGAG GCCGUU3AGGC CGAA AAGGAAAG 1598 1022 UAUGGGAU A CCAGCCCC 177 GGGGCUGG CUGAUGAG GCCGUUAGGC CGAA AUCCCAUA 1599 1032 CAGCCCCU C AUACAUUG 178 CAAUGUAU CUGAUGAG GCCGUUAGGC CGAA AGGGGCUG 1600 1035 CCCCUCAU A CAUUGAUA 179 UAUCAAUG CUGAUGAG GCCGUUAGGC CGAA AUGAGGGG 1601 1039 UCAUACAU U GAUAAAUU 180 AAUUUAUC CUGAUGAG GCCGUUAGGC CGAA AUGUAUGA 1602 1043 ACAUUGAU A AAUUGGUA 181 UACCAAUU CUGAUGAG GCCGUUAGGC CGAA AUCAAUGU 1603 1047 UGAUAAAU U GGUACAAG 182 CUUGUACC CUGAUGAG GCCGUUAGGC CGAA AUUUAUCA 1604 1051 AAAUUGGU A CAAGGGAU 183 AUCCCUUG CUGAUGAG GCCGUUAGGC CGAA ACCAAUUU 1605 1060 CAAGGGAU C AGCUUUUC 184 GAAAAGCU CUGAUGAG GCCGUUAGGC CGAA AUCCCUUG 1606 1065 GAUCAGCU U UUCCCAGC 185 GCUGGGAA CUGAUGAG GCCGUUAGGC CGAA AGCUGAUC 1607 1066 AUCAGCUU U UCCCAGCC 186 GGCUGGGA CUGAUGAG GCCGUUAGGC CGAA AAGCUGAU 1608 1067 UCAGCUUU U CCCAGCCC 187 GGGCUGGG CUGAUGAG GCCGUUAGGC CGAA AAAGCUGA 1609 1068 CAGCUULUU C CCAGCCCA 188 UGGGCUGG CUGAUGAG GCCGUUAGGC CGAA AAAAGCUG 1610 1082 CCACAUGU C CUGAUCAU 189 AUGAUCAG CUGAUGAG GCCGUUAGGC CGAA ACAUGUGG 1611 1088 GUCCUGAU C AUAUGCUU 190 AAGCAUAU CUGAUGAG GCCGUUAGGC CGAA AUCAGGAC 1612 1091 CUGAUCAU A UGCUUUUG 191 CAAAAGCA CUGAUGAG GCCGUUAGGC CGAA AUGAUCAG 1613 1096 CAUAUGCU U UUGAAUAG 192 CUAUUCAA CUGAUGAG GCCGUUAGGC CGAA AGCAUAUG 1614 1097 AUAUGCUU U UGAAUAGU 193 ACUAUUCA CUGAUGAG GCCGUUAGGC CGAA AAGCAUAU 1615 WO 01/57206 PCT/USO1/03504 56 1098 UAUGCUJU U GAAUAGUC 194 GACUAUUC CUGAUGAG GCCGUUAGGC CGAA AAAGCAUA 1616 1103 UUUUGAAU A GUCAGUUA 195 UAACUGAC CUGAUGAG GCCGUUAGGC CGAA AUUCAAAA 1617 1106 UGAAUAGU C AGUUACUU 196 AAGUAACU CUGAUGAG GCCGUUAGGC CGAA ACUAUUCA 1618 1110 UAGUCAGU U ACUUGGCA 197 UGCCAAGU CUGAUGAG GCCGUUAGGC CGAA ACUGACUA 1619 1111 AGUCAGUU A CUUGGCAC 198 GUGCCAAG CUGAUGAG GCCGUUAGGC CGAA AACUGACU 1620 1114 CAGUUACU U GGCACCCC 199 GGGGUGCC CUGAUGAG GCCGUUAGGC CGAA AGUAACUG 1621 1128 CCCAGGAU C CUCACAGA 200 UCUGUGAG CUGAUGAG GCCGUUAGGC CGAA AUCCUGGG 1622 1131 AGGAUCCU C ACAGAACC 201 GGUUCUGU CUGAUGAG GCCGUUAGGC CGAA AGGAUCCU 1623 1152 GCAGCGGU U GGUCAAAA 202 UUUUGACC CUGAUGAG GCCGUUAGGC CGAA ACCGCUGC 1624 1156 CGGUUGGU C AAAAGAAU 203 AUUCUUUJU CUGAUGAG GCCGUUAGGC CGAA ACCAACCG 1625 1173 GACACGAU U CUUUACCA 204 UGGUAAAG CUGAUGAG GCCGUUAGGC CGAA AUCGUGUC 1626 1174 ACACGAUU C UUUACCAA 205 UUGGUAAA CUGAUGAG GCCGUUAGGC CGAA AAUCGUGU 1627 1176 ACGAUUCU U UACCAAAU 206 AUUUGGUA CUGAUGAG GCCGUUAGGC CGAA AGAAUCGU 1628 1177 CGAUUCUU U ACCAAAUU 207 AAUUUGGU CUGAUGAG GCCGUUAGGC CGAA AAGAAUCG 1629 1178 GAUUCUUU A CCAAAUUG 208 CAAUUUGG CUGAUGAG GCCGUUAGGC CGAA AAAGAAUC 1630 1185 UACCAAAU U GGAUGCAG 209 CUGCAUCC CUGAUGAG GCCGUUAGGC CGAA AUUUGGUA 1631 1200 AGACAAAU C UUAUCAAU 210 AUUGAUAA CUGAUGAG GCCGUUAGGC CGAA AUUUGUCU 1632 1202 ACAAAUCU U AUCAAUGC 211 GCAUUGAU CUGAUGAG GCCGUUAGGC CGAA AGAUUUGU 1633 1203 CAAAUCUU A UCAAUGCC 212 GGCAUUGA CUGAUGAG GCCGUUAGGC CGAA AAGAUUUG 1634 1205 AAUCUUAU C AAUGCCUG 213 CAGGCAUU CUGAUGAG GCCGUJAGGC CGAA AUAAGAUU 1635 1223 AAGAGACU U GUGAGAAG 214 CUUCUCAC CUGAUGAG GCCGUUAGGC CGAA AGUCUCUU 1636 1233 UGAGAAGU U GGGCUAUC 215 GAUAGCCC CUGAUGAG GCCGUUAGGC CGAA ACUUCUCA 1637 1239 GUUGGGCU A UCAAUGGA 216 UCCAUUGA CUGAUGAG GCCGUUAGGC CGAA AGCCCAAC 1638 1241 UGGGCUAU C AAUGGAAG 217 CUUCCAUU CUGAUGAG GCCGUUAGGC CGAA AUAGCCCA 1639 1256 AGAAAAGU U GUAUGAAU 218 AUUCAUAC CUGAUGAG GCCGUUAGGC CGAA ACUUUUCU 1640 1259 AAAGUUGU A UGAAUCAG 219 CUGAUUCA CUGAUGAG GCCGUUAGGC CGAA ACAACUUU 1641 1265 GUAUGAAU C AGGUUACU 220 AGUAACCU CUGAUGAG GCCGUUAGGC CGAA AUUCAUAC 1642 1270 AAUCAGGU U ACUAUAUC 221 GAUAUAGU CUGAUGAG GCCGUUAGGC CGAA ACCUGAUU 1643 1271 AUCAGGUU A CUAUAUCA 222 UGAUAUAG CUGAUGAG GCCGUUAGGC CGAA AACCUGAU 1644 1274 AGGUUACU A UAUCAACA 223 UGUUGAUA CUGAUGAG GCCGUUAGGC CGAA AGUAACCU 1645 1276 GUUACUAU A UCAACAAC 224 GUUGUUGA CUGAUGAG GCCGUUAGGC CGAA AUAGUAAC 1646 1278 UACUAUAU C AACAACUG 225 CAGUUGUU CUGAUGAG GCCGUUAGGC CGAA AUAUAGUA 1647 1289 CAACUGAU A GGAGAAAC 226 GUUUCUCC CUGAUGAG GCCGUUAGGC CGAA AUCAGUUG 1648 1301 GAAACAAU A AACUCAUU 227 AAUGAGUU CUGAUGAG GCCGUUAGGC CGAA AUUGUUUC 1649 1306 AAUAAACU C AUUUUCAA 228 UUGAAAAU CUGAUGAG GCCGUUAGGC CGAA AGUUUAUU 1650 1309 AAACUCAU U UUCAAAGU 229 ACUUUGAA CUGAUGAG GCCGUUAGGC CGAA AUGAGUUU 1651 1310 AACUCAUJU U UCAAAGUG 230 CACUUUGA CUGAUGAG GCCGUUAGGC CGAA AAUGAGUU 1652 1311 ACUCAUUU U CAAAGUGA 231 UCACUUUG CUGAUGAG GCCGUUAGGC CGAA AAAUGAGU 1653 1312 CUCAUUUU C AAAGUGAA 232 UUCACUUU CUGAUGAG GCCGUUAGGC CGAA AAAAUGAG 1654 1322 AAGUGAAU U UGUUAGAA 233 UUCUAACA CUGAUGAG GCCGUUAGGC CGAA AUUCACUU 1655 1323 AGUGAAUU U GUUAGAAA 234 UUUCUAAC CUGAUGAG GCCGUUAGGC CGAA AAUUCACU 1656 1326 GAAUUUGU U AGAAAUGG 235 CCAUUUCU CUGAUGAG GCCGUUAGGC CGAA ACAAAUUC 1657 1327 AAUUUGUU A GAAAUGGA 236 UCCAUUUC CUGAUGAG GCCGUUAGGC CGAA AACAAAUU 1658 1340 UGGAUGAU A AAAUAUUG 237 CAAUAUUU CUGAUGAG GCCGUUAGGC CGAA AUCAUCCA 1659 1345 GAUAAAAU A UUGGUUGA 238 UCAACCAA CUGAUGAG GCCGUUAGGC CGAA AUUUUAUC 1660 1347 UAAAAUAU U GGUUGACU 239 AGUCAACC CUGAUGAG GCCGUUAGGC CGAA AUAUUUUA 1661 1351 AUAUUGGU U GACUUCCG 240 CGGAAGUC CUGAUGAG GCCGUUAGGC CGAA ACCAAUAU 1662 1356 GGUUGACU U CCGGCUUU 241 AAAGCCGG CUGAUGAG GCCGUUAGGC CGAA AGUCAACC 1663 1357 GUUGACUU C CGGCUUUC 242 GAAAGCCG CUGAUGAG GCCGUUAGGC CGAA AAGUCAAC 1664 WO 01/57206 PCT/USO1/03504 57 1363 UUCCGGCU U UCUAAGGG 243 CCCUUAGA CUGAUGAG GCCGUUAGGC CGAA AGCCGGAA 1665 1364 UCCGGCUU U CUAAGGGU 244 ACCCUUAG CUGAUGAG GCCGUUAGGC CGAA AAGCCGGA 1666 1365 CCGGCUUU C UAAGGGUG 245 CACCCUUA CUGAUGAG GCCGUUAGGC CGAA AAAGCCGG 1667 1367 GGCUUUCU A AGGGUGAU 246 AUCACCCU CUGAUGAG GCCGUUAGGC CGAA AGAAAGCC 1668 1380 UGAUGGAU U GGAGUUCA 247 UGAACUCC CUGAUGAG GCCGUUAGGC CGAA AUCCAUCA 1669 1386 AUUGGAGU U CAAGAGAC 248 GUCUCUUG CUGAUGAG GCCGUUAGGC CGAA ACUCCAAU 1670 1387 UUGGAGUU C AAGAGACA 249 UGUCUCUU CUGAUGAG GCCGUUAGGC CGAA AACUCCAA 1671 1398 GAGACACU U CCUGAAGA 250 UCUUCAGG CUGAUGAG GCCGUUAGGC CGAA AGUGUCUC 1672 1399 AGACACUU C CUGAAGAU 251 AUCUUCAG CUGAUGAG GCCGUUAGGC CGAA AAGUGUCU 1673 1408 CUGAAGAU U AAAGGGAA 252 UUCCCUUU CUGAUGAG GCCGUUAGGC CGAA AUCUUCAG 1674 1409 UGAAGAUU A AAGGGAAG 253 CUUCCCUU CUGAUGAG GCCGUUAGGC CGAA AAUCUUCA 1675 1423 AAGCUGAU U GAUAUUGU 254 ACAAUAUC CUGAUGAG GCCGUUAGGC CGAA AUCAGCUU 1676 1427 UGAUUGAU A UUGUGAGC 255 GCUCACAA CUGAUGAG GCCGUUAGGC CGAA AUCAAUCA 1677 1429 AUUGAUAU U GUGAGCAG 256 CUGCUCAC CUGAUGAG GCCGUUAGGC CGAA AUAUCAAU 1678 1447 CAGAAGGU U UGGCUUCC 257 GGAAGCCA CUGAUGAG GCCGUUAGGC CGAA ACCUUCUG 1679 1448 AGAAGGUU U GGCUUCCU 258 AGGAAGCC CUGAUGAG GCCGUUAGGC CGAA AACCUUCU 1680 1453 GUUUGGCU U CCUGCCAC 259 GUGGCAGG CUGAUGAG GCCGUUAGGC CGAA AGCCAAAC 1681 1454 UUUGGCUU C CUGCCACA 260 UGUGGCAG CUGAUGAG GCCGUUAGGC CGAA AAGCCAAA 1682 1467 CACAUGAU C GGACCAUC 261 GAUGGUCC CUGAUGAG GCCGUUAGGC CGAA AUCAUGUG 1683 1475 CGGACCAU C GGCUCUGG 262 CCAGAGCC CUGAUGAG GCCGUUAGGC CGAA AUGGUCCG 1684 1480 CAUCGGCU C UGGGGAAU 263 AUUCCCCA CUGAUGAG GCCGUUAGGC CGAA AGCCGAUG 1685 1489 UGGGGAAU C CUGGUGAA 264 UUCACCAG CUGAUGAG GCCGUUAGGC CGAA AUUCCCCA 1686 1499 UGGUGAAU A UAGUGCUG 265 CAGCACUA CUGAUGAG GCCGUUAGGC CGAA AUUCACCA 1687 1501 GUGAAUAU A GUGCUGCU 266 AGCAGCAC CUGAUGAG GCCGUUAGGC CGAA AUAUUCAC 1688 1510 GUGCUGCU A UGUUGACA 267 UGUCAACA CUGAUGAG GCCGUUAGGC CGAA AGCAGCAC 1689 1514 UGCUAUGU U GACAUUAU 268 AUAAUGUC CUGAUGAG GCCGUUAGGC CGAA ACAUAGCA 1690 1520 GUUGACAU U AUUCUUCC 269 GGAAGAAU CUGAUGAG GCCGUUAGGC CGAA AUGUCAAC 1691 1521 UUGACAUU A UUCUUCCU 270 AGGAAGAA CUGAUGAG GCCGUUAGGC CGAA AAUGUCAA 1692 1523 GACAUUAU U CUUCCUAG 271 CUAGGAAG CUGAUGAG GCCGUUAGGC CGAA AUAAUGUC 1693 1524 ACAUUAUU C UUCCUAGA 272 UCUAGGAA CUGAUGAG GCCGUUAGGC CGAA AAUAAUGU 1694 1526 AUUAUUCU U CCUAGAGA 273 UCUCUAGG CUGAUGAG GCCGUUAGGC CGAA AGAAUAAU 1695 1527 UUAUUCUU C CUAGAGAA 274 UUCUCUAG CUGAUGAG GCCGUUAGGC CGAA AAGAAUAA 1696 1530 UUCUUCCU A GAGAAGAU 275 AUCUUCUC CUGAUGAG GCCGUUAGGC CGAA AGGAAGAA 1697 1539 GAGAAGAU U AUCCUGUC 276 GACAGGAU CUGAUGAG GCCGUUAGGC CGAA AUCUUCUC 1698 1540 AGAAGAUU A UCCUGUCC 277 GGACAGGA CUGAUGAG GCCGUUAGGC CGAA AAUCUUCU 1699 1542 AAGAUUAU C CUGUCCUG 278 CAGGACAG CUGAUGAG GCCGUUAGGC CGAA AUAAUCUU 1700 1547 UAUCCUGU C CUGCAAAC 279 GUUUGCAG CUGAUGAG GCCGUUAGGC CGAA ACAGGAUA 1701 1563 CUGCAAAU A GUAGUUCC 280 GGAACUAC CUGAUGAG GCCGUUAGGC CGAA AUUUGCAG 1702 1566 CAAAUAGU A GUUCCUGA 281 UCAGGAAC CUGAUGAG GCCGUUAGGC CGAA ACUAUUUG 1703 1569 AUAGUAGU U CCUGAAGU 282 ACUUCAGG CUGAUGAG GCCGUUAGGC CGAA ACUACUAU 1704 1570 UAGUAGUU C CUGAAGUG 283 CACUUCAG CUGAUGAG GCCGUUAGGC CGAA AACUACUA 1705 1580 UGAAGUGU U CACUUCCC 284 GGGAAGUG CUGAUGAG GCCGUUAGGC CGAA ACACUUCA 1706 1581 GAAGUGUU C ACUUCCCU 285 AGGGAAGU CUGAUGAG GCCGUUAGGC CGAA AACACUUC 1707 1585 UGUUCACU U CCCUGUUU 286 AAACAGGG CUGAUGAG GCCGUUAGGC CGAA AGUGAACA 1708 1586 GUUCACUU C CCUGUUUA 287 UAAACAGG CUGAUGAG GCCGUUAGGC CGAA AAGUGAAC 1709 1592 UUCCCUGU U UAUCCAAA 288 UUUGGAUA CUGAUGAG GCCGUUAGGC CGAA ACAGGGAA 1710 1593 UCCCUGUU U AUCCAAAC 289 GUUUGGAU CUGAUGAG GCCGUUAGGC CGAA AACAGGGA 1711 1594 CCCUGUUU A UCCAAACA 290 UGUUUGGA CUGAUGAG GCCGUUAGGC CGAA AAACAGGG 1712 1596 CUGUUUAU C CAAACAUC 291 GAUGUUUG CUGAUGAG GCCGUUAGGC CGAA AUAAACAG 1713 WO 01/57206 PCT/USO1/03504 58 1604 CCAAACAU C UUCCAAUU 292 AAUUGGAA CUGAUGAG GCCGUUAGGC CGAA AUGUUUGG 1714 1606 AAACAUCU U CCAAUUUA 293 UAAAUUGG CUGAUGAG GCCGUUAGGC CGAA AGAUGUUU 1715 1607 AACAUCUU C CAAUUUAU 294 AUAAAUUG CUGAUGAG GCCGUUAGGC CGAA AAGAUGUU 1716 1612 CUUCCAAU U UAUUUGU 295 ACAAAAUA CUGAUGAG GCCGUUAGGC CGAA AUUGGAAG 1717 1613 UUCCAAUU U AUUUUGUU 296 AACAAAAU CUGAUGAG GCCGUUAGGC CGAA AAUUGGAA 1718 1614 UCCAAUUU A UUUUGUUU 297 AAACAAAA CUGAUGAG GCCGUUAGGC CGAA AAAUUGGA 1719 1616 CAAUUUAU U UUGUUUGU 298 ACAAACAA CUGAUGAG GCCGUUAGGC CGAA AUAAAUUG 1720 1617 AAUUUAUU U UGUUUGUU 299 AACAAACA CUGAUGAG GCCGUUAGGC CGAA AAUAAAUU 1721 1618 AUUUAUUU U GUUUGUUC 300 GAACAAAC CUGAUGAG GCCGUUAGGC CGAA AAAUAAAU 1722 1621 UAUUUUGU U UGUUCGGC 301 GCCGAACA CUGAUGAG GCCGUUAGGC CGAA ACAAAAUA 1723 1622 AUUUUGUU U GUUCGGCA 302 UGCCGAAC CUGAUGAG GCCGUUAGGC CGAA AACAAAAU 1724 1625 UUGUUUGU U CGGCAUAC 303 GUAUGCCG CUGAUGAG GCCGUUAGGC CGAA ACAAACAA 1725 1626 UGUUUGUU C GGCAUACA 304 UGUAUGCC CUGAUGAG GCCGUUAGGC CGAA AACAAACA 1726 1632 UUCGGCAU A CAAAUAAU 305 AUUAUUUG CUGAUGAG GCCGUUAGGC CGAA AUGCCGAA 1727 1638 AUACAAAU A AUACCUAU 306 AUAGGUAU CUGAUGAG GCCGUUAGGC CGAA AUUUGUAU 1728 1641 CAAAUAAU A CCUAUAUC 307 GAUAUAGG CUGAUGAG GCCGUJAGGC CGAA AUUAUUUG 1729 1645 UAAUACCU A UAUCUUAA 308 UUAAGAUA CUGAUGAG GCCGUUAGGC CGAA AGGUAUUA 1730 1647 AUACCUAU A UCUUAAUU 309 AAUUAAGA CUGAUGAG GCCGUUAGGC CGAA AUAGGUAU 1731 1649 ACCUAUAU C UUAAUUGU 310 ACAAUUAA CUGAUGAG GCCGUUAGGC CGAA AUAUAGGU 1732 1651 CUAUAUCU U AAUUGUAA 311 UUACAAUU CUGAUGAG GCCGUUAGGC CGAA AGAUAUAG 1733 1652 UAUAUCUU A AUUGUAAG 312 CUUACAAU CUGAUGAG GCCGUUAGGC CGAA AAGAUAUA 1734 1655 AUCUUAAU U GUAAGCAA 313 UUGCUUAC CUGAUGAG GCCGUUJAGGC CGAA AUUAAGAU 1735 1658 UUAAUUGU A AGCAAAAC 314 GUUUUGCU CUGAUGAG GCCGUUAGGC CGAA ACAAUUAA 1736 1668 GCAAAACU U UGGGGAAA 315 UUUCCCCA CUGAUGAG GCCGUUAGGC CGAA AGUUUUJGC 1737 1669 CAAAACUU U GGGGAAAG 316 CUUUCCCC CUGAUGAG GCCGUUAGGC CGAA AAGUUUUG 1738 1685 GGAUGAAU A GAAUUCAU 317 AUGAAUUC CUGAUGAG GCCGUUAGGC CGAA AUUCAUCC 1739 1690 AAUAGAAU U CAUUUGAU 318 AUCAAAUG CUGAUGAG GCCGUUAGGC CGAA AUUCUAUU 1740 1691 AUAGAAUU C AUUUGAUU 319 AAUCAAAU CUGAUGAG GCCGUUAGGC CGAA AAUUCUAU 1741 1694 GAAUUCAU U UGAUUAUU 320 AAUAAUCA CUGAUGAG GCCGUUAGGC CGAA AUGAAUUC 1742 1695 AAUUCAUU U GAUUAUUJU 321 AAAUAAUC CUGAUGAG GCCGUUAGGC CGAA AAUGAAUU 1743 1699 CAUUUGAU U AUUUCUUC 322 GAAGAAAU CUGAUGAG GCCGUUAGGC CGAA AUCAAAUG 1744 1700 AUUUGAUU A UUUCUUCA 323 UGAAGAAA CUGAUGAG GCCGUUAGGC CGAA AAUCAAAU 1745 1702 UUGAUUAU U UCTUCAUG 324 CAUGAAGA CUGAUGAG GCCGUUAGGC CGAA AUAAUCAA 1746 1703 UGAUUAUU U CUUCAUGU 325 ACAUGAAG CUGAUGAG GCCGUUAGGC CGAA AAUAAUCA 1747 1704 GAUUAUUU C UUCAUGUG 326 CACAUGAA CUGAUGAG GCCGUUAGGC CGAA AAAUAAUC 1748 1706 UUAUUUCU U CAUGUGUG 327 CACACAUG CUGAUGAG GCCGUUAGGC CGAA AGAAAUAA 1749 1707 UAUUUCUU C AUGUGUGU 328 ACACACAU CUGAUGAG GCCGUUAGGC CGAA AAGAAAUA 1750 1716 AUGUGUGU U UAGUAUCU 329 AGAUACUA CUGAUGAG GCCGUUAGGC CGAA ACACACAU 1751 1717 UGUGUGUU U AGUAUCUG 330 CAGAUACU CUGAUGAG GCCGUJAGGC CGAA AACACACA 1752 1718 GUGUGUUU A GUAUCUGA 331 UCAGAUAC CUGAUGAG GCCGUJAGGC CGAA AAACACAC 1753 1721 UGUUUAGU A UCUGAAUU 332 AAUUCAGA CUGAUGAG GCCGUUAGGC CGAA ACUAAACA 1754 1723 UUUAGUAU C UGAAUUUG 333 CAAAUUCA CUGAUGAG GCCGUUAGGC CGAA AUACUAAA 1755 1729 AUCUGAAU U UGAAACUC 334 GAGUUUCA CUGAUGAG GCCGUUAGGC CGAA AUUCAGAU 1756 1730 UCUGAAUU U GAAACUCA 335 UGAGUUUC CUGAUGAG GCCGUUAGGC CGAA AAUUCAGA 1757 1737 UUGAAACU C AUCUGGUG 336 CACCAGAU CUGAUGAG GCCGUUAGGC CGAA AGUUUCAA 1758 1740 AAACUCAU C UGGUGGAA 337 UUCCACCA CUGAUGAG GCCGUUAGGC CGAA AUGAGUUU 1759 1756 AACCAAGU U UCAGGGGA 338 UCCCCUGA CUGAUGAG GCCGUUAGGC CGAA ACUUGGUU 1760 1757 ACCAAGUU U CAGGGGAC 339 GUCCCCUG CUGAUGAG GCCGUUAGGC CGAA AACUUGGU 1761 1758 CCAAGUUU C AGGGGACA 340 UGUCCCCU CUGAUGAG GCCGUJAGGC CGAA AAACUUGG 1762 WO 01/57206 PCT/USO1/03504 59 1772 ACAUGAGU U UUCCAGCU 341 AGCUGGAA CUGAUGAG GCCGUUAGGC CGAA ACUCAUGU 1763 1773 CAUGAGUU U UCCAGCUU 342 AAGCUGGA CUGAUGAG GCCGUUAGGC CGAA AACUCAUG 1764 1774 AUGAGUUU U CCAGCUTU 343 AAAGCUGG CUGAUGAG GCCGUUAGGC CGAA AAACUCAU 1765 1775 UGAGUUUU C CAGCUUU 344 AAAAGCUG CUGAUGAG GCCGUUAGGC CGAA AAAACUCA 1766 1781 UUCCAGCU U UUAUACAC 345 GUGUAUAA CUGAUGAG GCCGUUAGGC CGAA AGCUGGAA 1767 1782 UCCAGCUU U UAUACACA 346 UGUGUAUA CUGAUGAG GCCGUUAGGC CGAA AAGCUGGA 1768 1783 CCAGCUUU U AUACACAC 347 GUGUGUAU CUGAUGAG GCCGUUAGGC CGAA AAAGCUGG 1769 1784 CAGCUUUU A UACACACG 348 CGUGUGUA CUGAUGAG GCCGUUAGGC CGAA AAAAGCUG 1770 1786 GCUEJUUAU A CACACGUA 349 UACGUGUG CUGAUGAG GCCGUUAGGC CGAA AUAAAAGC 1771 1794 ACACACGU A UCUCAUUU 350 AAAUGAGA CUGAUGAG GCCGUUAGGC CGAA ACGUGUGU 1772 1796 ACACGUAU C UCAUUUUU 351 AAAAAUGA CUGAUGAG GCCGUUAGGC CGAA AUACGUGU 1773 1798 ACGUAUCU C AUUUUUAU 352 AUAAAAAU CUGAUGAG GCCGUUAGGC CGAA AGAUACGU 1774 1801 UAUCUCAU U UUUAUCAA 353 UUGAUAAA CUGAUGAG GCCGUUAGGC CGAA AUGAGAUA 1775 1802 AUCUCAUU U UUAUCAAA 354 UTUGAUAA CUGAUGAG GCCGUUAGGC CGAA AAUGAGAU 1776 1803 UCUCAUUU U UAUCAAAA 355 UUUUGAUA CUGAUGAG GCCGUUAGGC CGAA AAAUGAGA 1777 1804 CUCAUUUU U AUCAAAAC 356 GUUUUGAU CUGAUGAG GCCGUUAGGC CGAA AAAAUGAG 1778 1805 UCAUUUUU A UCAAAACA 357 UGUUUUGA CUGAUGAG GCCGUUAGGC CGAA AAAAAUGA 1779 1807 AUUUUUAU C AAAACAUU 358 AAUGUUUU CUGAUGAG GCCGUUAGGC CGAA AUAAAAAU 1780 Input Sequence = AF016582 Cut Site UH/. Stem Length = 8. Core Sequence = CUGAUGAG GCCGUUAGGC CGAA AF016582 (Homo sapiens checkpoint kinase Chk1 (CHK1) mRNA; 1821 bp) Underlined region can be any X sequence or linker as previously defined herein.

WO 01/57206 PCT/USO1/03504 60 Table IV: Human Chk1 NCH Ribozyme and Substrate Sequence Pos Substrate Seq ID Ribozyme Rz Seq ID 9 GGCCGGAC A GUCCGCCG 359 CGGCGGAC CUGAUGAG GCCGUUAGGC CGAA IUCCGGCC 1781 13 GGACAGUC C GCCGAGGU 360 ACCUCGGC CUGAUGAG GCCGUUAGGC CGAA IACUGUCC 1782 16 CAGUCCGC C GAGGUGCU 361 AGCACCUC CUGAUGAG GCCGUUAGGC CGAA ICGGACUG 1783 24 CGAGGUGC U CGGUGGAG 362 CUCCACCG CUGAUGAG GCCGUUAGGC CGAA ICACCUCG 1784 35 GUGGAGUC A UGGCAGUG 363 CACUGCCA CUGAUGAG GCCGUUAGGC CGAA IACUCCAC 1785 40 GUCAUGGC A GUGCCCUU 364 AAGGGCAC CUGAUGAG GCCGUUAGGC CGAA ICCAUGAC 1786 45 GGCAGUGC C CUUUGUGG 365 CCACAAAG CUGAUGAG GCCGUUAGGC CGAA ICACUGCC 1787 46 GCAGUGCC C UUUGUGGA 366 UCCACAAA CUGAUGAG GCCGUUAGGC CGAA IGCACUGC 1788 47 CAGUGCCC U UUGUGGAA 367 UUCCACAA CUGAUGAG GCCGUUAGGC CGAA IGGCACUG 1789 59 UGGAAGAC U GGGACUUG 368 CAAGUCCC CUGAUGAG GCCGUUAGGC CGAA IUCUUCCA 1790 65 ACUGGGAC U UGGUGCAA 369 UUGCACCA CUGAUGAG GCCGUUAGGC CGAA IUCCCAGU 1791 72 CUUGGUGC A AACCCUGG 370 CCAGGGUU CUGAUGAG GCCGUUAGGC CGAA ICACCAAG 1792 76 GUGCAAAC C CUGGGAGA 371 UCUCCCAG CUGAUGAG GCCGUUAGGC CGAA IUUUGCAC 1793 77 UGCAAACC C UGGGAGAA 372 UUCUCCCA CUGAUGAG GCCGUUAGGC CGAA IGUUUGCA 1794 78 GCAAACCC U GGGAGAAG 373 CUUCUCCC CUGAUGAG GCCGUUAGGC CGAA IGGUUUGC 1795 91 GAAGGUGC C UAUGGAGA 374 UCUCCAUA CUGAUGAG GCCGUUAGGC CGAA ICACCUUC 1796 92 AAGGUGCC U AUGGAGAA 375 UUCUCCAU CUGAUGAG GCCGUUAGGC CGAA IGCACCUU 1797 105 AGAAGUUC A ACUUGCUG 376 CAGCAAGU CUGAUGAG GCCGUUAGGC CGAA IAACUUCU 1798 108 AGUUCAAC U UGCUGUGA 377 UCACAGCA CUGAUGAG GCCGUUAGGC CGAA IUUGAACU 1799 112 CAACUUGC U GUGAAUAG 378 CUAUUCAC CUGAUGAG GCCGUUAGGC CGAA ICAAGUUG 1800 127 AGAGUAAC U GAAGAAGC 379 GCUUCUUC CUGAUGAG GCCGUUAGGC CGAA IUUACUCU 1801 136 GAAGAAGC A GUCGCAGU 380 ACUGCGAC CUGAUGAG GCCGUUAGGC CGAA ICUUCUUC 1802 142 GCAGUCGC A GUGAAGAU 381 AUCUUCAC CUGAUGAG GCCGUUAGGC CGAA ICGACUGC 1803 169 AAGCGUGC C GUAGACUG 382 CAGUCUAC CUGAUGAG GCCGUUAGGC CGAA ICACGCUU 1804 176 CCGUAGAC U GUCCAGAA 383 UUCUGGAC CUGAUGAG GCCGUUAGGC CGAA IUCUACGG 1805 180 AGACUGUC C AGAAAAUA 384 UAUUUUCU CUGAUGAG GCCGUUAGGC CGAA IACAGUCU 1806 181 GACUGUCC A GAAAAUAU 385 AUAUUUUC CUGAUGAG GCCGUUAGGC CGAA IGACAGUC 1807 203 AAGAGAUC U GUAUCAAU 386 AUUGAUAC CUGAUGAG GCCGUUAGGC CGAA IAUCUCUU 1808 209 UCUGUAUC A AUAAAAUG 387 CAUUUUAU CUGAUGAG GCCGUUAGGC CGAA IAUACAGA 1809 219 UAAAAUGC U AAAUCAUG 388 CAUGAUUU CUGAUGAG GCCGUUAGGC CGAA ICAUUUUA 1810 225 GCUAAAUC A UGAAAAUG 389 CAUUUUCA CUGAUGAG GCCGUUAGGC CGAA IAUUUAGC 1811 245 UAAAAUUC U AUGGUCAC 390 GUGACCAU CUGAUGAG GCCGUUAGGC CGAA IAAUUUUA 1812 252 CUAUGGUC A CAGGAGAG 391 CUCUCCUG CUGAUGAG GCCGUUAGGC CGAA IACCAUAG 1813 254 AUGGUCAC A GGAGAGAA 392 UUCUCUCC CUGAUGAG GCCGUUAGGC CGAA IUGACCAU 1814 266 GAGAAGGC A AUAUCCAA 393 UUGGAUAU CUGAUGAG GCCGUUAGGC CGAA ICCUUCUC 1815 272 GCAAUAUC C AAUAUUUA 394 UAAAUAUU CUGAUGAG GCCGUUAGGC CGAA IAUAUUGC 1816 273 CAAUAUCC A AUAUUUAU 395 AUAAAUAU CUGAUGAG GCCGUUAGGC CGAA IGAUAUUG 1817 285 UUTJUAUUUC U GGAGUACU 396 AGUACUCC CUGAUGAG GCCGUUAGGC CGAA IAAAUAAA 1818 293 UGGAGUAC U GUAGUGGA 397 UCCACUAC CUGAUGAG GCCGUUAGGC CGAA IUACUCCA 1819 309 AGGAGAGC U UUUUGACA 398 UGUCAAAA CUGAUGAG GCCGUUAGGC CGAA ICUCUCCU 1820 317 UUUUUGAC A GAAUAGAG 399 CUCUAUUC CUGAUGAG GCCGUUAGGC CGAA IUCAAAAA 1821 327 AAUAGAGC C AGACAUAG 400 CUAUGUCU CUGAUGAG GCCGUUAGGC CGAA ICUCUAUU 1822 328 AUAGAGCC A GACAUAGG 401 CCUAUGUC CUGAUGAG GCCGUUAGGC CGAA IGCUCUAU 1823 332 AGCCAGAC A UAGGCAUG 402 CAUGCCUA CUGAUGAG GCCGUUAGGC CGAA IUCUGGCU 1824 338 ACAUAGGC A UGCCUGAA 403 UUCAGGCA CUGAUGAG GCCGUUAGGC CGAA ICCUAUGU 1825 WO 01/57206 PCT/USO1/03504 61 342 AGGCAUGC C UGAACCAG 404 CUGGUUCA CUGAUGAG GCCGUUAGGC CGAA ICAUGCCU 1826 343 GGCAUGCC U GAACCAGA 405 UCUGGUJC CUGAUGAG GCCGUUAGGC CGAA IGCAUGCC 1827 348 GCCUGAAC C AGAUGCUC 406 GAGCAUCU CUGAUGAG GCCGUUAGGC CGAA IUUCAGGC 1828 349 CCUGAACC A GAUGCUCA 407 UGAGCAUC CUGAUGAG GCCGUUAGGC CGAA IGUUCAGG 1829 355 CCAGAUGC U CAGAGAUU 408 AAUCUCUG CUGAUGAG GCCGUUAGGC CGAA ICAUCUGG 1830 357 AGAUGCUC A GAGAUUCU 409 AGAAUCUC CUGAUGAG GCCGUUAGGC CGAA IAGCAUCU 1831 365 AGAGAUUC U UCCAUCAA 410 UUGAUGGA CUGAUGAG GCCGUUAGGC CGAA IAAUCUCU 1832 368 GAUUCUUC C AUCAACUC 411 GAGUUGAU CUGAUGAG GCCGUUAGGC CGAA IAAGAAUC 1833 369 AUUCUUCC A UCAACUCA 412 UGAGUUGA CUGAUGAG GCCGUUAGGC CGAA IGAAGAAU 1834 372 CUUCCAUC A ACUCAUGG 413 CCAUGAGU CUGAUGAG GCCGUUAGGC CGAA IAUGGAAG 1835 375 CCAUCAAC U CAUGGCAG 414 CUGCCAUG CUGAUGAG GCCGUUAGGC CGAA IUUGAUGG 1836 377 AUCAACUC A UGGCAGGG 415 CCCUGCCA CUGAUGAG GCCGUUAGGC CGAA IAGUUGAU 1837 382 CUCAUGGC A GGGGUGGU 416 ACCACCCC CUGAUGAG GCCGUUAGGC CGAA ICCAUGAG 1838 396 GGUUJAUC U GCAUGGUA 417 UACCAUGC CUGAUGAG GCCGUUAGGC CGAA IAUAAACC 1839 399 UUAUCUGC A UGGUAUUG 418 CAAUACCA CUGAUGAG GCCGUUAGGC CGAA ICAGAUAA 1840 415 GGAAUAAC U CACAGGGA 419 UCCCUGUG CUGAUGAG GCCGUUAGGC CGAA IUUAUUCC 1841 417 AAUAACUC A CAGGGAUA 420 UAUCCCUG CUGAUGAG GCCGUUAGGC CGAA IAGUUAUU 1842 419 UAACUCAC A GGGAUAUU 421 AAUAUCCC CUGAUGAG GCCGUUAGGC CGAA IUGAGUUA 1843 432 UAUUAAAC C AGAAAAUC 422 GAUUUUCU CUGAUGAG GCCGUUAGGC CGAA IUUUAAUA 1844 433 AUUAAACC A GAAAAUCU 423 AGAUUUUC CUGAUGAG GCCGUUAGGC CGAA IGUUUAAU 1845 441 AGAAAAUC U UCUGUUGG 424 CCAACAGA CUGAUGAG GCCGUUAGGC CGAA IAUUUUCU 1846 444 AAAUCUUC U GUUGGAUG 425 CAUCCAAC CUGAUGAG GCCGUUAGGC CGAA IAAGAUUU 1847 464 GGGAUAAC C UCAAAAUC 426 GAUUUUGA CUGAUGAG GCCGUUAGGC CGAA IUUAUCCC 1848 465 GGAUAACC U CAAAAUCU 427 AGAUUUUG CUGAUGAG GCCGUUAGGC CGAA IGUUAUCC 1849 467 AUAACCUC A AAAUCUCA 428 UGAGAUUU CUGAUGAG GCCGUUAGGC CGAA IAGGUUAU 1850 473 UCAAAAUC U CAGACUUU 429 AAAGUCUG CUGAUGAG GCCGUUAGGC CGAA IAUUUUGA 1851 475 AAAAUCUC A GACUUUGG 430 CCAAAGUC CUGAUGAG GCCGUUAGGC CGAA IAGAUUUU 1852 479 UCUCAGAC U UUGGCUUG 431 CAAGCCAA CUGAUGAG GCCGUUAGGC CGAA IUCUGAGA 1853 485 ACUUUGGC U UGGCAACA 432 UGUUGCCA CUGAUGAG GCCGUUAGGC CGAA ICCAAAGU 1854 490 GGCUUGGC A ACAGUAUU 433 AAUACUGU CUGAUGAG GCCGUUAGGC CGAA ICCAAGCC 1855 493 UUGGCAAC A GUAUUUCG 434 CGAAAUAC CUGAUGAG GCCGUUAGGC CGAA IUUGCCAA 1856 530 UGUUGAAC A AGAUGUGU 435 ACACAUCU CUGAUGAG GCCGUUAGGC CGAA IUUCAACA 1857 544 UGUGGUAC U UUACCAUA 436 UAUGGUAA CUGAUGAG GCCGUTJAGGC CGAA IUACCACA 1858 549 UACUUUAC C AUAUGUUG 437 CAACAUAU CUGAUGAG GCCGUUAGGC CGAA IUAAAGUA 1859 550 ACUUUACC A UAUGUUGC 438 GCAACAUA CUGAUGAG GCCGUUAGGC CGAA IGUAAAGU 1860 559 UAUGUUGC U CCAGAACU 439 AGUUCUGG CUGAUGAG GCCGUUAGGC CGAA ICAACAUA 1861 561 UGUUGCUC C AGAACUUC 440 GAAGUUCU CUGAUGAG GCCGUUAGGC CGAA IAGCAACA 1862 562 GUUGCUCC A GAACUUCU 441 AGAAGUUC CUGAUGAG GCCGUUAGGC CGAA IGAGCAAC 1863 567 UCCAGAAC U UCUGAAGA 442 UCUUCAGA CUGAUGAG GCCGUU3AGGC CGAA IUUCUGGA 1864 570 AGAACUUC U GAAGAGAA 443 UUCUCUUC CUGAUGAG GCCGUUAGGC CGAA IAAGUUCU 1865 588 AGAAUUUC A UGCAGAAC 444 GUUCUGCA CUGAUGAG GCCGUUAGGC CGAA IAAAUUCU 1866 592 UUUCAUGC A GAACCAGU 445 ACUGGUUC CUGAUGAG GCCGUUAGGC CGAA ICAUGAAA 1867 597 UGCAGAAC C AGUUGAUG 446 CAUCAACU CUGAUGAG GCCGUJAGGC CGAA IUUCUGCA 1868 598 GCAGAACC A GUUGAUGU 447 ACAUCAAC CUGAUGAG GCCGUUAGGC CGAA IGUUCUGC 1869 613 GUUUGGUC C UGUGGAAU 448 AUUCCACA CUGAUGAG GCCGUJAGGC CGAA IACCAAAC 1870 614 UUUGGUCC U GUGGAAUA 449 UAUUCCAC CUGAUGAG GCCGUUAGGC CGAA IGACCAAA 1871 627 AAUAGUAC U UACUGCAA 450 UUGCAGUA CUGAUGAG GCCGUUAGGC CGAA IUACUAUU 1872 631 GUACUUAC U GCAAUGCU 451 AGCAUUGC CUGAUGAG GCCGUUAGGC CGAA IUAAGUAC 1873 634 CUUACUGC A AUGCUCGC 452 GCGAGCAU CUGAUGAG GCCGUUAGGC CGAA ICAGUAAG 1874 WO 01/57206 PCT/USO1/03504 62 639 UGCAAUGC U CGCUGGAG 453 CUCCAGCG CUGAUGAG GCCGUUAGGC CGAA ICAUUGCA 1875 643 AUGCUCGC U GGAGAAUU 454 AAUUTCUCC CUGAUGAG GCCGUUAGGC CGAA ICGAGCAU 1876 654 AGAAUUGC C AUGGGACC 455 GGUCCCAU CUGAUGAG GCCGUUAGGC CGAA ICAAUUCU 1877 655 GAAUUGCC A UGGGACCA 456 UGGUCCCA CUGAUGAG GCCGUUAGGC CGAA IGCAAUUC 1878 662 CAUGGGAC C AACCCAGU 457 ACUGGGUU CUGAUGAG GCCGUTJAGGC CGAA IUCCCAUG 1879 663 AUGGGACC A ACCCAGUG 458 CACUGGGU CUGAUGAG GCCGUUAGGC CGAA IGUCCCAU 1880 666 GGACCAAC C CAGUGACA 459 UGUCACUG CUGAUGAG GCCGUUAGGC CGAA IUUGGUCC 1881 667 GACCAACC C AGUGACAG 460 CUGUCACU CUGAUGAG GCCGUUAGGC CGAA IGUUGGUC 1882 668 ACCAACCC A GUGACAGC 461 GCUGUCAC CUGAUGAG GCCGUUAGGC CGAA IGGUUGGU 1883 674 CCAGUGAC A GCUGUCAG 462 CUGACAGC CUGAUGAG GCCGUUAGGC CGAA IUCACUGG 1884 677 GUGACAGC U GUCAGGAG 463 CUCCUGAC CUGAUGAG GCCGUUAGGC CGAA ICUGUCAC 1885 681 CAGCUGUC A GGAGUAUU 464 AAUACUCC CUGAUGAG GCCGUUAGGC CGAA IACAGCUG 1886 691 GAGUAUUC U GACUGGAA 465 UUCCAGUC CUGAUGAG GCCGUUAGGC CGAA IAAUACUC 1887 695 AUUCUGAC U GGAAAGAA 466 UUCUUUCC CUGAUGAG GCCGUUAGGC CGAA IUCAGAAU 1888 712 AAAAAAAC A UACCUCAA 467 UUGAGGUA CUGAUGAG GCCGUUAGGC CGAA IUUUUUJ 1889 716 AAACAUAC C UCAACCCU 468 AGGGUUGA CUGAUGAG GCCGUUAGGC CGAA IUAUGUUU 1890 717 AACAUACC U CAACCCUU 469 AAGGGUUG CUGAUGAG GCCGUUAGGC CGAA IGUAUGUU 1891 719 CAUACCUC A ACCCUUGG 470 CCAAGGGU CUGAUGAG GCCGUUAGGC CGAA IAGGUAUG 1892 722 ACCUCAAC C CUUGGAAA 471 UUUCCAAG CUGAUGAG GCCGUUAGGC CGAA IUUGAGGU 1893 723 CCUCAACC C UUGGAAAA 472 UUUUCCAA CUGAUGAG GCCGUUAGGC CGAA IGUUGAGG 1894 724 CUCAACCC U UGGAAAAA 473 UUUUUCCA CUGAUGAG GCCGUUAGGC CGAA IGGUUGAG 1895 742 AUCGAUUC U GCUCCUCU 474 AGAGGAGC CUGAUGAG GCCGUUAGGC CGAA IAAUCGAU 1896 745 GAUUCUGC U CCUCUAGC 475 GCUAGAGG CUGAUGAG GCCGUUAGGC CGAA ICAGAAUC 1897 747 UUCUGCUC C UCUAGCUC 476 GAGCUAGA CUGAUGAG GCCGUUAGGC CGAA IAGCAGAA 1898 748 UCUGCUCC U CUAGCUCU 477 AGAGCUAG CUGAUGAG GCCGUUAGGC CGAA IGAGCAGA 1899 750 UGCUCCUC U AGCUCUGC 478 GCAGAGCU CUGAUGAG GCCGUUAGGC CGAA IAGGAGCA 1900 754 CCUCUAGC U CUGCUGCA 479 UGCAGCAG CUGAUGAG GCCGUUAGGC CGAA ICUAGAGG 1901 756 UCUAGCUC U GCUGCAUA 480 UAUGCAGC CUGAUGAG GCCGUUAGGC CGAA IAGCUAGA 1902 759 AGCUCUGC U GCAUAAAA 481 UUUUAUGC CUGAUGAG GCCGUUAGGC CGAA ICAGAGCU 1903 762 UCUGCUGC A UAAAAUCU 482 AGAUUUA CUGAUGAG GCCGUUAGGC CGAA ICAGCAGA 1904 770 AUAAAAUC U UAGUUGAG 483 CUCAACUA CUGAUGAG GCCGUUAGGC CGAA IAUUUUAU 1905 783 UGAGAAUC C AUCAGCAA 484 UUGCUGAU CUGAUGAG GCCGUUAGGC CGAA IAUUCUCA 1906 784 GAGAAUCC A UCAGCAAG 485 CUUGCUGA CUGAUGAG GCCGUUAGGC CGAA IGAUUCUC 1907 787 AAUCCAUC A GCAAGAAU 486 AUUCUUGC CUGAUGAG GCCGUUAGGC CGAA IAUGGAUU 1908 790 CCAUCAGC A AGAAUUAC 487 GUAAUUCU CUGAUGAG GCCGUUAGGC CGAA ICUGAUGG 1909 799 AGAAUUAC C AUUCCAGA 488 UCUGGAAU CUGAUGAG GCCGUUAGGC CGAA IUAAUUCU 1910 800 GAAUUACC A UUCCAGAC 489 GUCUGGAA CUGAUGAG GCCGUUAGGC CGAA IGUAAUUC 1911 804 UACCAUUC C AGACAUCA 490 UGAUGUCU CUGAUGAG GCCGUUfAGGC CGAA IAAUGGUA 1912 805 ACCAUUCC A GACAUCAA 491 UUGAUGUC CUGAUGAG GCCGUUAGGC CGAA IGAAUGGU 1913 809 UUCCAGAC A UCAAAAAA 492 UUUUUUGA CUGAUGAG GCCGUUAGGC CGAA IUCUGGAA 1914 812 CAGACAUC A AAAAAGAU 493 AUCUUUUU CUGAUGAG GCCGUUAGGC CGAA IAUGUCUG 1915 830 GAUGGUAC A ACAAACCC 494 GGGUUUGU CUGAUGAG GCCGUUAGGC CGAA IUACCAUC 1916 833 GGUACAAC A AACCCCUC 495 GAGGGGUU CUGAUGAG GCCGUUAGGC CGAA IUUGUACC 1917 837 CAACAAAC C CCUCAAGA 496 UCUUGAGG CUGAUGAG GCCGUUAGGC CGAA IUUUGUUG 1918 838 AACAAACC C CUCAAGAA 497 UUCUUGAG CUGAUGAG GCCGUUAGGC CGAA IGUUUGUU 1919 839 ACAAACCC C UCAAGAAA 498 UUUCUUGA CUGAUGAG GCCGUUAGGC CGAA IGGUUUGU 1920 840 CAAACCCC U CAAGAAAG 499 CUUUCUUG CUGAUGAG GCCGUUAGGC CGAA IGGGUUUG 1921 842 AACCCCUC A AGAAAGGG 500 CCCUUUCU CUGAUGAG GCCGUUAGGC CGAA IAGGGGUU 1922 853 AAAGGGGC A AAAAGGCC 501 GGCCUUUU CUGAUGAG GCCGUUAGGC CGAA ICCCCUUU 1923 WO 01/57206 PCT/USO1/03504 63 861 AAAAAGGC C CCGAGUCA 502 UGACUCGG CUGAUGAG GCCGUUAGGC CGAA ICCUUUUU 1924 862 AAAAGGCC C CGAGUCAC 503 GUGACUCG CUGAUGAG GCCGUUAGGC CGAA IGCCUUUU 1925 863 AAAGGCCC C GAGUCACU 504 AGUGACUC CUGAUGAG GCCGUUAGGC CGAA IGGCCUUJU 1926 869 CCCGAGUC A CUUCAGGU 505 ACCUGAAG CUGAUGAG GCCGUUAGGC CGAA IACUCGGG 1927 871 CGAGUCAC U UCAGGUGG 506 CCACCUGA CUGAUGAG GCCGUUAGGC CGAA IUGACUCG 1928 874 GUCACUUC A GGUGGUGU 507 ACACCACC CUGAUGAG GCCGUUAGGC CGAA IAAGUGAC 1929 886 GGUGUGUC A GAGUCUCC 508 GGAGACUC CUGAUGAG GCCGUUAGGC CGAA IACACACC 1930 892 UCAGAGUC U CCCAGUGG 509 CCACUGGG CUGAUGAG GCCGUUAGGC CGAA IACUCUGA 1931 894 AGAGUCUC C CAGUGGAU 510 AUCCACUG CUGAUGAG GCCGUUAGGC CGAA IAGACUCU 1932 895 GAGUCUCC C AGUGGAUU 511 AAUCCACU CUGAUGAG GCCGUUAGGC CGAA IGAGACUC 1933 896 AGUCUCCC A GUGGAUUU 512 AAAUCCAC CUGAUGAG GCCGUUAGGC CGAA IGGAGACU 1934 907 GGAUUUUC U AAGCACAU 513 AUGUGCUU CUGAUGAG GCCGUUAGGC CGAA IAAAAUCC 1935 912 UUCUAAGC A CAUUCAAU 514 AUUGAAUG CUGAUGAG GCCGUUAGGC CGAA ICUUAGAA 1936 914 CUAAGCAC A UUCAAUCC 515 GGAUUGAA CUGAUGAG GCCGUUAGGC CGAA IUGCUUAG 1937 918 GCACAUUC A AUCCAAUU 516 AAUUGGAU CUGAUGAG GCCGUUAGGC CGAA IAAUGUGC 1938 922 AUUCAAUC C AAUUUGGA 517 UCCAAAUU CUGAUGAG GCCGUUAGGC CGAA IAUUGAAU 1939 923 UUCAAUCC A AUUUGGAC 518 GUCCAAAU CUGAUGAG GCCGUUAGGC CGAA IGAUUGAA 1940 932 AUUUGGAC U UCUCUCCA 519 UGGAGAGA CUGAUGAG GCCGUUAGGC CGAA IUCCAAAU 1941 935 UGGACUUC U CUCCAGUA 520 UACUGGAG CUGAUGAG GCCGUUAGGC CGAA IAAGUCCA 1942 937 GACUUCUC U CCAGUAAA 521 UUUACUGG CUGAUGAG GCCGUUAGGC CGAA IAGAAGUC 1943 939 CUUCUCUC C AGUAAACA 522 UGUUUACU CUGAUGAG GCCGUUAGGC CGAA IAGAGAAG 1944 940 UUCUCUCC A GUAAACAG 523 CUGUUUAC CUGAUGAG GCCGUUAGGC CGAA IGAGAGAA 1945 947 CAGUAAAC A GUGCUUCU 524 AGAAGCAC CUGAUGAG GCCGUUAGGC CGAA IUUUACUG 1946 952 AACAGUGC U UCUAGUGA 525 UCACUAGA CUGAUGAG GCCGUUAGGC CGAA ICACUGUU 1947 955 AGUGCUUC U AGUGAAGA 526 UCUUCACU CUGAUGAG GCCGUUAGGC CGAA IAAGCACU 1948 977 UGAAGUAC U CCAGUUCU 527 AGAACUGG CUGAUGAG GCCGUUAGGC CGAA IUACUUCA 1949 979 AAGUACUC C AGUUCUCA 528 UGAGAACU CUGAUGAG GCCGUUAGGC CGAA IAGUACUU 1950 980 AGUACUCC A GUUCUCAG 529 CUGAGAAC CUGAUGAG GCCGUUAGGC CGAA IGAGUACU 1951 985 UCCAGUUC U CAGCCAGA 530 UCUGGCUG CUGAUGAG GCCGUUAGGC CGAA IAACUGGA 1952 987 CAGUUCUC A GCCAGAAC 531 GUUCUGGC CUGAUGAG GCCGUUAGGC CGAA IAGAACUG 1953 990 UUCUCAGC C AGAACCCC 532 GGGGUUCU CUGAUGAG GCCGUUAGGC CGAA ICUGAGAA 1954 991 UCUCAGCC A GAACCCCG 533 CGGGGUUC CUGAUGAG GCCGUUAGGC CGAA IGCUGAGA 1955 996 GCCAGAAC C CCGCACAG 534 CUGUGCGG CUGAUGAG GCCGUUAGGC CGAA IUUCUGGC 1956 997 CCAGAACC C CGCACAGG 535 CCUGUGCG CUGAUGAG GCCGUUAGGC CGAA IGUUCUGG 1957 998 CAGAACCC C GCACAGGU 536 ACCUGUGC CUGAUGAG GCCGUUAGGC CGAA IGGUUCUG 1958 1001 AACCCCGC A CAGGUCUU 537 AAGACCUG CUGAUGAG GCCGUUAGGC CGAA ICGGGGUU 1959 1003 CCCCGCAC A GGUCUUUC 538 GAAAGACC CUGAUGAG GCCGUUAGGC CGAA IUGCGGGG 1960 1008 CACAGGUC U UUCCUUAU 539 AUAAGGAA CUGAUGAG GCCGUUAGGC CGAA IACCUGUG 1961 1012 GGUCUUUC C UUAUGGGA 540 UCCCAUAA CUGAUGAG GCCGUUAGGC CGAA IAAAGACC 1962 1013 GUCUUUCC U UAUGGGAU 541 AUCCCAUA CUGAUGAG GCCGUUAGGC CGAA IGAAAGAC 1963 1024 UGGGAUAC C AGCCCCUC 542 GAGGGGCU CUGAUGAG GCCGUUAGGC CGAA IUAUCCCA 1964 1025 GGGAUACC A GCCCCUCA 543 UGAGGGGC CUGAUGAG GCCGUUAGGC CGAA IGUAUCCC 1965 1028 AUACCAGC C CCUCAUAC 544 GUAUGAGG CUGAUGAG GCCGUUAGGC CGAA ICUGGUAU 1966 1029 UACCAGCC C CUCAUACA 545 UGUAUGAG CUGAUGAG GCCGUUAGGC CGAA IGCUGGUA 1967 1030 ACCAGCCC C UCAUACAU 546 AUGUAUGA CUGAUGAG GCCGUUAGGC CGAA IGGCUGGU 1968 1031 CCAGCCCC U CAUACAUU 547 AAUGUAUG CUGAUGAG GCCGUUAGGC CGAA IGGGCUGG 1969 1033 AGCCCCUC A UACAUUGA 548 UCAAUGUA CUGAUGAG GCCGUUAGGC CGAA IAGGGGCU 1970 1037 CCUCAUAC A UUGAUAAA 549 UUUAUCAA CUGAUGAG GCCGUUAGGC CGAA IUAUGAGG 1971 1053 AUUGGUAC A AGGGAUCA 550 UGAUCCCU CUGAUGAG GCCGUUAGGC CGAA IUACCAAU 1972 WO 01/57206 PCT/USO1/03504 64 1061 AAGGGAUC A GCUUUUCC 551 GGAAAAGC CUGAUGAG GCCGUUAGGC CGAA IAUCCCUU 1973 1064 GGAUCAGC U UUUCCCAG 552 CUGGGAAA CUGAUGAG GCCGUUAGGC CGAA ICUGAUCC 1974 1069 AGCUUUUC C CAGCCCAC 553 GUGGGCUG CUGAUGAG GCCGUUAGGC CGAA IAAAAGCU 1975 1070 GCUUUUCC C AGCCCACA 554 UGUGGGCU CUGAUGAG GCCGUUAGGC CGAA IGAAAAGC 1976 1071 CUUUUCCC A GCCCACAU 555 AUGUGGGC CUGAUGAG GCCGUUAGGC CGAA IGGAAAAG 1977 1074 UUCCCAGC C CACAUGUC 556 GACAUGUG CUGAUGAG GCCGUUAGGC CGAA ICUGGGAA 1978 1075 UCCCAGCC C ACAUGUCC 557 GGACAUGU CUGAUGAG GCCGUUAGGC CGAA IGCUGGGA 1979 1076 CCCAGCCC A CAUGUCCU 558 AGGACAUG CUGAUGAG GCCGU UAGGC CGAA IGGCUGGG 1980 1078 CAGCCCAC A UGUCCUGA 559 UCAGGACA CUGAUGAG GCCGUUAGGC CGAA IUGGGCUG 1981 1083 CACAUGUC C UGAUCAUA 560 UAUGAUCA CUGAUGAG GCCGUUAGGC CGAA IACAUGUG 1982 1084 ACAUGUCC U GAUCAUAU 561 AUAUGAUC CUGAUGAG GCCGUUAGGC CGAA IGACAUGU 1983 1089 UCCUGAUC A UAUGCUUU 562 AAAGCAUA CUGAUGAG GCCGUUAGGC CGAA IAUCAGGA 1984 1095 UCAUAUGC U UUUGAAUA 563 UAUUCAAA CUGAUGAG GCCGUUAGGC CGAA ICAUAUGA 1985 1107 GAAUAGUC A GUUACUUG 564 CAAGUAAC CUGAUGAG GCCGUUAGGC CGAA IACUAUUC 1986 1113 UCAGU UAC U UGGCACCC 565 GGGUGCCA CUGAUGAG GCCGU UAGGC CGAA IUAACUGA 1987 1118 UACUUGGC A CCCCAGGA 566 UCCUGGGG CUGAUGAG GCCGUUAGGC CGAA ICCAAGUA 1988 1120 CUUGGCAC C CCAGGAUC 567 GAUCCUGG CUGAUGAG GCCGUUAGGC CGAA IUGCCAAG 1989 1121 UUGGCACC C CAGGAUCC 568 GGAUCCUG CUGAUGAG GCCGUUAGGC CGAA IGUGCCAA 1990 1122 UGGCACCC C AGGAUCCU 569 AGGAUCCU CUGAUGAG GCCGUUAGGC CGAA IGGUGCCA 1991 1123 GGCACCCC A GGAUCCUC 570 GAGGAUCC CUGAUGAG GCCGUUAGGC CGAA IGGGUGCC 1992 1129 CCAGGAUC C UCACAGAA 571 UUCUGUGA CUGAUGAG GCCGUUAGGC CGAA IAUCCUGG 1993 1130 CAGGAUCC U CACAGAAC 572 GUUCUGUG CUGAUGAG GCCGUUAGGC CGAA IGAUCCUG 1994 1132 GGAUCCUC A CAGAACCC 573 GGGUUCUG CUGAUGAG GCCGUUAGGC CGAA IAGGAUCC 1995 1134 AUCCUCAC A GAACCCCU 574 AGGGGUUC CUGAUGAG GCCGUUAGGC CGAA IUGAGGAU 1996 1139 CACAGAAC C CCUGGCAG 575 CUGCCAGG CUGAUGAG GCCGUUAGGC CGAA IUUCUGUG 1997 1140 ACAGAACC C CUGGCAGC 576 GCUGCCAG CUGAUGAG GCCGUUAGGC CGAA IGUUCUGU 1998 1141 CAGAACCC C UGGCAGCG 577 CGCUGCCA CUGAUGAG GCCGUUAGGC CGAA IGGUUCUG 1999 1142 AGAACCCC U GGCAGCGG 578 CCGCUGCC CUGAUGAG GCCGUUAGGC CGAA IGGGUUCU 2000 1146 CCCCUGGC A GCGGUUGG 579 CCAACCGC CUGAUGAG GCCGUUAGGC CGAA ICCAGGGG 2001 1157 GGUUGGUC A AAAGAAUG 580 CAUUCUUU CUGAUGAG GCCGUUAGGC CGAA IACCAACC 2002 1168 AGAAUGAC A CGAUUCUU 581 AAGAAUCG CUGAUGAG GCCGUUAGGC CGAA IUCAUUCU 2003 1175 CACGAUUC U UUACCAAA 582 UUUGGUAA CUGAUGAG GCCGU UAGGC CGAA IAAUCGUG 2004 1180 UUCUUUAC C AAAUUGGA 583 UCCAAUUU CUGAUGAG GCCGUUAGGC CGAA IUAAAGAA 2005 1181 UCUUUACC A AAUUGGAU 584 AUCCAAUU CUGAUGAG GCCGUUAGGC CGAA IGUAAAGA 2006 1192 UUGGAUGC A GACAAAUC 585 GAUUUGUC CUGAUGAG GCCGUUAGGC CGAA ICAUCCAA 2007 1196 AUGCAGAC A AAUCUUAU 586 AUAAGAUU CUGAUGAG GCCGUUAGGC CGAA IUCUGCAU 2008 1201 GACAAAUC U UAUCAAUG 587 CAUUGAUA CUGAUGAG GCCGUUAGGC CGAA IAUUUGUC 2009 1206 AUCUUAUC A AUGCCUGA 588 UCAGGCAU CUGAUGAG GCCGUUAGGC CGAA IAUAAGAU 2010 1211 AUCAAUGC C UGAAAGAG 589 CUCUUUCA CUGAUGAG GCCGUUAGGC CGAA ICAUUGAU 2011 1212 UCAAUGCC U GAAAGAGA 590 UCUCUUUC CUGAUGAG GCCGUUAGGC CGAA IGCAU UGA 2012 1222 AAAGAGAC U UGUGAGAA 591 UUCUCACA CUGAUGAG GCCGUUAGGC CGAA IUCUCUUU 2013 1238 AGUUGGGC U AUCAAUGG 592 CCAUUGAU CUGAUGAG GCCGUUAGGC CGAA ICCCAACU 2014 1242 GGGCUAUC A AUGGAAGA 593 UCUUCCAU CUGAUGAG GCCGUUAGGC CGAA IAUAGCCC 2015 1266 UAUGAAUC A GGUUACUA 594 UAGUAACC CUGAUGAG GCCGUTUAGGC CGAA IAUUCAUA 2016 1273 CAGGUUAC U AUAUCAAC 595 GUUGAUAU CUGAUGAG GCCGUUAGGC CGAA IUAACCUG 2017 1279 ACUAUAUC A ACAACUGA 596 UCAGUUGU CUGAUGAG GCCGUUAGGC CGAA IAUAUAGU 2018 1282 AUAUCAAC A ACUGAUAG 597 CUAUCAGU CUGAUGAG GCCGUUAGGC CGAA IUUGAUAU 2019 1285 UCAACAAC U GAUAGGAG 598 CUCCUAUC CUGAUGAG GCCGUUAGGC CGAA IUUGUUGA 2020 1298 GGAGAAAC A AUAAACUC 599 GAGUUUAU CUGAUGAG GCCGUUAGGC CGAA IUU UCUCC 2021 WO 01/57206 PCT/USO1/03504 65 1305 CAAUAAAC U CAUUUUCA 600 UGAAAAUG CUGAUGAG GCCGUUAGGC CGAA IUTUAUUG 2022 1307 AUAAACUC A UUTUCAAA 601 UUUGAAAA CUGAUGAG GCCGUUAGGC CGAA IAGUUUAU 2023 1313 UCAUTUUC A AAGUGAAU 602 AUUCACUU CUGAUGAG GCCGUUAGGC CGAA IAAAAUGA 2024 1355 UGGUUGAC U UCCGGCUU 603 AAGCCGGA CUGAUGAG GCCGUUAGGC CGAA IUCAACCA 2025 1358 UUGACUUC C GGCUUUCU 604 AGAAAGCC CUGAUGAG GCCGUUAGGC CGAA IAAGUCAA 2026 1362 CUUCCGGC U UUCUAAGG 605 CCUUAGAA CUGAUGAG GCCGUUAGGC CGAA ICCGGAAG 2027 1366 CGGCUUUC U AAGGGUGA 606 UCACCCUU CUGAUGAG GCCGUUAGGC CGAA IAAAGCCG 2028 1388 UGGAGUUC A AGAGACAC 607 GUGUCUCU CUGAUGAG GCCGUUAGGC CGAA IAACUCCA 2029 1395 CAAGAGAC A CUUCCUGA 608 UCAGGAAG CUGAUGAG GCCGUUAGGC CGAA IUCUCUUG 2030 1397 AGAGACAC U UCCUGAAG 609 CUUCAGGA CUGAUGAG GCCGUUAGGC CGAA IUGUCUCU 2031 1400 GACACUUC C UGAAGAUU 610 AAUCUUCA CUGAUGAG GCCGUUAGGC CGAA IAAGUGUC 2032 1401 ACACUUCC U GAAGAUUA 611 UAAUCUUC CUGAUGAG GCCGUUAGGC CGAA IGAAGUGU 2033 1419 AGGGAAGC U GAUUGAUA 612 UAUCAAUC CUGAUGAG GCCGUUAGGC CGAA ICUUCCCU 2034 1436 UUGUGAGC A GCCAGAAG 613 CUUCUGGC CUGAUGAG GCCGUUAGGC CGAA ICUCACAA 2035 1439 UGAGCAGC C AGAAGGUU 614 AACCUUCU CUGAUGAG GCCGUUAGGC CGAA ICUGCUCA 2036 1440 GAGCAGCC A GAAGGUUU 615 AAACCUUC CUGAUGAG GCCGUUAGGC CGAA IGCUGCUC 2037 1452 GGUUUGGC U UCCUGCCA 616 UGGCAGGA CUGAUGAG GCCGUUAGGC CGAA ICCAAACC 2038 1455 UUGGCUUC C UGCCACAU 617 AUGUGGCA CUGAUGAG GCCGUUAGGC CGAA IAAGCCAA 2039 1456 UGGCUUCC U GCCACAUG 618 CAUGUGGC CUGAUGAG GCCGUUAGGC CGAA IGAAGCCA 2040 1459 CUUCCUGC C ACAUGAUC 619 GAUCAUGU CUGAUGAG GCCGUUAGGC CGAA ICAGGAAG 2041 1460 UUCCUGCC A CAUGAUCG 620 CGAUCAUG CUGAUGAG GCCGUUAGGC CGAA IGCAGGAA 2042 1462 CCUGCCAC A UGAUCGGA 621 UCCGAUCA CUGAUGAG GCCGUUAGGC CGAA IUGGCAGG 2043 1472 GAUCGGAC C AUCGGCUC 622 GAGCCGAU CUGAUGAG GCCGUUAGGC CGAA IUCCGAUC 2044 1473 AUCGGACC A UCGGCUCU 623 AGAGCCGA CUGAUGAG GCCGUUAGGC CGAA IGUCCGAU 2045 1479 CCAUCGGC U CUGGGGAA 624 UUCCCCAG CUGAUGAG GCCGUUAGGC CGAA ICCGAUGG 2046 1481 AUCGGCUC U GGGGAAUC 625 GAUJCCCC CUGAUGAG GCCGUUAGGC CGAA IAGCCGAU 2047 1490 GGGGAAUC C UGGUGAAU 626 AUUCACCA CUGAUGAG GCCGUUAGGC CGAA IAUUCCCC 2048 1491 GGGAAUCC U GGUGAAUA 627 UAUUCACC CUGAUGAG GCCGUUAGGC CGAA IGAUUCCC 2049 1506 UAUAGUGC U GCUAUGUU 628 AACAUAGC CUGAUGAG GCCGUUAGGC CGAA ICACUAUA 2050 1509 AGUGCUGC U AUGUUGAC 629 GUCAACAU CUGAUGAG GCCGUUAGGC CGAA ICAGCACU 2051 1518 AUGUUGAC A UUAUUCUU 630 AAGAAUAA CUGAUGAG GCCGUUAGGC CGAA IUCAACAU 2052 1525 CAUUAUUC U UCCUAGAG 631 CUCUAGGA CUGAUGAG GCCGUUAGGC CGAA IAAUAAUG 2053 1528 UAUUCUUC C UAGAGAAG 632 CUUCUCUA CUGAUGAG GCCGUUAGGC CGAA IAAGAAUA 2054 1529 AUUCUUCC U AGAGAAGA 633 UCUUCUCU CUGAUGAG GCCGUUAGGC CGAA IGAAGAAU 2055 1543 AGAUUAUC C UGUCCUGC 634 GCAGGACA CUGAUGAG GCCGUUAGGC CGAA IAUAAUCU 2056 1544 GAUUAUCC U GUCCUGCA 635 UGCAGGAC CUGAUGAG GCCGUUAGGC CGAA IGAUAAUC 2057 1548 AUCCUGUC C UGCAAACU 636 AGUUUGCA CUGAUGAG GCCGUUAGGC CGAA IACAGGAU 2058 1549 UCCUGUCC U GCAAACUG 637 CAGUUUGC CUGAUGAG GCCGUUAGGC CGAA IGACAGGA 2059 1552 UGUCCUGC A AACUGCAA 638 UUGCAGUU CUGAUGAG GCCGUUAGGC CGAA ICAGGACA 2060 1556 CUGCAAAC U GCAAAUAG 639 CUAUUUGC CUGAUGAG GCCGUUAGGC CGAA IUUUGCAG 2061 1559 CAAACUGC A AAUAGUAG 640 CUACUAUU CUGAUGAG GCCGUUAGGC CGAA ICAGUUUG 2062 1571 AGUAGUUC C UGAAGUGU 641 ACACUJCA CUGAUGAG GCCGUUAGGC CGAA IAACUACU 2063 1572 GUAGUUCC U GAAGUGUU 642 AACACUUC CUGAUGAG GCCGUUAGGC CGAA IGAACUAC 2064 1582 AAGUGUUC A CUUCCCUG 643 CAGGGAAG CUGAUGAG GCCGUUAGGC CGAA IAACACUU 2065 1584 GUGUUCAC U UCCCUGUU 644 AACAGGGA CUGAUGAG GCCGUUAGGC CGAA IUGAACAC 2066 1587 UUCACUUC C CUGUUUAU 645 AUAAACAG CUGAUGAG GCCGUUAGGC CGAA IAAGUGAA 2067 1588 UCACUUCC C UGUUUAUC 646 GAUAAACA CUGAUGAG GCCGUUAGGC CGAA IGAAGUGA 2068 1589 CACUUCCC U GUUUAUCC 647 GGAUAAAC CUGAUGAG GCCGUUAGGC CGAA IGGAAGUG 2069 1597 UGUUUAUC C AAACAUCU 648 AGAUGUUU CUGAUGAG GCCGUUAGGC CGAA IAUAAACA 2070 WO 01/57206 PCT/USO1/03504 66 1598 GUUUAUCC A AACAUCUU 649 AAGAUGUU CUGAUGAG GCCGUUAGGC CGAA IGAUAAAC 2071 1602 AUCCAAAC A UCUUCCAA 650 UUGGAAGA CUGAUGAG GCCGUUAGGC CGAA IUUUGGAU 2072 1605 CAAACAUC U UCCAAUUU 651 AAAUUGGA CUGAUGAG GCCGUUAGGC CGAA IAUGUUUG 2073 1608 ACAUCUUC C AAUUUAUU 652 AAUAAAUU CUGAUGAG GCCGUUAGGC CGAA IAAGAUGU 2074 1609 CAUCUUCC A AUUUAUUU 653 AAAUAAAU CUGAUGAG GCCGUUAGGC CGAA IGAAGAUG 2075 1630 UGUUCGGC A UACAAAUA 654 UAUUUGUA CUGAUGAG GCCGUUAGGC CGAA ICCGAACA 2076 1634 CGGCAUAC A AAUAAUAC 655 GUAUUAUU CUGAUGAG GCCGUUAGGC CGAA IUAUGCCG 2077 1643 AAUAAUAC C UAUAUCUU 656 AAGAUAUA CUGAUGAG GCCGUUAGGC CGAA IUAUUAUU 2078 1644 AUAAUACC U AUAUCUUA 657 UAAGAUAU CUGAUGAG GCCGUUAGGC CGAA IGUAUUAU 2079 1650 CCUAUAUC U UAAUUGUA 658 UACAAUUA CUGAUGAG GCCGUUAGGC CGAA IAUAUAGG 2080 1662 UUGUAAGC A AAACUUUG 659 CAAAGUU CUGAUGAG GCCGUUAGGC CGAA ICUUACAA 2081 1667 AGCAAAAC U UUGGGGAA 660 UUCCCCAA CUGAUGAG GCCGUUAGGC CGAA IUUUEGCU 2082 1692 UAGAAUUC A UUUGAUUA 661 UAAUCAAA CUGAUGAG GCCGUUAGGC CGAA IAAUUCUA 2083 1705 AUUAUUUC U UCAUGUGU 662 ACACAUGA CUGAUGAG GCCGUUAGGC CGAA IAAAUAAU 2084 1708 AUUUCUUC A UGUGUGUU 663 AACACACA CUGAUGAG GCCGUUAGGC CGAA IAAGAAAU 2085 1724 UUAGUAUC U GAAUUUGA 664 UCAAAUUC CUGAUGAG GCCGUUAGGC CGAA IAUACUAA 2086 1736 UUUGAAAC U CAUCUGGU 665 ACCAGAUG CUGAUGAG GCCGUUAGGC CGAA IUUUCAAA 2087 1738 UGAAACUC A UCUGGUGG 666 CCACCAGA CUGAUGAG GCCGUUAGGC CGAA IAGUUUCA 2088 1741 AACUCAUC U GGUGGAAA 667 UUUCCACC CUGAUGAG GCCGUUAGGC CGAA IAUGAGUU 2089 1751 GUGGAAAC C AAGUUUCA 668 UGAAACUU CUGAUGAG GCCGUUAGGC CGAA IUUUCCAC 2090 1752 UGGAAACC A AGUUUCAG 669 CUGAAACU CUGAUGAG GCCGUUAGGC CGAA IGUUUCCA 2091 1759 CAAGUUUC A GGGGACAU 670 AUGUCCCC CUGAUGAG GCCGUUAGGC CGAA IAAACUUG 2092 1766 CAGGGGAC A UGAGUUUU 671 AAAACUCA CUGAUGAG GCCGUUAGGC CGAA IUCCCCUG 2093 1776 GAGUUUUC C AGCUUUUA 672 UAAAAGCU CUGAUGAG GCCGUUAGGC CGAA IAAAACUC 2094 1777 AGUUUUCC A GCUUUUAU 673 AUAAAAGC CUGAUGAG GCCGUUAGGC CGAA IGAAAACU 2095 1780 UUUCCAGC U UUUAUACA 674 UGUAUAAA CUGAUGAG GCCGUUAGGC CGAA ICUGGAAA 2096 1788 UUUUAUAC A CACGUAUC 675 GAUACGUG CUGAUGAG GCCGUUAGGC CGAA IUAUAAAA 2097 1790 UUAUACAC A CGUAUCUC 676 GAGAUACG CUGAUGAG GCCGUUAGGC CGAA IUGUAUAA 2098 1797 CACGUAUC U CAUUUUUA 677 UAAAAAUG CUGAUGAG GCCGUUAGGC CGAA IAUACGUG 2099 1799 CGUAUCUC A UUUUUAUC 678 GAUAAAAA CUGAUGAG GCCGUUAGGC CGAA IAGAUACG 2100 1808 UUUUUAUC A AAACAUUU 679 AAAUGUUU CUGAUGAG GCCGUUAGGC CGAA IAUAAAAA 2101 1813 AUCAAAAC A UUUUGUUJU 680 AAACAAAA CUGAUGAG GCCGUUAGGC CGAA IUUUUGAU 2102 Input Sequence = AF016582 Cut Site = CH/. Stem Length = 8. Core Sequence = CUGAUGAG GCCGUUAGGC CGAA AF016582 (Homo sapiens checkpoint kinase Chk1 (CHKI) mRNA; 1821 bp) Underlined region can be any X sequence or linker as previously defined herein. I= Inosine 5 WO 01/57206 PCT/USO1/03504 67 Table V: Human Chk1 G-Cleaver Ribozyme and Substrate Sequence Pos Substrate Seq ID Ribozyme Rz Seq ID 14 GACAGUCC G CCGAGGUG 681 CACCUCGG UGAUGGCAUGCACUAUGCGCG GGACUGUC 2103 17 AGUCCGCC G AGGUGCUC 682 GAGCACCU UGAUGGCAUGCACUAUGCGCG GGCGGACU 2104 22 GCCGAGGU G CUCGGUGG 683 CCACCGAG UGAUGGCAUGCACUAUGCGCG ACCUCGGC 2105 43 AUGGCAGU G CCCUUUGU 684 ACAAAGGG UGAUGGCAUGCACUAUGCGCG ACUGCCAU 2106 50 UGCCCUUU G UGGAAGAC 685 GUCUUCCA UGAUGGCAUGCACUAUGCGCG AAAGGGCA 2107 70 GACUUGGU G CAAACCCU 686 AGGGUUUG UGAUGGCAUGCACUAUGCGCG ACCAAGUC 2108 89 GAGAAGGU G CCUAUGGA 687 UCCAUAGG UGAUGGCAUGCACUAUGCGCG ACCUUCUC 2109 110 UUCAACUU G CUGUGAAU 688 AUUCACAG UGAUGGCAUGCACUAUGCGCG AAGUUGAA 2110 113 AACUUGCU G UGAAUAGA 689 UCUAUUCA UGAUGGCAUGCACUAUGCGCG AGCAAGUU 2111 115 CUUGCUGU G AAUAGAGU 690 ACUCUAUU UGAUGGCAUGCACUAUGCGCG ACAGCAAG 2112 128 GAGUAACU G AAGAAGCA 691 UGCUUCUU UGAUGGCAUGCACUAUGCGCG AGUUACUC 2113 140 AAGCAGUC G CAGUGAAG 692 CUUCACUG UGAUGGCAUGCACUAUGCGCG GACUGCUU 2114 145 GUCGCAGU G AAGAUUGU 693 ACAAUCUU UGAUGGCAUGCACUAUGCGCG ACUGCGAC 2115 152 UGAAGAUU G UAGAUAUG 694 CAUAUCUA UGAUGGCAUGCACUAUGCGCG AAUCUUCA 2116 160 GUAGAUAU G AAGCGUGC 695 GCACGCUU UGAUGGCAUGCACUAUGCGCG AUAUCUAC 2117 167 UGAAGCGU G CCGUAGAC 696 GUCUACGG UGAUGGCAUGCACUAUGCGCG ACGCUCA 2118 177 CGUAGACU G UCCAGAAA 697 UUUCUGGA UGAUGGCAUGCACUAUGCGCG AGUCUACG 2119 204 AGAGAUCU G UAUCAAUA 698 UAUUGAUA UGAUGGCAUGCACUAUGCGCG AGAUCUCU 2120 217 AAUAAAAU G CUAAAUCA 699 UGAUUUAG UGAUGGCAUGCACUAUGCGCG AUUUUAUU 2121 227 UAAAUCAU G AAAAUGUA 700 UACAUUUU UGAUGGCAUGCACUAUGCGCG AUGAUUUA 2122 233 AUGAAAAU G UAGUAAAA 701 UUUUACUA UGAUGGCAUGCACUAUGCGCG AUUUUCAU 2123 294 GGAGUACU G UAGUGGAG 702 CUCCACUA UGAUGGCAUGCACUAUGCGCG AGUACUCC 2124 314 AGCUUUUU G ACAGAAUA 703 UAUUCUGU UGAUGGCAUGCACUAUGCGCG AAAAAGCU 2125 340 AUAGGCAU G CCUGAACC 704 GGUUCAGG UGAUGGCAUGCACUAUGCGCG AUGCCUAU 2126 344 GCAUGCCU G AACCAGAU 705 AUCUGGUU UGAUGGCAUGCACUAUGCGCG AGGCAUGC 2127 353 AACCAGAU G CUCAGAGA 706 UCUCUGAG UGAUGGCAUGCACUAUGCGCG AUCUGGUU 2128 397 GUUUAUCU G CAUGGUAU 707 AUACCAUG UGAUGGCAUGCACUAUGCGCG AGAUAAAC 2129 445 AAUCUUCU G UUGGAUGA 708 UCAUCCAA UGAUGGCAUGCACUAUGCGCG AGAAGAUU 2130 452 UGUUGGAU G AAAGGGAU 709 AUCCCUUU UGAUGGCAUGCACUAUGCGCG AUCCAACA 2131 515 AUAAUCGU G AGCGUUUG 710 CAAACGCU UGAUGGCAUGCACUAUGCGCG ACGAUUAU 2132 523 GAGCGUUU G UUGAACAA 711 UUGUUCAA UGAUGGCAUGCACUAUGCGCG AAACGCUC 2133 526 CGUUUGUU G AACAAGAU 712 AUCUUGUU UGAUGGCAUGCACUAUGCGCG AACAAACG 2134 535 AACAAGAU G UGUGGUAC 713 GUACCACA UGAUGGCAUGCACUAUGCGCG AUCUUGUU 2135 537 CAAGAUGU G UGGUACUU 714 AAGUACCA UGAUGGCAUGCACUAUGCGCG ACAUCUUG 2136 554 UACCAUAU G UUGCUCCA 715 UGGAGCAA UGAUGGCAUGCACUAUGCGCG AUAUGGUA 2137 557 CAUAUGUU G CUCCAGAA 716 UUCUGGAG UGAUGGCAUGCACUAUGCGCG AACAUAUG 2138 571 GAACUUCU G AAGAGAAG 717 CUUCUCUU UGAUGGCAUGCACUAUGCGCG AGAAGUUC 2139 590 AAUUUCAU G CAGAACCA 718 UGGUUCUG UGAUGGCAUGCACUAUGCGCG AUGAAAUU 2140 602 AACCAGUU G AUGUUUGG 719 CCAAACAU UGAUGGCAUGCACUAUGCGCG AACUGGUU 2141 605 CAGUUGAU G UUUGGUCC 720 GGACCAAA UGAUGGCAUGCACUAUGCGCG AUCAACUG 2142 615 UUGGUCCU G UGGAAUAG 721 CUAUUCCA UGAUGGCAUGCACUAUGCGCG AGGACCAA 2143 632 UACUUACU G CAAUGCUC 722 GAGCAUUG UGAUGGCAUGCACUAUGCGCG AGUAAGUA 2144 637 ACUGCAAU G CUCGCUGG 723 CCAGCGAG UGAUGGCAUGCACUAUGCGCG AUUGCAGU 2145 641 CAAUGCUC G CUGGAGAA 724 UUCUCCAG UGAUGGCAUGCACUAUGCGCG GAGCAUUG 2146 652 GGAGAAUU G CCAUGGGA 725 UCCCAUGG UGAUGGCAUGCACUAUGCGCG AAUUCUCC 2147 671 AACCCAGU G ACAGCUGU 726 ACAGCUGU UGAUGGCAUGCACUAUGCGCG ACUGGGUU 2148 WO 01/57206 PCT/USO1/03504 68 678 UGACAGCU G UCAGGAGU 727 ACUCCUGA UGAUGGCAUGCACUAUGCGCG AGCUGUCA 2149 692 AGUAUUCU G ACUGGAAA 728 UUUCCAGU UGAUGGCAUGCACUAUGCGCG AGAAUACU 2150 737 AAAAAAUC G AUUCUGCU 729 AGCAGAAU UGAUGGCAUGCACUAUGCGCG GAUUUUUU 2151 743 UCGAUUCU G CUCCUCUA 730 UAGAGGAG UGAUGGCAUGCACUAUGCGCG AGAAUCGA 2152 757 CUAGCUCU G CUGCAUAA 731 UUAUGCAG UGAUGGCAUGCACUAUGCGCG AGAGCUAG 2153 760 GCUCUGCU G CAUAAAAU 732 AUUTUAUG UGAUGGCAUGCACUAUGCGCG AGCAGAGC 2154 776 UCUUAGUU G AGAAUCCA 733 UGGAUUCU UGAUGGCAUGCACUAUGCGCG AACUAAGA 2155 864 AAGGCCCC G AGUCACUU 734 AAGUGACU UGAUGGCAUGCACUAUGCGCG GGGGCCUU 2156 881 CAGGUGGU G UGUCAGAG 735 CUCUGACA UGAUGGCAUGCACUAUGCGCG ACCACCUG 2157 883 GGUGGUGU G UCAGAGUC 736 GACUCUGA UGAUGGCAUGCACUAUGCGCG ACACCACC 2158 950 UAAACAGU G CUUCUAGU 737 ACUAGAAG UGAUGGCAUGCACUAUGCGCG ACUGUUUA 2159 959 CUUCUAGU G AAGAAAAU 738 AUUUUCUU UGAUGGCAUGCACUAUGCGCG ACUAGAAG 2160 968 AAGAAAAU G UGAAGUAC 739 GUACUUCA UGAUGGCAUGCACUAUGCGCG AUJUUCUU 2161 970 GAAAAUGU G AAGUACUC 740 GAGUACUU UGAUGGCAUGCACUAUGCGCG ACALTUUUC 2162 999 AGAACCCC G CACAGGUC 741 GACCUGUG UGAUGGCAUGCACUAUGCGCG GGGGUUCU 2163 1040 CAUACAUU G AUAAAUUG 742 CAAUUUAU UGAUGGCAUGCACUAUGCGCG AAUGUAUG 2164 1080 GCCCACAU G UCCUGAUC 743 GAUCAGGA UGAUGGCAUGCACUAUGCGCG AUGUGGGC 2165 1085 CAUGUCCU G AUCAUAUG 744 CAUAUGAU UGAUGGCAUGCACUAUGCGCG AGGACAUG 2166 1093 GAUCAUAU G CUUUUGAA 745 UUCAAAAG UGAUGGCAUGCACUAUGCGCG AUAUGAUC 2167 1099 AUGCUUUU G AAUAGUCA 746 UGACUAUU UGAUGGCAUGCACUAUGCGCG AAAAGCAU 2168 1165 AAAAGAAU G ACACGAUU 747 AAUCGUGU UGAUGGCAUGCACUAUGCGCG AUUCUUUU 2169 1170 AAUGACAC G AUUCUYUA 748 UAAAGAAU UGAUGGCAUGCACUAUGCGCG GUGUCAUU 2170 1190 AAUUGGAU G CAGACAAA 749 UUUGUCUG UGAUGGCAUGCACUAUGCGCG AUCCAAUU 2171 1209 UUAUCAAU G CCUGAAAG 750 CUUUCAGG UGAUGGCAUGCACUAUGCGCG AUUGAUAA 2172 1213 CAAUGCCU G AAAGAGAC 751 GUCUCUUU UGAUGGCAUGCACUAUGCGCG AGGCAUUG 2173 1224 AGAGACUU G UGAGAAGU 752 ACUUCUCA UGAUGGCAUGCACUAUGCGCG AAGUCUCU 2174 1226 AGACUUGU G AGAAGUUG 753 CAACUUCU UGAUGGCAUGCACUAUGCGCG ACAAGUCU 2175 1257 GAAAAGUU G UAUGAAUC 754 GAUUCAUA UGAUGGCAUGCACUAUGCGCG AACUUUUC 2176 1261 AGUUGUAU G AAUCAGGU 755 ACCUGAUU UGAUGGCAUGCACUAUGCGCG AUACAACU 2177 1286 CAACAACU G AUAGGAGA 756 UCUCCUAU UGAUGGCAUGCACUAUGCGCG AGUUGUUG 2178 1318 UUCAAAGU G AAUUUGUU 757 AACAAAUU UGAUGGCAUGCACUAUGCGCG ACUUUGAA 2179 1324 GUGAAUUU G UUAGAAAU 758 AUUUCUAA UGAUGGCAUGCACUAUGCGCG AAAUUCAC 2180 1337 AAAUGGAU G AUAAAAUA 759 UAUUUUAU UGAUGGCAUGCACUAUGCGCG AUCCAUUU 2181 1352 UAUUGGUU G ACUUCCGG 760 CCGGAAGU UGAUGGCAUGCACUAUGCGCG AACCAAUA 2182 1373 CUAAGGGU G AUGGAUUG 761 CAAUCCAU UGAUGGCAUGCACUAUGCGCG ACCCUUAG 2183 1402 CACUUCCU G AAGAUUAA 762 UUAAUCUU UGAUGGCAUGCACUAUGCGCG AGGAAGUG 2184 1420 GGGAAGCU G AUUGAUAU 763 AUAUCAAU UGAUGGCAUGCACUAUGCGCG AGCUUCCC 2185 1424 AGCUGAUU G AUAUUGUG 764 CACAAUAU UGAUGGCAUGCACUAUGCGCG AAUCAGCU 2186 1430 UUGAUAUU G UGAGCAGC 765 GCUGCUCA UGAUGGCAUGCACUAUGCGCG AAUAUCAA 2187 1432 GAUAUUGU G AGCAGCCA 766 UGGCUGCU UGAUGGCAUGCACUAUGCGCG ACAAUAUC 2188 1457 GGCUUCCU G CCACAUGA 767 UCAUGUGG UGAUGGCAUGCACUAUGCGCG AGGAAGCC 2189 1464 UGCCACAU G AUCGGACC 768 GGUCCGAU UGAUGGCAUGCACUAUGCGCG AUGUGGCA 2190 1495 AUCCUGGU G AAUAUAGU 769 ACUAUAUU UGAUGGCAUGCACUAUGCGCG ACCAGGAU 2191 1504 AAUAUAGU G CUGCUAUG 770 CAUAGCAG UGAUGGCAUGCACUAUGCGCG ACUAUAUU 2192 1507 AUAGUGCU G CUAUGUUG 771 CAACAUAG UGAUGGCAUGCACUAUGCGCG AGCACUAU 2193 1512 GCUGCUAU G UUGACAUU 772 AAUGUCAA UGAUGGCAUGCACUAUGCGCG AUAGCAGC 2194 1515 GCUAUGUU G ACAUUAUU 773 AAUAAUGU UGAUGGCAUGCACUAUGCGCG AACAUAGC 2195 1545 AUUAUCCU G UCCUGCAA 774 UUGCAGGA UGAUGGCAUGCACUAUGCGCG AGGAUAAU 2196 1550 CCUGUCCU G CAAACUGC 775 GCAGUUUG UGAUGGCAUGCACUAUGCGCG AGGACAGG 2197 WO 01/57206 PCT/USO1/03504 69 1557 UGCAAACU G CAAAUAGU 776 ACUAUUUG UGAUGGCAUGCACUAUGCGCG AGUUUGCA 2198 1573 UAGUUCCU G AAGUGUUC 777 GAACACUU UGAUGGCAUGCACUAUGCGCG AGGAACUA 2199 1578 CCUGAAGU G UJCACUUC 778 GAAGUGAA UGAUGGCAUGCACUAUGCGCG ACUUCAGG 2200 1590 ACUUCCCU G UUUAUCCA 779 UGGAUAAA UGAUGGCAUGCACUAUGCGCG AGGGAAGU 2201 1619 UUUAUUUU G UUUGUUCG 780 CGAACAAA UGAUGGCAUGCACUAUGCGCG AAAAUAAA 2202 1623 UUUUGUUU G UUCGGCAU 781 AUGCCGAA UGAUGGCAUGCACUAUGCGCG AAACAAAA 2203 1656 UCUUAAUU G UAAGCAAA 782 UUUGCUUA UGAUGGCAUGCACUAUGCGCG AAUUAAGA 2204 1681 GAAAGGAU G AAUAGAAU 783 AUUCUAUU UGAUGGCAUGCACUAUGCGCG AUCCUUUC 2205 1696 AUUCAUUU G AUUAUUUC 784 GAAAUAAU UGAUGGCAUGCACUAUGCGCG AAAUGAAU 2206 1710 UUCUUCAU G UGUGUUUA 785 UAAACACA UGAUGGCAUGCACUAUGCGCG AUGAAGAA 2207 1712 CUUCAUGU G UGUUUAGU 786 ACUAAACA UGAUGGCAUGCACUAUGCGCG ACAUGAAG 2208 1714 UCAUGUGU G UUUAGUJAU 787 AUACUAAA UGAUGGCAUGCACUAUGCGCG ACACAUGA 2209 1725 UAGUAUCU G AAUUGAA 788 UUCAAAUU UGAUGGCAUGCACUAUGCGCG AGAUACUA 2210 1731 CUGAAUUU G AAACUCAU 789 AUGAGUUU UGAUGGCAUGCACUAUGCGCG AAAUUCAG 2211 1768 GGGGACAU G AGUUUUCC 790 GGAAAACU UGAUGGCAUGCACUAUGCGCG AUGUCCCC 2212 Input Sequence= AF016582. Cut Site =YG/M or UG/U. Stem Length = 8. Core Sequence = UGAUG GCAUGCACUAUGC GCG AF016582 (Homo sapiens checkpoint kinase Chkl (CHK1) mRNA; 1821 bp) WO 01/57206 PCT/USO1/03504 70 Table VI: Human Chk1 Zinzyme Ribozyme and Substrate Sequence Pos Substrate Seq ID Ribozyme Rz Seq ID 10 GCCGGACA G UCCGCCGA 791 UCGGCGGA GCCGAAAGGCGAGUCAAGGUCU UGUCCGGC 2213 14 GACAGUCC G CCGAGGUG 792 CACCUCGG GCCGAAAGGCGAGUCAAGGUCU GGACUGUC 2214 20 CCGCCGAG G UGCUCGGU 793 ACCGAGCA GCCGAAAGGCGAGUCAAGGUCU CUCGGCGG 2215 22 GCCGAGGU G CUCGGUGG 794 CCACCGAG GCCGAAAGGCGAGUCAAGGUCU ACCUCGGC 2216 27 GGUGCUCG G UGGAGUCA 795 UGACUCCA GCCGAAAGGCGAGUCAAGGUCU CGAGCACC 2217 32 UCGGUGGA G UCAUGGCA 796 UGCCAUGA GCCGAAAGGCGAGUCAAGGUCU UCCACCGA 2218 38 GAGUCAUG G CAGUGCCC 797 GGGCACUG GCCGAAAGGCGAGUCAAGGUCU CAUGACUC 2219 41 UCAUGGCA G UGCCCUUU 798 AAAGGGCA GCCGAAAGGCGAGUCAAGGUCU UGCCAUGA 2220 43 AUGGCAGU G CCCUUUGU 799 ACAAAGGG GCCGAAAGGCGAGUCAAGGUCU ACUGCCAU 2221 50 UGCCCUUU G UGGAAGAC 800 GUCUUCCA GCCGAAAGGCGAGUCAAGGUCU AAAGGGCA 2222 68 GGGACUUG G UGCAAACC 801 GGUUUGCA GCCGAAAGGCGAGUCAAGGUCU CAAGUCCC 2223 70 GACUUGGU G CAAACCCU 802 AGGGUUJUG GCCGAAAGGCGAGUCAAGGUCU ACCAAGUC 2224 87 GGGAGAAG G UGCCUAUG 803 CAUAGGCA GCCGAAAGGCGAGUCAAGGUCU CUUCUCCC 2225 89 GAGAAGGU G CCUAUGGA 804 UCCAUAGG GCCGAAAGGCGAGUCAAGGUCU ACCUUCUC 2226 101 AUGGAGAA G UUCAACUU 805 AAGUUGAA GCCGAAAGGCGAGUCAAGGUCU UUCUCCAU 2227 110 UUCAACUU G CUGUGAAU 806 AUUCACAG GCCGAAAGGCGAGUCAAGGUCU AAGUUGAA 2228 113 AACUUGCU G UGAAUAGA 807 UCUAUUCA GCCGAAAGGCGAGUCAAGGUCU AGCAAGUU 2229 122 UGAAUAGA G UAACUGAA 808 UUCAGUUA GCCGAAAGGCGAGUCAAGGUCU UCUAUUCA 2230 134 CUGAAGAA G CAGUCGCA 809 UGCGACUG GCCGAAAGGCGAGUCAAGGUCU UUCUUCAG 2231 137 AAGAAGCA G UCGCAGUG 810 CACUGCGA GCCGAAAGGCGAGUCAAGGUCU UGCUUCUU 2232 140 AAGCAGUC G CAGUGAAG 811 CUUCACUG GCCGAAAGGCGAGUCAAGGUCU GACUGCUU 2233 143 CAGUCGCA G UGAAGAUU 812 AAUCUUCA GCCGAAAGGCGAGUCAAGGUCU UGCGACUG 2234 152 UGAAGAUU G UAGAUAUG 813 CAUAUCUA GCCGAAAGGCGAGUCAAGGUCU AAUCUUCA 2235 163 GAUAUGAA G CGUGCCGU 814 ACGGCACG GCCGAAAGGCGAGUCAAGGUCU UUCAUAUC 2236 165 UAUGAAGC G UGCCGUAG 815 CUACGGCA GCCGAAAGGCGAGUCAAGGUCU GCUUCAUA 2237 167 UGAAGCGU G CCGUAGAC 816 GUCUACGG GCCGAAAGGCGAGUCAAGGUCU ACGCUUCA 2238 170 AGCGUGCC G UAGACUGU 817 ACAGUCUA GCCGAAAGGCGAGUCAAGGUCU GGCACGCU 2239 177 CGUAGACU G UCCAGAAA 818 UUUCUGGA GCCGAAAGGCGAGUCAAGGUCU AGUCUACG 2240 204 AGAGAUCU G UAUCAAUA 819 UAUUGAUA GCCGAAAGGCGAGUCAAGGUCU AGAUCUCU 2241 217 AAUAAAAU G CUAAAUCA 820 UGAUUTJAG GCCGAAAGGCGAGUCAAGGUCU AUUUUAUU 2242 233 AUGAAAAU G UAGUAAAA 821 UUUTUACUA GCCGAAAGGCGAGUCAAGGUCU AUUUCAU 2243 236 AAAAUGUA G UAAAAUUC 822 GAAUUUUA GCCGAAAGGCGAGUCAAGGUCU UACAUUUU 2244 249 AUUCUAUG G UCACAGGA 823 UCCUGUGA GCCGAAAGGCGAGUCAAGGUCU CAUAGAAU 2245 264 GAGAGAAG G CAAUAUCC 824 GGAUAUUG GCCGAAAGGCGAGUCAAGGUCU CUUCUCUC 2246 289 UUUCUGGA G UACUGUAG 825 CUACAGUA GCCGAAAGGCGAGUCAAGGUCU UCCAGAAA 2247 294 GGAGUACU G UAGUGGAG 826 CUCCACUA GCCGAAAGGCGAGUCAAGGUCU AGUACUCC 2248 297 GUACUGUA G UGGAGGAG 827 CUCCUCCA GCCGAAAGGCGAGUCAAGGUCU UACAGUAC 2249 307 GGAGGAGA G CUUUUUGA 828 UCAAAAAG GCCGAAAGGCGAGUCAAGGUCU UCUCCUCC 2250 325 AGAAUAGA G CCAGACAU 829 AUGUCUGG GCCGAAAGGCGAGUCAAGGUCU UCUAUUCU 2251 336 AGACAUAG G CAUGCCUG 830 CAGGCAUG GCCGAAAGGCGAGUCAAGGUCU CUAUGUCU 2252 340 AUAGGCAU G CCUGAACC 831 GGUUCAGG GCCGAAAGGCGAGUCAAGGUCU AUGCCUAU 2253 353 AACCAGAU G CUCAGAGA 832 UCUCUGAG GCCGAAAGGCGAGUCAAGGUCU AUCUGGUU 2254 380 AACUCAUG G CAGGGGUG 833 CACCCCUG GCCGAAAGGCGAGUCAAGGUCU CAUGAGUU 2255 386 UGGCAGGG G UGGUUUAU 834 AUAAACCA GCCGAAAGGCGAGUCAAGGUCU CCCUGCCA 2256 389 CAGGGGUG G UUUAUCUG 835 CAGAUAAA GCCGAAAGGCGAGUCAAGGUCU CACCCCUG 2257 WO 01/57206 PCT/USO1/03504 71 397 GUUUAUCU G CAUGGUAU 836 AUACCAUG GCCGAAAGGCGAGUCAAGGUCU AGAUAAAC 2258 402 UCUGCAUG G UAUUGGAA 837 UUCCAAUA GCCGAAAGGCGAGUCAAGGUCU CAUGCAGA 2259 445 AAUCUUCU G UUGGAUGA 838 UCAUCCAA GCCGAAAGGCGAGUCAAGGUCU AGAAGAUU 2260 483 AGACUUUG G CUUGGCAA 839 UUGCCAAG GCCGAAAGGCGAGUCAAGGUCU CAAAGUCU 2261 488 UUGGCUUG G CAACAGUA 840 UACUGUUG GCCGAAAGGCGAGUCAAGGUCU CAAGCCAA 2262 494 UGGCAACA G UAUUUCGG 841 CCGAAAUA GCCGAAAGGCGAGUCAAGGUCU UGUUGCCA 2263 502 GUAUUUCG G UAUAAUAA 842 UUAUUAUA GCCGAAAGGCGAGUCAAGGUCU CGAAAUAC 2264 513 UAAUAAUC G UGAGCGUU 843 AACGCUCA GCCGAAAGGCGAGUCAAGGUCU GAUUAUUA 2265 517 AAUCGUGA G CGUTUGUU 844 AACAAACG GCCGAAAGGCGAGUCAAGGUCU UCACGAUU 2266 519 UCGUGAGC G UUGUUGA 845 UCAACAAA GCCGAAAGGCGAGUCAAGGUCU GCUCACGA 2267 523 GAGCGUUU G UUGAACAA 846 UUGUUCAA GCCGAAAGGCGAGUCAAGGUCU AAACGCUC 2268 535 AACAAGAU G UGUGGUAC 847 GUACCACA GCCGAAAGGCGAGUCAAGGUCU AUCUUGUU 2269 537 CAAGAUGU G UGGUACUU 848 AAGUACCA GCCGAAAGGCGAGUCAAGGUCU ACAUCUUG 2270 540 GAUGUGUG G UACUUUAC 849 GUAAAGUA GCCGAAAGGCGAGUCAAGGUCU CACACAUC 2271 554 UACCAUAU G UUGCUCCA 850 UGGAGCAA GCCGAAAGGCGAGUCAAGGUCU AUAUGGUA 2272 557 CAUAUGUU G CUCCAGAA 851 UUCUGGAG GCCGAAAGGCGAGUCAAGGUCU AACAUAUG 2273 590 AAUUUCAU G CAGAACCA 852 UGGUUCUG GCCGAAAGGCGAGUCAAGGUCU AUGAAAUU 2274 599 CAGAACCA G UUGAUGUU 853 AACAUCAA GCCGAAAGGCGAGUCAAGGUCU UGGUUCUG 2275 605 CAGUUGAU G UUUGGUCC 854 GGACCAAA GCCGAAAGGCGAGUCAAGGUCU AUCAACUG 2276 610 GAUGUUUG G UCCUGUGG 855 CCACAGGA GCCGAAAGGCGAGUCAAGGUCU CAAACAUC 2277 615 UUGGUCCU G UGGAAUAG 856 CUAUUCCA GCCGAAAGGCGAGUCAAGGUCU AGGACCAA 2278 623 GUGGAAUA G UACUUACU 857 AGUAAGUA GCCGAAAGGCGAGUCAAGGUCU UAUUCCAC 2279 632 UACUUACU G CAAUGCUC 858 GAGCAUUG GCCGAAAGGCGAGUCAAGGUCU AGUAAGUA 2280 637 ACUGCAAU G CUCGCUGG 859 CCAGCGAG GCCGAAAGGCGAGUCAAGGUCU AUUGCAGU 2281 641 CAAUGCUC G CUGGAGAA 860 UUCUCCAG GCCGAAAGGCGAGUCAAGGUCU GAGCAUUG 2282 652 GGAGAAUU G CCAUGGGA 861 UCCCAUGG GCCGAAAGGCGAGUCAAGGUCU AAUUCUCC 2283 669 CCAACCCA G UGACAGCU 862 AGCUGUCA GCCGAAAGGCGAGUCAAGGUCU UGGGUUGG 2284 675 CAGUGACA G CUGUCAGG 863 CCUGACAG GCCGAAAGGCGAGUCAAGGUCU UGUCACUG 2285 678 UGACAGCU G UCAGGAGU 864 ACUCCUGA GCCGAAAGGCGAGUCAAGGUCU AGCUGUCA 2286 685 UGUCAGGA G UAUUCUGA 865 UCAGAAUA GCCGAAAGGCGAGUCAAGGUCU UCCUGACA 2287 743 UCGAUUCU G CUCCUCUA 866 UAGAGGAG GCCGAAAGGCGAGUCAAGGUCU AGAAUCGA 2288 752 CUCCUCUA G CUCUGCUG 867 CAGCAGAG GCCGAAAGGCGAGUCAAGGUCU UAGAGGAG 2289 757 CUAGCUCU G CUGCAUAA 868 UUAUGCAG GCCGAAAGGCGAGUCAAGGUCU AGAGCUAG 2290 760 GCUCUGCU G CAUAAAAU 869 AUUUUAUG GCCGAAAGGCGAGUCAAGGUCU AGCAGAGC 2291 773 AAAUCUUA G UUGAGAAU 870 AUUCUCAA GCCGAAAGGCGAGUCAAGGUCU UAAGAUUU 2292 788 AUCCAUCA G CAAGAAUU 871 AAUUCUUG GCCGAAAGGCGAGUCAAGGUCU UGAUGGAU 2293 826 GAUAGAUG G UACAACAA 872 UUGUUGUA GCCGAAAGGCGAGUCAAGGUCU CAUCUAUC 2294 851 AGAAAGGG G CAAAAAGG 873 CCUUUUUG GCCGAAAGGCGAGUCAAGGUCU CCCUUUCU 2295 859 GCAAAAAG G CCCCGAGU 874 ACUCGGGG GCCGAAAGGCGAGUCAAGGUCU CUUUUUGC 2296 866 GGCCCCGA G UCACUUCA 875 UGAAGUGA GCCGAAAGGCGAGUCAAGGUCU UCGGGGCC 2297 876 CACUUCAG G UGGUGUGU 876 ACACACCA GCCGAAAGGCGAGUCAAGGUCU CUGAAGUG 2298 879 UUCAGGUG G UGUGUCAG 877 CUGACACA GCCGAAAGGCGAGUCAAGGUCU CACCUGAA 2299 881 CAGGUGGU G UGUCAGAG 878 CUCUGACA GCCGAAAGGCGAGUCAAGGUCU ACCACCUG 2300 883 GGUGGUGU G UCAGAGUC 879 GACUCUGA GCCGAAAGGCGAGUCAAGGUCU ACACCACC 2301 889 GUGUCAGA G UCUCCCAG 880 CUGGGAGA GCCGAAAGGCGAGUCAAGGUCU UCUGACAC 2302 897 GUCUCCCA G UGGAUUUU 881 AAAAUCCA GCCGAAAGGCGAGUCAAGGUCU UGGGAGAC 2303 910 UUUUCUAA G CACAUUCA 882 UGAAUGUG GCCGAAAGGCGAGUCAAGGUCU UUAGAAAA 2304 941 UCUCUCCA G UAAACAGU 883 ACUGUUUA GCCGAAAGGCGAGUCAAGGUCU UGGAGAGA 2305 948 AGUAAACA G UGCUUCUA 884 UAGAAGCA GCCGAAAGGCGAGUCAAGGUCU UGUUUACU 2306 WO 01/57206 PCT/USO1/03504 72 950 UAAACAGU G CUUCUAGU 885 ACUAGAAG GCCGAAAGGCGAGUCAAGGUCU ACUGUUUA 2307 957 UGCUUCUA G UGAAGAAA 886 UUUCUUCA GCCGAAAGGCGAGUCAAGGUCU UAGAAGCA 2308 968 AAGAAAAU G UGAAGUAC 887 GUACUUCA GCCGAAAGGCGAGUCAAGGUCU AUUUUCUU 2309 973 AAUGUGAA G UACUCCAG 888 CUGGAGUA GCCGAAAGGCGAGUCAAGGUCU UUCACAUU 2310 981 GUACUCCA G UUCUCAGC 889 GCUGAGAA GCCGAAAGGCGAGUCAAGGUCU UGGAGUAC 2311 988 AGUUCUCA G CCAGAACC 890 GGUUCUGG GCCGAAAGGCGAGUCAAGGUCU UGAGAACU 2312 999 AGAACCCC G CACAGGUC 891 GACCUGUG GCCGAAAGGCGAGUCAAGGUCU GGGGUUCU 2313 1005 CCGCACAG G UCUUUCCU 892 AGGAAAGA GCCGAAAGGCGAGUCAAGGUCU CUGUGCGG 2314 1026 GGAUACCA G CCCCUCAU 893 AUGAGGGG GCCGAAAGGCGAGUCAAGGUCU UGGUAUCC 2315 1049 AUAAAUUG G UACAAGGG 894 CCCUUGUA GCCGAAAGGCGAGUCAAGGUCU CAAUUUAU 2316 1062 AGGGAUCA G CUUUUCCC 895 GGGAAAAG GCCGAAAGGCGAGUCAAGGUCU UGAUCCCU 2317 1072 UUUUCCCA G CCCACAUG 896 CAUGUGGG GCCGAAAGGCGAGUCAAGGUCU UGGGAAAA 2318 1080 GCCCACAU G UCCUGAUC 897 GAUCAGGA GCCGAAAGGCGAGUCAAGGUCU AUGUGGGC 2319 1093 GAUCAUAU G CUUUUGAA 898 UUCAAAAG GCCGAAAGGCGAGUCAAGGUCU AUAUGAUC 2320 1104 UUUGAAUA G UCAGUUAC 899 GUAACUGA GCCGAAAGGCGAGUCAAGGUCU UAUUCAAA 2321 1108 AAUAGUCA G UUACUUGG 900 CCAAGUAA GCCGAAAGGCGAGUCAAGGUCU UGACUAUU 2322 1116 GUUACUUG G CACCCCAG 901 CUGGGGUG GCCGAAAGGCGAGUCAAGGUCU CAAGUAAC 2323 1144 AACCCCUG G CAGCGGUU 902 AACCGCUG GCCGAAAGGCGAGUCAAGGUCU CAGGGGUU 2324 1147 CCCUGGCA G CGGUUGGU 903 ACCAACCG GCCGAAAGGCGAGUCAAGGUCU UGCCAGGG 2325 1150 UGGCAGCG G UUGGUCAA 904 UUGACCAA GCCGAAAGGCGAGUCAAGGUCU CGCUGCCA 2326 1154 AGCGGUUG G UCAAAAGA 905 UCUUUUGA GCCGAAAGGCGAGUCAAGGUCU CAACCGCU 2327 1190 AAUUGGAU G CAGACAAA 906 UUUGUCUG GCCGAAAGGCGAGUCAAGGUCU AUCCAAUU 2328 1209 UUAUCAAU G CCUGAAAG 907 CUUUCAGG GCCGAAAGGCGAGUCAAGGUCU AUUGAUAA 2329 1224 AGAGACUU G UGAGAAGU 908 ACUUCUCA GCCGAAAGGCGAGUCAAGGUCU AAGUCUCU 2330 1231 UGUGAGAA G UUGGGCUA 909 UAGCCCAA GCCGAAAGGCGAGUCAAGGUCU UUCUCACA 2331 1236 GAAGUUGG G CUAUCAAU 910 AUUGAUAG GCCGAAAGGCGAGUCAAGGUCU CCAACUUC 2332 1254 GAAGAAAA G UUGUAUGA 911 UCAUACAA GCCGAAAGGCGAGUCAAGGUCU UUUUCUUC 2333 1257 GAAAAGUU G UAUGAAUC 912 GAUUCAUA GCCGAAAGGCGAGUCAAGGUCU AACUUUUC 2334 1268 UGAAUCAG G UUACUAUA 913 UAUAGUAA GCCGAAAGGCGAGUCAAGGUCU CUGAUUCA 2335 1316 UUUUCAAA G UGAAUUUG 914 CAAAUUCA GCCGAAAGGCGAGUCAAGGUCU UUUGAAAA 2336 1324 GUGAAUUU G UUAGAAAU 915 AUUUCUAA GCCGAAAGGCGAGUCAAGGUCU AAAUUCAC 2337 1349 AAAUAUUG G UUGACUUC 916 GAAGUCAA GCCGAAAGGCGAGUCAAGGUCU CAAUALTUU 2338 1360 GACUUCCG G CUUUCUAA 917 UUAGAAAG GCCGAAAGGCGAGUCAAGGUCU CGGAAGUC 2339 1371 UUCUAAGG G UGAUGGAU 918 AUCCAUCA GCCGAAAGGCGAGUCAAGGUCU CCUUAGAA 2340 1384 GGATUGGA G UUCAAGAG 919 CUCUUGAA GCCGAAAGGCGAGUCAAGGUCU UCCAAUCC 2341 1417 AAAGGGAA G CUGAUUGA 920 UCAAUCAG GCCGAAAGGCGAGUCAAGGUCU UUCCCUUU 2342 1430 UUGAUAUU G UGAGCAGC 921 GCUGCUCA GCCGAAAGGCGAGUCAAGGUCU AAUAUCAA 2343 1434 UAUUGUGA G CAGCCAGA 922 UCUGGCUG GCCGAAAGGCGAGUCAAGGUCU UCACAAUA 2344 1437 UGUGAGCA G CCAGAAGG 923 CCUUCUGG GCCGAAAGGCGAGUCAAGGUCU UGCUCACA 2345 1445 GCCAGAAG G UUUGGCUU 924 AAGCCAAA GCCGAAAGGCGAGUCAAGGUCU CUUCUGGC 2346 1450 AAGGUUUG G CUUCCUGC 925 GCAGGAAG GCCGAAAGGCGAGUCAAGGUCU CAAACCUU 2347 1457 GGCUUCCU G CCACAUGA 926 UCAUGUGG GCCGAAAGGCGAGUCAAGGUCU AGGAAGCC 2348 1477 GACCAUCG G CUCUGGGG 927 CCCCAGAG GCCGAAAGGCGAGUCAAGGUCU CGAUGGUC 2349 1493 GAAUCCUG G UGAAUAUA 928 UAUAUUCA GCCGAAAGGCGAGUCAAGGUCU CAGGAUUC 2350 1502 UGAAUAUA G UGCUGCUA 929 UAGCAGCA GCCGAAAGGCGAGUCAAGGUCU UAUAUUCA 2351 1504 AAUAUAGU G CUGCUAUG 930 CAUAGCAG GCCGAAAGGCGAGUCAAGGUCU ACUAUAUU 2352 1507 AUAGUGCU G CUAUGUUG 931 CAACAUAG GCCGAAAGGCGAGUCAAGGUCU AGCACUAU 2353 1512 GCUGCUAU G UUGACAUU 932 AAUGUCAA GCCGAAAGGCGAGUCAAGGUCU AUAGCAGC 2354 1545 AUUAUCCU G UCCUGCAA 933 UUGCAGGA GCCGAAAGGCGAGUCAAGGUCU AGGAUAAU 2355 WO 01/57206 PCT/USO1/03504 73 1550 CCUGUCCU G CAAACUGC 934 GCAGUUUG GCCGAAAGGCGAGUCAAGGUCU AGGACAGG 2356 1557 UGCAAACU G CAAAUAGU 935 ACUAUUUG GCCGAAAGGCGAGUCAAGGUCU AGUUUGCA 2357 1564 UGCAAAUA G UAGUUCCU 936 AGGAACUA GCCGAAAGGCGAGUCAAGGUCU UAUUUGCA 2358 1567 AAAUAGUA G UUCCUGAA 937 UUCAGGAA GCCGAAAGGCGAGUCAAGGUCU UACUAUUU 2359 1576 UUCCUGAA G UGUUCACU 938 AGUGAACA GCCGAAAGGCGAGUCAAGGUCU UUCAGGAA 2360 1578 CCUGAAGU G UUCACUUC 939 GAAGUGAA GCCGAAAGGCGAGUCAAGGUCU ACUUCAGG 2361 1590 ACUUCCCU G UUUAUCCA 940 UGGAUAAA GCCGAAAGGCGAGUCAAGGUCU AGGGAAGU 2362 1619 UUUAUUUU G UUUGUUCG 941 CGAACAAA GCCGAAAGGCGAGUCAAGGUCU AAAAUAAA 2363 1623 UUUUGUUU G UUCGGCAU 942 AUGCCGAA GCCGAAAGGCGAGUCAAGGUCU AAACAAAA 2364 1628 UUUGUUCG G CAUACAAA 943 UUUGUAUG GCCGAAAGGCGAGUCAAGGUCU CGAACAAA 2365 1656 UCUUAAUU G UAAGCAAA 944 UUUGCUUA GCCGAAAGGCGAGUCAAGGUCU AAUUAAGA 2366 1660 AAUUGUAA G CAAAACUU 945 AAGUUUUG GCCGAAAGGCGAGUCAAGGUCU UUACAAUU 2367 1710 UUCUUCAU G UGUGUUUA 946 UAAACACA GCCGAAAGGCGAGUCAAGGUCU AUGAAGAA 2368 1712 CUUCAUGU G UGUUUAGU 947 ACUAAACA GCCGAAAGGCGAGUCAAGGUCU ACAUGAAG 2369 1714 UCAUGUGU G UUUAGUAU 948 AUACUAAA GCCGAAAGGCGAGUCAAGGUCU ACACAUGA 2370 1719 UGUGUUUA G UAUCUGAA 949 UUCAGAUA GCCGAAAGGCGAGUCAAGGUCU UAAACACA 2371 1743 CUCAUCUG G UGGAAACC 950 GGUUUCCA GCCGAAAGGCGAGUCAAGGUCU CAGAUGAG 2372 1754 GAAACCAA G UUUCAGGG 951 CCCUGAAA GCCGAAAGGCGAGUCAAGGUCU UUGGUUUC 2373 1770 GGACAUGA G UUUUCCAG 952 CUGGAAAA GCCGAAAGGCGAGUCAAGGUCU UCAUGUCC 2374 1778 GUUUUCCA G CUUUUAUA 953 UAUAAAAG GCCGAAAGGCGAGUCAAGGUCU UGGAAAAC 2375 1792 AUACACAC G UAUCUCAU 954 AUGAGAUA GCCGAAAGGCGAGUCAAGGUCU GUGUGUAU 2376 Input Sequence = AF016582. Cut Site = G/Y Stem Length = 8 . Core Sequence = GCcgaaagGCGaGuCaaGGuCu AF016582 (Homo sapiens checkpoint kinase Chkl (CHK1) mRNA; 1821 bp) WO 01/57206 PCT/USO1/03504 74 Table VII: Human Chk1 DNAzyme and Substrate Sequence Pos Substrate Seq ID DNAzyme Seq ID 10 GCCGGACA G UCCGCCGA 791 TCGGCGGA GGCTAGCTACAACGA TGTCCGGC 2377 14 GACAGUCC G CCGAGGUG 792 CACCTCGG GGCTAGCTACAACGA GGACTGTC 2378 20 CCGCCGAG G UGCUCGGU 793 ACCGAGCA GGCTAGCTACAACGA CTCGGCGG 2379 22 GCCGAGGU G CUCGGUGG 794 CCACCGAG GGCTAGCTACAACGA ACCTCGGC 2380 27 GGUGCUCG G UGGAGUCA 795 TGACTCCA GGCTAGCTACAACGA CGAGCACC 2381 32 UCGGUGGA G UCAUGGCA 796 TGCCATGA GGCTAGCTACAACGA TCCACCGA 2382 38 GAGUCAUG G CAGUGCCC 797 GGGCACTG GGCTAGCTACAACGA CATGACTC 2383 41 UCAUGGCA G UGCCCUUU 798 AAAGGGCA GGCTAGCTACAACGA TGCCATGA 2384 43 AUGGCAGU G CCCUUUGU 799 ACAAAGGG GGCTAGCTACAACGA ACTGCCAT 2385 50 UGCCCUUU G UGGAAGAC 800 GTCTTCCA GGCTAGCTACAACGA AAAGGGCA 2386 68 GGGACUUG G UGCAAACC 801 GGTTTGCA GGCTAGCTACAACGA CAAGTCCC 2387 70 GACUUGGU G CAAACCCU 802 AGGGTTTG GGCTAGCTACAACGA ACCAAGTC 2388 87 GGGAGAAG G UGCCUAUG 803 CATAGGCA GGCTAGCTACAACGA CTTCTCCC 2389 89 GAGAAGGU G CCUAUGGA 804 TCCATAGG GGCTAGCTACAACGA ACCTTCTC 2390 101 AUGGAGAA G UUCAACUU 805 AAGTTGAA GGCTAGCTACAACGA TTCTCCAT 2391 110 UUCAACUU G CUGUGAAU 806 ATTCACAG GGCTAGCTACAACGA AAGTTGAA 2392 113 AACUUGCU G UGAAUAGA 807 TCTATTCA GGCTAGCTACAACGA AGCAAGTT 2393 122 UGAAUAGA G UAACUGAA 808 TTCAGTTA GGCTAGCTACAACGA TCTATTCA 2394 134 CUGAAGAA G CAGUCGCA 809 TGCGACTG GGCTAGCTACAACGA TTCTTCAG 2395 137 AAGAAGCA G UCGCAGUG 810 CACTGCGA GGCTAGCTACAACGA TGCTTCTT 2396 140 AAGCAGUC G CAGUGAAG 811 CTTCACTG GGCTAGCTACAACGA GACTGCTT 2397 143 CAGUCGCA G UGAAGAUU 812 AATCTTCA GGCTAGCTACAACGA TGCGACTG 2398 152 UGAAGAUU G UAGAUAUG 813 CATATCTA GGCTAGCTACAACGA AATCTTCA 2399 163 GAUAUGAA G CGUGCCGU 814 ACGGCACG GGCTAGCTACAACGA TTCATATC 2400 165 UAUGAAGC G UGCCGUAG 815 CTACGGCA GGCTAGCTACAACGA GCTTCATA 2401 167 UGAAGCGU G CCGUAGAC 816 GTCTACGG GGCTAGCTACAACGA ACGCTTCA 2402 170 AGCGUGCC G UAGACUGU 817 ACAGTCTA GGCTAGCTACAACGA GGCACGCT 2403 177 CGUAGACU G UCCAGAAA 818 TTTCTGGA GGCTAGCTACAACGA AGTCTACG 2404 204 AGAGAUCU G UAUCAAUA 819 TATTGATA GGCTAGCTACAACGA AGATCTCT 2405 217 AAUAAAAU G CUAAAUCA 820 TGATTTAG GGCTAGCTACAACGA ATTTTATT 2406 233 AUGAAAAU G UAGUAAAA 821 TTTTACTA GGCTAGCTACAACGA ATTTTCAT 2407 236 AAAAUGUA G UAAAAUUC 822 GAATTTTA GGCTAGCTACAACGA TACATTTT 2408 249 AUUCUAUG G UCACAGGA 823 TCCTGTGA GGCTAGCTACAACGA CATAGAAT 2409 264 GAGAGAAG G CAAUAUCC 824 GGATATTG GGCTAGCTACAACGA CTTCTCTC 2410 289 UUUCUGGA G UACUGUAG 825 CTACAGTA GGCTAGCTACAACGA TCCAGAAA 2411 294 GGAGUACU G UAGUGGAG 826 CTCCACTA GGCTAGCTACAACGA AGTACTCC 2412 297 GUACUGUA G UGGAGGAG 827 CTCCTCCA GGCTAGCTACAACGA TACAGTAC 2413 307 GGAGGAGA G CUUUUUGA 828 TCAAAAAG GGCTAGCTACAACGA TCTCCTCC 2414 325 AGAAUAGA G CCAGACAU 829 ATGTCTGG GGCTAGCTACAACGA TCTATTCT 2415 336 AGACAUAG G CAUGCCUG 830 CAGGCATG GGCTAGCTACAACGA CTATGTCT 2416 340 AUAGGCAU G CCUGAACC 831 GGTTCAGG GGCTAGCTACAACGA ATGCCTAT 2417 353 AACCAGAU G CUCAGAGA 832 TCTCTGAG GGCTAGCTACAACGA ATCTGGTT 2418 380 AACUCAUG G CAGGGGUG 833 CACCCCTG GGCTAGCTACAACGA CATGAGTT 2419 386 UGGCAGGG G UGGUUUAU 834 ATAAACCA GGCTAGCTACAACGA CCCTGCCA 2420 389 CAGGGGUG G UUUAUCUG 835 CAGATAAA GGCTAGCTACAACGA CACCCCTG 2421 397 GUUUAUCU G CAUGGUAU 836 ATACCATG GGCTAGCTACAACGA AGATAAAC 2422 WO 01/57206 PCT/USO1/03504 75 402 UCUGCAUG G UAUUGGAA 837 TTCCAATA GGCTAGCTACAACGA CATGCAGA 2423 445 AAUCUUCU G UUGGAUGA 838 TCATCCAA GGCTAGCTACAACGA AGAAGATT 2424 483 AGACUUUG G CUUGGCAA 839 TTGCCAAG GGCTAGCTACAACGA CAAAGTCT 2425 488 UUGGCUUG G CAACAGUA 840 TACTGTTG GGCTAGCTACAACGA CAAGCCAA 2426 494 UGGCAACA G UAUUUCGG 841 CCGAAATA GGCTAGCTACAACGA TGTTGCCA 2427 502 GUAUUUCG G UAUAAUAA 842 TTATTATA GGCTAGCTACAACGA CGAAATAC 2428 513 UAAUAAUC G UGAGCGUU 843 AACGCTCA GGCTAGCTACAACGA GATTATTA 2429 517 AAUCGUGA G CGUUUGUU 844 AACAAACG GGCTAGCTACAACGA TCACGATT 2430 519 UCGUGAGC G UUUGUUGA 845 TCAACAAA GGCTAGCTACAACGA GCTCACGA 2431 523 GAGCGUUU G UUGAACAA 846 TTGTTCAA GGCTAGCTACAACGA AAACGCTC 2432 535 AACAAGAU G UGUGGUAC 847 GTACCACA GGCTAGCTACAACGA ATCTTGTT 2433 537 CAAGAUGU G UGGUACUU 848 AAGTACCA GGCTAGCTACAACGA ACATCTTG 2434 540 GAUGUGUG G UACUUUAC 849 GTAAAGTA GGCTAGCTACAACGA CACACATC 2435 554 UACCAUAU G UUGCUCCA 850 TGGAGCAA GGCTAGCTACAACGA ATATGGTA 2436 557 CAUAUGUU G CUCCAGAA 851 TTCTGGAG GGCTAGCTACAACGA AACATATG 2437 590 AAUUUCAU G CAGAACCA 852 TGGTTCTG GGCTAGCTACAACGA ATGAAATT 2438 599 CAGAACCA G UUGAUGUU 853 AACATCAA GGCTAGCTACAACGA TGGTTCTG 2439 605 CAGUUGAU G UUUGGUCC 854 GGACCAAA GGCTAGCTACAACGA ATCAACTG 2440 610 GAUGUUUG G UCCUGUGG 855 CCACAGGA GGCTAGCTACAACGA CAAACATC 2441 615 UUGGUCCU G UGGAAUAG 856 CTATTCCA GGCTAGCTACAACGA AGGACCAA 2442 623 GUGGAAUA G UACUTACU 857 AGTAAGTA GGCTAGCTACAACGA TATTCCAC 2443 632 UACUUACU G CAAUGCUC 858 GAGCATTG GGCTAGCTACAACGA AGTAAGTA 2444 637 ACUGCAAU G CUCGCUGG 859 CCAGCGAG GGCTAGCTACAACGA ATTGCAGT 2445 641 CAAUGCUC G CUGGAGAA 860 TTCTCCAG GGCTAGCTACAACGA GAGCATTG 2446 652 GGAGAAUU G CCAUGGGA 861 TCCCATGG GGCTAGCTACAACGA AATTCTCC 2447 669 CCAACCCA G UGACAGCU 862 AGCTGTCA GGCTAGCTACAACGA TGGGTTGG 2448 675 CAGUGACA G CUGUCAGG 863 CCTGACAG GGCTAGCTACAACGA TGTCACTG 2449 678 UGACAGCU G UCAGGAGU 864 ACTCCTGA GGCTAGCTACAACGA AGCTGTCA 2450 685 UGUCAGGA G UAUUCUGA 865 TCAGAATA GGCTAGCTACAACGA TCCTGACA 2451 743 UCGAUUCU G CUCCUCUA 866 TAGAGGAG GGCTAGCTACAACGA AGAATCGA 2452 752 CUCCUCUA G CUCUGCUG 867 CAGCAGAG GGCTAGCTACAACGA TAGAGGAG 2453 757 CUAGCUCU G CUGCAUAA 868 TTATGCAG GGCTAGCTACAACGA AGAGCTAG 2454 760 GCUCUGCU G CAUAAAAU 869 ATTTTATG GGCTAGCTACAACGA AGCAGAGC 2455 773 AAAUCUUA G UUGAGAAU 870 ATTCTCAA GGCTAGCTACAACGA TAAGATTT 2456 788 AUCCAUCA G CAAGAAUU 871 AATTCTTG GGCTAGCTACAACGA TGATGGAT 2457 826 GAUAGAUG G UACAACAA 872 TTGTTGTA GGCTAGCTACAACGA CATCTATC 2458 851 AGAAAGGG G CAAAAAGG 873 CCTTTTTG GGCTAGCTACAACGA CCCTTTCT 2459 859 GCAAAAAG G CCCCGAGU 874 ACTCGGGG GGCTAGCTACAACGA CTTTTTGC 2460 866 GGCCCCGA G UCACUUCA 875 TGAAGTGA GGCTAGCTACAACGA TCGGGGCC 2461 876 CACUUCAG G UGGUGUGU 876 ACACACCA GGCTAGCTACAACGA CTGAAGTG 2462 879 UUCAGGUG G UGUGUCAG 877 CTGACACA GGCTAGCTACAACGA CACCTGAA 2463 881 CAGGUGGU G UGUCAGAG 878 CTCTGACA GGCTAGCTACAACGA ACCACCTG 2464 883 GGUGGUGU G UCAGAGUC 879 GACTCTGA GGCTAGCTACAACGA ACACCACC 2465 889 GUGUCAGA G UCUCCCAG 880 CTGGGAGA GGCTAGCTACAACGA TCTGACAC 2466 897 GUCUCCCA G UGGAUUUU 881 AAAATCCA GGCTAGCTACAACGA TGGGAGAC 2467 910 UUUUCUAA G CACAUUCA 882 TGAATGTG GGCTAGCTACAACGA TTAGAAAA 2468 941 UCUCUCCA G UAAACAGU 883 ACTGTTTA GGCTAGCTACAACGA TGGAGAGA 2469 948 AGUAAACA G UGCUUCUA 884 TAGAAGCA GGCTAGCTACAACGA TGTTTACT 2470 950 UAAACAGU G CUUCUAGU 885 ACTAGAAG GGCTAGCTACAACGA ACTGTTTA 2471 WO 01/57206 PCT/USO1/03504 76 957 UGCUUCUA G UGAAGAAA 886 TTTCTTCA GGCTAGCTACAACGA TAGAAGCA 2472 968 AAGAAAAU G UGAAGUAC 887 GTACTTCA GGCTAGCTACAACGA ATTTTCTT 2473 973 AAUGUGAA G UACUCCAG 888 CTGGAGTA GGCTAGCTACAACGA TTCACATT 2474 981 GUACUCCA G UUCUCAGC 889 GCTGAGAA GGCTAGCTACAACGA TGGAGTAC 2475 988 AGUUCUCA G CCAGAACC 890 GGTTCTGG GGCTAGCTACAACGA TGAGAACT 2476 999 AGAACCCC G CACAGGUC 891 GACCTGTG GGCTAGCTACAACGA GGGGTTCT 2477 1005 CCGCACAG G UCUUUCCU 892 AGGAAAGA GGCTAGCTACAACGA CTGTGCGG 2478 1026 GGAUACCA G CCCCUCAU 893 ATGAGGGG GGCTAGCTACAACGA TGGTATCC 2479 1049 AUAAAUUG G UACAAGGG 894 CCCTTGTA GGCTAGCTACAACGA CAATTTAT 2480 1062 AGGGAUCA G CUUUUCCC 895 GGGAAAAG GGCTAGCTACAACGA TGATCCCT 2481 1072 UUUUCCCA G CCCACAUG 896 CATGTGGG GGCTAGCTACAACGA TGGGAAAA 2482 1080 GCCCACAU G UCCUGAUC 897 GATCAGGA GGCTAGCTACAACGA ATGTGGGC 2483 1093 GAUCAUAU G CUUULTGAA 898 TTCAAAAG GGCTAGCTACAACGA ATATGATC 2484 1104 UUUGAAUA G UCAGUUAC 899 GTAACTGA GGCTAGCTACAACGA TATTCAAA 2485 1108 AAUAGUCA G UUACUUGG 900 CCAAGTAA GGCTAGCTACAACGA TGACTATT 2486 1116 GUUACUUG G CACCCCAG 901 CTGGGGTG GGCTAGCTACAACGA CAAGTAAC 2487 1144 AACCCCUG G CAGCGGUU 902 AACCGCTG GGCTAGCTACAACGA CAGGGGTT 2488 1147 CCCUGGCA G CGGUUGGU 903 ACCAACCG GGCTAGCTACAACGA TGCCAGGG 2489 1150 UGGCAGCG G UUGGUCAA 904 TTGACCAA GGCTAGCTACAACGA CGCTGCCA 2490 1154 AGCGGUUG G UCAAAAGA 905 TCTTTTGA GGCTAGCTACAACGA CAACCGCT 2491 1190 AAUUGGAU G CAGACAAA 906 TTTGTCTG GGCTAGCTACAACGA ATCCAATT 2492 1209 UUAUCAAU G CCUGAAAG 907 CTTTCAGG GGCTAGCTACAACGA ATTGATAA 2493 1224 AGAGACUU G UGAGAAGU 908 ACTTCTCA GGCTAGCTACAACGA AAGTCTCT 2494 1231 UGUGAGAA G UUGGGCUA 909 TAGCCCAA GGCTAGCTACAACGA TTCTCACA 2495 1236 GAAGUUGG G CUAUCAAU 910 ATTGATAG GGCTAGCTACAACGA CCAACTTC 2496 1254 GAAGAAAA G UUGUAUGA 911 TCATACAA GGCTAGCTACAACGA TTTTCTTC 2497 1257 GAAAAGUU G UAUGAAUC 912 GATTCATA GGCTAGCTACAACGA AACTTTTC 2498 1268 UGAAUCAG G UUACUAUA 913 TATAGTAA GGCTAGCTACAACGA CTGATTCA 2499 1316 UUUUCAAA G UGAAUUUG 914 CAAATTCA GGCTAGCTACAACGA TTTGAAAA 2500 1324 GUGAAUUU G UUAGAAAU 915 ATTTCTAA GGCTAGCTACAACGA AAATTCAC 2501 1349 AAAUAUUG G UUGACUUC 916 GAAGTCAA GGCTAGCTACAACGA CAATATTT 2502 1360 GACUUCCG G CUUUCUAA 917 TTAGAAAG GGCTAGCTACAACGA CGGAAGTC 2503 1371 UUCUAAGG G UGAUGGAU 918 ATCCATCA GGCTAGCTACAACGA CCTTAGAA 2504 1384 GGAUUGGA G UUCAAGAG 919 CTCTTGAA GGCTAGCTACAACGA TCCAATCC 2505 1417 AAAGGGAA G CUGAUUGA 920 TCAATCAG GGCTAGCTACAACGA TTCCCTTT 2506 1430 UUGAUAUU G UGAGCAGC 921 GCTGCTCA GGCTAGCTACAACGA AATATCAA 2507 1434 UAUUGUGA G CAGCCAGA 922 TCTGGCTG GGCTAGCTACAACGA TCACAATA 2508 1437 UGUGAGCA G CCAGAAGG 923 CCTTCTGG GGCTAGCTACAACGA TGCTCACA 2509 1445 GCCAGAAG G UUUGGCUU 924 AAGCCAAA GGCTAGCTACAACGA CTTCTGGC 2510 1450 AAGGUUUG G CUUCCUGC 925 GCAGGAAG GGCTAGCTACAACGA CAAACCTT 2511 1457 GGCUUCCU G CCACAUGA 926 TCATGTGG GGCTAGCTACAACGA AGGAAGCC 2512 1477 GACCAUCG G CUCUGGGG 927 CCCCAGAG GGCTAGCTACAACGA CGATGGTC 2513 1493 GAAUCCUG G UGAAUAUA 928 TATATTCA GGCTAGCTACAACGA CAGGATTC 2514 1502 UGAAUAUA G UGCUGCUA 929 TAGCAGCA GGCTAGCTACAACGA TATATTCA 2515 1504 AAUAUAGU G CUGCUAUG 930 CATAGCAG GGCTAGCTACAACGA ACTATATT 2516 1507 AUAGUGCU G CUAUGUUG 931 CAACATAG GGCTAGCTACAACGA AGCACTAT 2517 1512 GCUGCUAU G UUGACAUU 932 AATGTCAA GGCTAGCTACAACGA ATAGCAGC 2518 1545 AUUAUCCU G UCCUGCAA 933 TTGCAGGA GGCTAGCTACAACGA AGGATAAT 2519 1550 CCUGUCCU G CAAACUGC 934 GCAGTTTG GGCTAGCTACAACGA AGGACAGG 2520 WO 01/57206 PCT/USO1/03504 77 1557 UGCAAACU G CAAAUAGU 935 ACTATTTG GGCTAGCTACAACGA AGTTTGCA 2521 1564 UGCAAAUA G UAGUUCCU 936 AGGAACTA GGCTAGCTACAACGA TATTTGCA 2522 1567 AAAUAGUA G UUCCUGAA 937 TTCAGGAA GGCTAGCTACAACGA TACTATTT 2523 1576 UUCCUGAA G UGUUCACU 938 AGTGAACA GGCTAGCTACAACGA TTCAGGAA 2524 1578 CCUGAAGU G UUCACUUC 939 GAAGTGAA GGCTAGCTACAACGA ACTTCAGG 2525 1590 ACUUCCCU G UUUAUCCA 940 TGGATAAA GGCTAGCTACAACGA AGGGAAGT 2526 1619 UUUAUUUU G UUUGUUCG 941 CGAACAAA GGCTAGCTACAACGA AAAATAAA 2527 1623 UUUUGUUU G UUCGGCAU 942 ATGCCGAA GGCTAGCTACAACGA AAACAAAA 2528 1628 UUUGUUCG G CAUACAAA 943 TTTGTATG GGCTAGCTACAACGA CGAACAAA 2529 1656 UCUUAAUU G UAAGCAAA 944 TTTGCTTA GGCTAGCTACAACGA AATTAAGA 2530 1660 AAUJGUAA G CAAAACUU 945 AAGTTTTG GGCTAGCTACAACGA TTACAATT 2531 1710 UUCUUCAU G UGUGUUUA 946 TAAACACA GGCTAGCTACAACGA ATGAAGAA 2532 1712 CUUCAUGU G UGUUUAGU 947 ACTAAACA GGCTAGCTACAACGA ACATGAAG 2533 1714 UCAUGUGU G UUUAGUAU 948 ATACTAAA GGCTAGCTACAACGA ACACATGA 2534 1719 UGUGUUUA G UAUCUGAA 949 TTCAGATA GGCTAGCTACAACGA TAAACACA 2535 1743 CUCAUCUG G UGGAAACC 950 GGTTTCCA GGCTAGCTACAACGA CAGATGAG 2536 1754 GAAACCAA G UUUCAGGG 951 CCCTGAAA GGCTAGCTACAACGA TTGGTTTC 2537 1770 GGACAUGA G UUUUCCAG 952 CTGGAAAA GGCTAGCTACAACGA TCATGTCC 2538 1778 GUUUUCCA G CUUUUAUA 953 TATAAAAG GGCTAGCTACAACGA TGGAAAAC 2539 1792 AUACACAC G UAUCUCAU 954 ATGAGATA GGCTAGCTACAACGA GTGTGTAT 2540 35 GUGGAGUC A UGGCAGUG 955 CACTGCCA GGCTAGCTACAACGA GACTCCAC 2541 57 UGUGGAAG A CUGGGACU 956 AGTCCCAG GGCTAGCTACAACGA CTTCCACA 2542 63 AGACUGGG A CUUGGUGC 957 GCACCAAG GGCTAGCTACAACGA CCCAGTCT 2543 74 UGGUGCAA A CCCUGGGA 958 TCCCAGGG GGCTAGCTACAACGA TTGCACCA 2544 93 AGGUGCCU A UGGAGAAG 959 CTTCTCCA GGCTAGCTACAACGA AGGCACCT 2545 106 GAAGUUCA A CUUGCUGU 960 ACAGCAAG GGCTAGCTACAACGA TGAACTTC 2546 117 UGCUGUGA A UAGAGUAA 961 TTACTCTA GGCTAGCTACAACGA TCACAGCA 2547 125 AUAGAGUA A CUGAAGAA 962 TTCTTCAG GGCTAGCTACAACGA TACTCTAT 2548 149 CAGUGAAG A UUGUAGAU 963 ATCTACAA GGCTAGCTACAACGA CTTCACTG 2549 156 GAUUGUAG A UAUGAAGC 964 GCTTCATA GGCTAGCTACAACGA CTACAATC 2550 158 UUGUAGAU A UGAAGCGU 965 ACGCTTCA GGCTAGCTACAACGA ATCTACAA 2551 174 UGCCGUAG A CUGUCCAG 966 CTGGACAG GGCTAGCTACAACGA CTACGGCA 2552 186 UCCAGAAA A UAUUAAGA 967 TCTTAATA GGCTAGCTACAACGA TTTCTGGA 2553 188 CAGAAAAU A UUAAGAAA 968 TTTCTTAA GGCTAGCTACAACGA ATTTTCTG 2554 200 AGAAAGAG A UCUGUAUC 969 GATACAGA GGCTAGCTACAACGA CTCTTTCT 2555 206 AGAUCUGU A UCAAUAAA 970 TTTATTGA GGCTAGCTACAACGA ACAGATCT 2556 210 CUGUAUCA A UAAAAUGC 971 GCATTTTA GGCTAGCTACAACGA TGATACAG 2557 215 UCAAUAAA A UGCUAAAU 972 ATTTAGCA GGCTAGCTACAACGA TTTATTGA 2558 222 AAUGCUAA A UCAUGAAA 973 TTTCATGA GGCTAGCTACAACGA TTAGCATT 2559 225 GCUAAAUC A UGAAAAUG 974 CATTTTCA GGCTAGCTACAACGA GATTTAGC 2560 231 UCAUGAAA A UGUAGUAA 975 TTACTACA GGCTAGCTACAACGA TTTCATGA 2561 241 GUAGUAAA A UUCUAUGG 976 CCATAGAA GGCTAGCTACAACGA TTTACTAC 2562 246 AAAAUUCU A UGGUCACA 977 TGTGACCA GGCTAGCTACAACGA AGAATTTT 2563 252 CUAUGGUC A CAGGAGAG 978 CTCTCCTG GGCTAGCTACAACGA GACCATAG 2564 267 AGAAGGCA A UAUCCAAU 979 ATTGGATA GGCTAGCTACAACGA TGCCTTCT 2565 269 AAGGCAAU A UCCAAUAU 980 ATATTGGA GGCTAGCTACAACGA ATTGCCTT 2566 274 AAUAUCCA A UAUUUAUU 981 AATAAATA GGCTAGCTACAACGA TGGATATT 2567 276 UAUCCAAU A UUUAUUUC 982 GAAATAAA GGCTAGCTACAACGA ATTGGATA 2568 280 CAAUAUUU A UUUCUGGA 983 TCCAGAAA GGCTAGCTACAACGA AAATATTG 2569 WO 01/57206 PCT/USO1/03504 78 291 UCUGGAGU A CUGUAGUG 984 CACTACAG GGCTAGCTACAACGA ACTCCAGA 2570 315 GCUUUUUG A CAGAAUAG 985 CTATTCTG GGCTAGCTACAACGA CAAAAAGC 2571 320 UUGACAGA A UAGAGCCA 986 TGGCTCTA GGCTAGCTACAACGA TCTGTCAA 2572 330 AGAGCCAG A CAUAGGCA 987 TGCCTATG GGCTAGCTACAACGA CTGGCTCT 2573 332 AGCCAGAC A UAGGCAUG 988 CATGCCTA GGCTAGCTACAACGA GTCTGGCT 2574 338 ACAUAGGC A UGCCUGAA 989 TTCAGGCA GGCTAGCTACAACGA GCCTATGT 2575 346 AUGCCUGA A CCAGAUGC 990 GCATCTGG GGCTAGCTACAACGA TCAGGCAT 2576 351 UGAACCAG A UGCUCAGA 991 TCTGAGCA GGCTAGCTACAACGA CTGGTTCA 2577 361 GCUCAGAG A UUCUUCCA 992 TGGAAGAA GGCTAGCTACAACGA CTCTGAGC 2578 369 AUUCUUCC A UCAACUCA 993 TGAGTTGA GGCTAGCTACAACGA GGAAGAAT 2579 373 UUCCAUCA A CUCAUGGC 994 GCCATGAG GGCTAGCTACAACGA TGATGGAA 2580 377 AUCAACUC A UGGCAGGG 995 CCCTGCCA GGCTAGCTACAACGA GAGTTGAT 2581 393 GGUGGUU A UCUGCAUG 996 CATGCAGA GGCTAGCTACAACGA AAACCACC 2582 399 UUAUCUGC A UGGUAUUG 997 CAATACCA GGCTAGCTACAACGA GCAGATAA 2583 404 UGCAUGGU A UUGGAAUA 998 TATTCCAA GGCTAGCTACAACGA ACCATGCA 2584 410 GUAUUGGA A UAACUCAC 999 GTGAGTTA GGCTAGCTACAACGA TCCAATAC 2585 413 UUGGAAUA A CUCACAGG 1000 CCTGTGAG GGCTAGCTACAACGA TATTCCAA 2586 417 AAUAACUC A CAGGGAUA 1001 TATCCCTG GGCTAGCTACAACGA GAGTTATT 2587 423 UCACAGGG A UAUUAAAC 1002 GTTTAATA GGCTAGCTACAACGA CCCTGTGA 2588 425 ACAGGGAU A UUAAACCA 1003 TGGTTTAA GGCTAGCTACAACGA ATCCCTGT 2589 430 GAUAUUAA A CCAGAAAA 1004 TTTTCTGG GGCTAGCTACAACGA TTAATATC 2590 438 ACCAGAAA A UCUUCUGU 1005 ACAGAAGA GGCTAGCTACAACGA TTTCTGGT 2591 450 UCUGUUGG A UGAAAGGG 1006 CCCTTTCA GGCTAGCTACAACGA CCAACAGA 2592 459 UGAAAGGG A UAACCUCA 1007 TGAGGTTA GGCTAGCTACAACGA CCCTTTCA 2593 462 AAGGGAUA A CCUCAAAA 1008 TTTTGAGG GGCTAGCTACAACGA TATCCCTT 2594 470 ACCUCAAA A UCUCAGAC 1009 GTCTGAGA GGCTAGCTACAACGA TTTGAGGT 2595 477 AAUCUCAG A CUUUGGCU 1010 AGCCAAAG GGCTAGCTACAACGA CTGAGATT 2596 491 GCUUGGCA A CAGUAUUU 1011 AAATACTG GGCTAGCTACAACGA TGCCAAGC 2597 496 GCAACAGU A UUUCGGUA 1012 TACCGAAA GGCTAGCTACAACGA ACTGTTGC 2598 504 AUUUCGGU A UAAUAAUC 1013 GATTATTA GGCTAGCTACAACGA ACCGAAAT 2599 507 UCGGUAUA A UAAUCGUG 1014 CACGATTA GGCTAGCTACAACGA TATACCGA 2600 510 GUAUAAUA A UCGUGAGC 1015 GCTCACGA GGCTAGCTACAACGA TATTATAC 2601 528 UUUGUUGA A CAAGAUGU 1016 ACATCTTG GGCTAGCTACAACGA TCAACAAA 2602 533 UGAACAAG A UGUGUGGU 1017 ACCACACA GGCTAGCTACAACGA CTTGTTCA 2603 542 UGUGUGGU A CUUUACCA 1018 TGGTAAAG GGCTAGCTACAACGA ACCACACA 2604 547 GGUACUUU A CCAUAUGU 1019 ACATATGG GGCTAGCTACAACGA AAAGTACC 2605 550 ACUUUACC A UAUGUUGC 1020 GCAACATA GGCTAGCTACAACGA GGTAAAGT 2606 552 UUUACCAU A UGUUGCUC 1021 GAGCAACA GGCTAGCTACAACGA ATGGTAAA 2607 565 GCUCCAGA A CUUCUGAA 1022 TTCAGAAG GGCTAGCTACAACGA TCTGGAGC 2608 583 AGAAGAGA A UUUCAUGC 1023 GCATGAAA GGCTAGCTACAACGA TCTCTTCT 2609 588 AGAAUUUC A UGCAGAAC 1024 GTTCTGCA GGCTAGCTACAACGA GAAATTCT 2610 595 CAUGCAGA A CCAGUUGA 1025 TCAACTGG GGCTAGCTACAACGA TCTGCATG 2611 603 ACCAGUTJG A UGUUUGGU 1026 ACCAAACA GGCTAGCTACAACGA CAACTGGT 2612 620 CCUGUGGA A UAGUACUU 1027 AAGTACTA GGCTAGCTACAACGA TCCACAGG 2613 625 GGAAUAGU A CUUACUGC 1028 GCAGTAAG GGCTAGCTACAACGA ACTATTCC 2614 629 UAGUACUU A CUGCAAUG 1029 CATTGCAG GGCTAGCTACAACGA AAGTACTA 2615 635 UUACUGCA A UGCUCGCU 1030 AGCGAGCA GGCTAGCTACAACGA TGCAGTAA 2616 649 GCUGGAGA A UUGCCAUG 1031 CATGGCAA GGCTAGCTACAACGA TCTCCAGC 2617 655 GAAUUGCC A UGGGACCA 1032 TGGTCCCA GGCTAGCTACAACGA GGCAATTC 2618 WO 01/57206 PCT/USO1/03504 79 660 GCCAUGGG A CCAACCCA 1033 TGGGTTGG GGCTAGCTACAACGA CCCATGGC 2619 664 UGGGACCA A CCCAGUGA 1034 TCACTGGG GGCTAGCTACAACGA TGGTCCCA 2620 672 ACCCAGUG A CAGCUGUC 1035 GACAGCTG GGCTAGCTACAACGA CACTGGGT 2621 687 UCAGGAGU A UUCUGACU 1036 AGTCAGAA GGCTAGCTACAACGA ACTCCTGA 2622 693 GUAUUCUG A CUGGAAAG 1037 CTTTCCAG GGCTAGCTACAACGA CAGAATAC 2623 710 AAAAAAAA A CAUACCUC 1038 GAGGTATG GGCTAGCTACAACGA TTTTTTTT 2624 712 AAAAAAAC A UACCUCAA 1039 TTGAGGTA GGCTAGCTACAACGA GTTTTTTT 2625 714 AAAAACAU A CCUCAACC 1040 GGTTGAGG GGCTAGCTACAACGA ATGTTTTT 2626 720 AUACCUCA A CCCUUGGA 1041 TCCAAGGG GGCTAGCTACAACGA TGAGGTAT 2627 734 GGAAAAAA A UCGAUUCU 1042 AGAATCGA GGCTAGCTACAACGA TTTTTTCC 2628 738 AAAAAUCG A UUCUGCUC 1043 GAGCAGAA GGCTAGCTACAACGA CGATTTTT 2629 762 UCUGCUGC A UAAAAUCU 1044 AGATTTTA GGCTAGCTACAACGA GCAGCAGA 2630 767 UGCAUAAA A UCUUAGUU 1045 AACTAAGA GGCTAGCTACAACGA TTTATGCA 2631 780 AGUUGAGA A UCCAUCAG 1046 CTGATGGA GGCTAGCTACAACGA TCTCAACT 2632 784 GAGAAUCC A UCAGCAAG 1047 CTTGCTGA GGCTAGCTACAACGA GGATTCTC 2633 794 CAGCAAGA A UUACCAUU 1048 AATGGTAA GGCTAGCTACAACGA TCTTGCTG 2634 797 CAAGAAUU A CCAUUCCA 1049 TGGAATGG GGCTAGCTACAACGA AATTCTTG 2635 800 GAAUUACC A UUCCAGAC 1050 GTCTGGAA GGCTAGCTACAACGA GGTAATTC 2636 807 CAUUCCAG A CAUCAAAA 1051 TTTTGATG GGCTAGCTACAACGA CTGGAATG 2637 809 UUCCAGAC A UCAAAAAA 1052 TTTTTTGA GGCTAGCTACAACGA GTCTGGAA 2638 819 CAAAAAAG A UAGAUGGU 1053 ACCATCTA GGCTAGCTACAACGA CTTTTTTG 2639 823 AAAGAUAG A UGGUACAA 1054 TTGTACCA GGCTAGCTACAACGA CTATCTTT 2640 828 UAGAUGGU A CAACAAAC 1055 GTTTGTTG GGCTAGCTACAACGA ACCATCTA 2641 831 AUGGUACA A CAAACCCC 1056 GGGGTTTG GGCTAGCTACAACGA TGTACCAT 2642 835 UACAACAA A CCCCUCAA 1057 TTGAGGGG GGCTAGCTACAACGA TTGTTGTA 2643 869 CCCGAGUC A CUUCAGGU 1058 ACCTGAAG GGCTAGCTACAACGA GACTCGGG 2644 901 CCCAGUGG A UUUUCUAA 1059 TTAGAAAA GGCTAGCTACAACGA CCACTGGG 2645 912 UUCUAAGC A CAUUCAAU 1060 ATTGAATG GGCTAGCTACAACGA GCTTAGAA 2646 914 CUAAGCAC A UUCAAUCC 1061 GGATTGAA GGCTAGCTACAACGA GTGCTTAG 2647 919 CACAUUCA A UCCAAUUJU 1062 AAATTGGA GGCTAGCTACAACGA TGAATGTG 2648 924 UCAAUCCA A UUUGGACU 1063 AGTCCAAA GGCTAGCTACAACGA TGGATTGA 2649 930 CAAUUUGG A CUUCUCUC 1064 GAGAGAAG GGCTAGCTACAACGA CCAAATTG 2650 945 UCCAGUAA A CAGUGCUU 1065 AAGCACTG GGCTAGCTACAACGA TTACTGGA 2651 966 UGAAGAAA A UGUGAAGU 1066 ACTTCACA GGCTAGCTACAACGA TTTCTTCA 2652 975 UGUGAAGU A CUCCAGUU 1067 AACTGGAG GGCTAGCTACAACGA ACTTCACA 2653 994 CAGCCAGA A CCCCGCAC 1068 GTGCGGGG GGCTAGCTACAACGA TCTGGCTG 2654 1001 AACCCCGC A CAGGUCUU 1069 AAGACCTG GGCTAGCTACAACGA GCGGGGTT 2655 1015 CUUUCCUU A UGGGAUAC 1070 GTATCCCA GGCTAGCTACAACGA AAGGAAAG 2656 1020 CUUAUGGG A UACCAGCC 1071 GGCTGGTA GGCTAGCTACAACGA CCCATAAG 2657 1022 UAUGGGAU A CCAGCCCC 1072 GGGGCTGG GGCTAGCTACAACGA ATCCCATA 2658 1033 AGCCCCUC A UACAUUGA 1073 TCAATGTA GGCTAGCTACAACGA GAGGGGCT 2659 1035 CCCCUCAU A CAUUGAUA 1074 TATCAATG GGCTAGCTACAACGA ATGAGGGG 2660 1037 CCUCAUAC A UUGAUAAA 1075 TTTATCAA GGCTAGCTACAACGA GTATGAGG 2661 1041 AUACAUUG A UAAAUUGG 1076 CCAATTTA GGCTAGCTACAACGA CAATGTAT 2662 1045 AUUGAUAA A UUGGUACA 1077 TGTACCAA GGCTAGCTACAACGA TTATCAAT 2663 1051 AAAUUGGU A CAAGGGAU 1078 ATCCCTTG GGCTAGCTACAACGA ACCAATTT 2664 1058 UACAAGGG A UCAGCUUU 1079 AAAGCTGA GGCTAGCTACAACGA CCCTTGTA 2665 1076 CCCAGCCC A CAUGUCCU 1080 AGGACATG GGCTAGCTACAACGA GGGCTGGG 2666 1078 CAGCCCAC A UGUCCUGA 1081 TCAGGACA GGCTAGCTACAACGA GTGGGCTG 2667 WO 01/57206 PCT/USO1/03504 80 1086 AUGUCCUG A UCAUAUGC 1082 GCATATGA GGCTAGCTACAACGA CAGGACAT 2668 1089 UCCUGAUC A UAUGCUUU 1083 AAAGCATA GGCTAGCTACAACGA GATCAGGA 2669 1091 CUGAUCAU A UGCUUUUG 1084 CAAAAGCA GGCTAGCTACAACGA ATGATCAG 2670 1101 GCUUUUGA A UAGUCAGU 1085 ACTGACTA GGCTAGCTACAACGA TCAAAAGC 2671 1111 AGUCAGUU A CUUGGCAC 1086 GTGCCAAG GGCTAGCTACAACGA AACTGACT 2672 1118 UACUUGGC A CCCCAGGA 1087 TCCTGGGG GGCTAGCTACAACGA GCCAAGTA 2673 1126 ACCCCAGG A UCCUCACA 1088 TGTGAGGA GGCTAGCTACAACGA CCTGGGGT 2674 1132 GGAUCCUC A CAGAACCC 1089 GGGTTCTG GGCTAGCTACAACGA GAGGATCC 2675 1137 CUCACAGA A CCCCUGGC 1090 GCCAGGGG GGCTAGCTACAACGA TCTGTGAG 2676 1163 UCAAAAGA A UGACACGA 1091 TCGTGTCA GGCTAGCTACAACGA TCTTTTGA 2677 1166 AAAGAAUG A CACGAUUC 1092 GAATCGTG GGCTAGCTACAACGA CATTCTTT 2678 1168 AGAAUGAC A CGAUUCUU 1093 AAGAATCG GGCTAGCTACAACGA GTCATTCT 2679 1171 AUGACACG A UUCUUUAC 1094 GTAAAGAA GGCTAGCTACAACGA CGTGTCAT 2680 1178 GAUUCUUU A CCAAAUUG 1095 CAATTTGG GGCTAGCTACAACGA AAAGAATC 2681 1183 UUUACCAA A UUGGAUGC *1096 GCATCCAA GGCTAGCTACAACGA TTGGTAAA 2682 1188 CAAAUUGG A UGCAGACA 1097 TGTCTGCA GGCTAGCTACAACGA CCAATTTG 2683 1194 GGAUGCAG A CAAAUCUUJ 1098 AAGATTTG GGCTAGCTACAACGA CTGCATCC 2684 1198 GCAGACAA A UCUUAUCA 1099 TGATAAGA GGCTAGCTACAACGA TTGTCTGC 2685 1203 CAAAUCUU A UCAAUGCC 1100 GGCATTGA GGCTAGCTACAACGA AAGATTTG 2686 1207 UCUUAUCA A UGCCUGAA 1101 TTCAGGCA GGCTAGCTACAACGA TGATAAGA 2687 1220 UGAAAGAG A CUUGUGAG 1102 CTCACAAG GGCTAGCTACAACGA CTCTTTCA 2688 1239 GUUGGGCU A UCAAUGGA 1103 TCCATTGA GGCTAGCTACAACGA AGCCCAAC 2689 1243 GGCUAUCA A UGGAAGAA 1104 TTCTTCCA GGCTAGCTACAACGA TGATAGCC 2690 1259 AAAGUUGU A UGAAUCAG 1105 CTGATTCA GGCTAGCTACAACGA ACAACTTT 2691 1263 UUGUAUGA A UCAGGUUA 1106 TAACCTGA GGCTAGCTACAACGA TCATACAA 2692 1271 AUCAGGUU A CUAUAUCA 1107 TGATATAG GGCTAGCTACAACGA AACCTGAT 2693 1274 AGGUUACU A UAUCAACA 1108 TGTTGATA GGCTAGCTACAACGA AGTAACCT 2694 1276 GUUACUAU A UCAACAAC 1109 GTTGTTGA GGCTAGCTACAACGA ATAGTAAC 2695 1280 CUAUAUCA A CAACUGAU 1110 ATCAGTTG GGCTAGCTACAACGA TGATATAG 2696 1283 UAUCAACA A CUGAUAGG 1111 CCTATCAG GGCTAGCTACAACGA TGTTGATA 2697 1287 AACAACUG A UAGGAGAA 1112 TTCTCCTA GGCTAGCTACAACGA CAGTTGTT 2698 1296 UAGGAGAA A CAAUAAAC 1113 GTTTATTG GGCTAGCTACAACGA TTCTCCTA 2699 1299 GAGAAACA A UAAACUCA 1114 TGAGTTTA GGCTAGCTACAACGA TGTTTCTC 2700 1303 AACAAUAA A CUCAUUUU 1115 AAAATGAG GGCTAGCTACAACGA TTATTGTT 2701 1307 AUAAACUC A UUUUCAAA 1116 TTTGAAAA GGCTAGCTACAACGA GAGTTTAT 2702 1320 CAAAGUGA A UUUGUUAG 1117 CTAACAAA GGCTAGCTACAACGA TCACTTTG 2703 1331 UGUUAGAA A UGGAUGAU 1118 ATCATCCA GGCTAGCTACAACGA TTCTAACA 2704 1335 AGAAAUGG A UGAUAAAA 1119 TTTTATCA GGCTAGCTACAACGA CCATTTCT 2705 1338 AAUGGAUG A UAAAAUAU 1120 ATATTTTA GGCTAGCTACAACGA CATCCATT 2706 1343 AUGAUAAA A UAUUGGUU 1121 AACCAATA GGCTAGCTACAACGA TTTATCAT 2707 1345 GAUAAAAU A UUGGUUGA 1122 TCAACCAA GGCTAGCTACAACGA ATTTTATC 2708 1353 AUUGGUUG A CUUCCGGC 1123 GCCGGAAG GGCTAGCTACAACGA CAACCAAT 2709 1374 UAAGGGUG A UGGAUUGG 1124 CCAATCCA GGCTAGCTACAACGA CACCCTTA 2710 1378 GGUGAUGG A UUGGAGUU 1125 AACTCCAA GGCTAGCTACAACGA CCATCACC 2711 1393 UUCAAGAG A CACUUCCU 1126 AGGAAGTG GGCTAGCTACAACGA CTCTTGAA 2712 1395 CAAGAGAC A CUUCCUGA 1127 TCAGGAAG GGCTAGCTACAACGA GTCTCTTG 2713 1406 UCCUGAAG A UUAAAGGG 1128 CCCTTTAA GGCTAGCTACAACGA CTTCAGGA 2714 1421 GGAAGCUG A UUGAUAUJ 1129 AATATCAA GGCTAGCTACAACGA CAGCTTCC 2715 1425 GCUGAUUG A UAUUGUGA 1130 TCACAATA GGCTAGCTACAACGA CAATCAGC 2716 WO 01/57206 PCT/USO1/03504 81 1427 UGAUUGAU A UUGUGAGC 1131 GCTCACAA GGCTAGCTACAACGA ATCAATCA 2717 1460 UUCCUGCC A CAUGAUCG 1132 CGATCATG GGCTAGCTACAACGA GGCAGGAA 2718 1462 CCUGCCAC A UGAUCGGA 1133 TCCGATCA GGCTAGCTACAACGA GTGGCAGG 2719 1465 GCCACAUG A UCGGACCA 1134 TGGTCCGA GGCTAGCTACAACGA CATGTGGC 2720 1470 AUGAUCGG A CCAUCGGC 1135 GCCGATGG GGCTAGCTACAACGA CCGATCAT 2721 1473 AUCGGACC A UCGGCUCU 1136 AGAGCCGA GGCTAGCTACAACGA GGTCCGAT 2722 1487 UCUGGGGA A UCCUGGUG 1137 CACCAGGA GGCTAGCTACAACGA TCCCCAGA 2723 1497 CCUGGUGA A UAUAGUGC 1138 GCACTATA GGCTAGCTACAACGA TCACCAGG 2724 1499 UGGUGAAU A UAGUGCUG 1139 CAGCACTA GGCTAGCTACAACGA ATTCACCA 2725 1510 GUGCUGCU A UGUUGACA 1140 TGTCAACA GGCTAGCTACAACGA AGCAGCAC 2726 1516 CUAUGUUG A CAUUAUUC 1141 GAATAATG GGCTAGCTACAACGA CAACATAG 2727 1518 AUGUUGAC A UUAUUCUU 1142 AAGAATAA GGCTAGCTACAACGA GTCAACAT 2728 1521 UUGACAUU A UUCUUCCU 1143 AGGAAGAA GGCTAGCTACAACGA AATGTCAA 2729 1537 UAGAGAAG A UUAUCCUG 1144 CAGGATAA GGCTAGCTACAACGA CTTCTCTA 2730 1540 AGAAGAUU A UCCUGUCC 1145 GGACAGGA GGCTAGCTACAACGA AATCTTCT 2731 1554 UCCUGCAA A CUGCAAAU 1146 ATTTGCAG GGCTAGCTACAACGA TTGCAGGA 2732 1561 AACUGCAA A UAGUAGUU 1147 AACTACTA GGCTAGCTACAACGA TTGCAGTT 2733 1582 AAGUGUUC A CUUCCCUG 1148 CAGGGAAG GGCTAGCTACAACGA GAACACTT 2734 1594 CCCUGUUU A UCCAAACA 1149 TGTTTGGA GGCTAGCTACAACGA AAACAGGG 2735 1600 UUAUCCAA A CAUCUUCC 1150 GGAAGATG GGCTAGCTACAACGA TTGGATAA 2736 1602 AUCCAAAC A UCUUCCAA 1151 TTGGAAGA GGCTAGCTACAACGA GTTTGGAT 2737 1610 AUCUUCCA A UUUAUUUU 1152 AAAATAAA GGCTAGCTACAACGA TGGAAGAT 2738 1614 UCCAAUUU A UUUUGUUU 1153 AAACAAAA GGCTAGCTACAACGA AAATTGGA 2739 1630 UGUUCGGC A UACAAAUA 1154 TATTTGTA GGCTAGCTACAACGA GCCGAACA 2740 1632 UUCGGCAU A CAAAUAAU 1155 ATTATTTG GGCTAGCTACAACGA ATGCCGAA 2741 1636 GCAUACAA A UAAUACCU 1156 AGGTATTA GGCTAGCTACAACGA TTGTATGC 2742 1639 UACAAAUA A UACCUAUA 1157 TATAGGTA GGCTAGCTACAACGA TATTTGTA 2743 1641 CAAAUAAU A CCUAUAUC 1158 GATATAGG GGCTAGCTACAACGA ATTATTTG 2744 1645 UAAUACCU A UAUCUUAA 1159 TTAAGATA GGCTAGCTACAACGA AGGTATTA 2745 1647 AUACCUAU A UCUUAAUU 1160 AATTAAGA GGCTAGCTACAACGA ATAGGTAT 2746 1653 AUAUCUUA A UUGUAAGC 1161 GCTTACAA GGCTAGCTACAACGA TAAGATAT 2747 1665 UAAGCAAA A CUUUGGGG 1162 CCCCAAAG GGCTAGCTACAACGA TTTGCTTA 2748 1679 GGGAAAGG A UGAAUAGA 1163 TCTATTCA GGCTAGCTACAACGA CCTTTCCC 2749 1683 AAGGAUGA A UAGAAUUC 1164 GAATTCTA GGCTAGCTACAACGA TCATCCTT 2750 1688 UGAAUAGA A UUCAUUUG 1165 CAAATGAA GGCTAGCTACAACGA TCTATTCA 2751 1692 UAGAAUUC A UUUGAUUA 1166 TAATCAAA GGCTAGCTACAACGA GAATTCTA 2752 1697 UUCAUUUG A UUAUUUCU 1167 AGAAATAA GGCTAGCTACAACGA CAAATGAA 2753 1700 AUUUGAUU A UUUCUUCA . 1168 TGAAGAAA GGCTAGCTACAACGA AATCAAAT 2754 1708 AUUUCUUC A UGUGUGUU 1169 AACACACA GGCTAGCTACAACGA GAAGAAAT 2755 1721 UGUUUAGU A UCUGAAUU 1170 AATTCAGA GGCTAGCTACAACGA ACTAAACA 2756 1727 GUAUCUGA A UUUGAAAC 1171 GTTTCAAA GGCTAGCTACAACGA TCAGATAC 2757 1734 AAUUUGAA A CUCAUCUG 1172 CAGATGAG GGCTAGCTACAACGA TTCAAATT 2758 1738 UGAAACUC A UCUGGUGG 1173 CCACCAGA GGCTAGCTACAACGA GAGTTTCA 2759 1749 UGGUGGAA A CCAAGUUU 1174 AAACTTGG GGCTAGCTACAACGA TTCCACCA 2760 1764 UUCAGGGG A CAUGAGUU 1175 AACTCATG GGCTAGCTACAACGA CCCCTGAA 2761 1766 CAGGGGAC A UGAGUUUU 1176 AAAACTCA GGCTAGCTACAACGA GTCCCCTG 2762 1784 CAGCUUUU A UACACACG 1177 CGTGTGTA GGCTAGCTACAACGA AAAAGCTG 2763 1786 GCUUUUAU A CACACGUA 1178 TACGTGTG GGCTAGCTACAACGA ATAAAAGC 2764 1788 UUUUAUAC A CACGUAUC 1179' GATACGTG GGCTAGCTACAACGA GTATAAAA 2765 WO 01/57206 PCT/USO1/03504 82 1790 UUAUACAC A CGUAUCUC 1180 GAGATACG GGCTAGCTACAACGA GTGTATAA 2766 1794 ACACACGU A UCUCAUUU 1181 AAATGAGA GGCTAGCTACAACGA ACGTGTGT 2767 1799 CGUAUCUC A UUUUUAUC 1182 GATAAAAA GGCTAGCTACAACGA GAGATACG 2768 1805 UCAUUUUU A UCAAAACA 1183 TGTTTTGA GGCTAGCTACAACGA AAAAATGA 2769 1811 UUAUCAAA A CAUUUUGU 1184 ACAAAATG GGCTAGCTACAACGA TTTGATAA 2770 1813 AUCAAAAC A UUUUGUUU 1185 AAACAAAA GGCTAGCTACAACGA GTTTTGAT 2771 Input Sequence = AF016582 Cut Site = R/Y Stem Length= 8. Core Sequence= GGCTAGCTACAACGA AF016582 (Homo sapiens checkpoint kinase Chkl (CHK1) mRNA; 1821 bp) WO 01/57206 PCT/USO1/03504 83 -cr~ oi m d Lfl fl vN CD ) 0 H CNI M lq L O W m 0 O 0 Hi Cq M1 ,: Ll w.f L- op N Nq l 04 Nq N N Nq N Nq N N N Nj Nq N N~ CN Nq Nl q N Nq N N Nq N Nl ',7U) U UC B C) u C) EUUtUUUUUUUUUUUUUUUUU OU cn 4 9U 6 , w uuuu -4 OHMUUUUUUUUCCU)U)UCUU NJUu u u u uu u uu uu u uU 0 C) U U U C) C))U C)C" )U C ) C)U U U C ) U C)U U C)U C)U N 2 ) ') Z : D t) : D t) ) ) t : D t) ) ) : 0 u u u u u u u u u u u u uu u u u u u u u u utu u 0 0 0 0 0 0 0 0 00 CD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 H H H H H H H H N N N u 0 0 u m am 0 u C, - (0 u f ~ ~ ~ ) C U U U C~fu tflOO C) u C) ~ B) u) 0 C)0 R0 )) U 0 04u 0 (N N (N H CD 00 O 0 HO (N u NO (N U NO 00~~~ ~~ Fz OH HuN m lI nI H (N (N (N mm 0 K n In N H H H H H H WO 01/57206 PCT/US01/03504 84 0 O N N w E E c ) tO o 0 0 N m En En r c Oo o o 0 H N m z En E co a, o 0 0 0000000 H H H H H H H H rH l N N N N NN N NN N m NNNNN N N N N N N N N N N N N N N N N N N N N N N N N N 000 0000m00m00mw000000om00000000mw00w0 mm mm :~0: 00 000000000 0000000000000 UD U f ussBs ssus ss s u u ss sses 0000 0000000000000000000000008 0 00000000000000000000000000000 S0u U 0000000000000000000000000000000 0000000000000000000000000000000 0000000000000000000000000000U0 u U4 0 u U u u S u Uo si gBuu 0000 4 F44 00 00 0 00 0 0 00 00 0 ut 0 0U Ho Nu No uo En En u 0o 0u H 8 0 0 0R E n 00 BB u u8 E ~s u8 8 ui s BB u uuBuuuuus go 0 0 u~ 8 QU U2 U 04 SEs 0 NE 0 N o C H N q N n 0 0 - 0 ) 0 N m En 0 0 0 0 0 m 0 0 0 H H H ND N- N M Nm N N N N Nq N N N N N'IV N ~ ~ E n E E n E n E WO 01/57206 PCT/USOI/03504 85 H c m t, in wn N- co m 0 H c m p Lo in t- co) o~ 0 H q rn ;d Ln wn N D o) oa H ~0 0u 0U00 9uU BU~ 0 00 ,:4U 0 B 0 U0D CD 54~ 000 0000 0000000 00 o oo t f c 0:D -F u~ u~0 0 0 0 00 0 0 0 ~ o u0 u u00000000u00000u0000u000000 u u u 00 U 0 0UUU00UUUUUUUUU uUU U U U U U U U U U U U U U uuuuuuuuuuuuuuuuuuuuuuuuuuuu uu 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U u u u u u~0 u U U0~ C)~ ~ u u000 uuuu u i a) in a) in a) a) in :in in a) in ) in in a nD a:) in a) in :n ) ) ) a) in a) in in i 00ED0 0 0 0 u t~ Uu~~0 u B 'D u ~~' N 0 Ca in 0 n m (I N9(IC n i n C NI N 0 C n i a i n a l in i C a H (I C in in N ND in i n i n (Iin i n N N i n in in in in ignion i n i n n i n i C n i n i n i n WO 01/57206 PCT/USO1/03504 86 c m zv L W D 'r- N o 0) 0 H c\1 ro ,v Lf, o N 0 ) o\ H N' m 4, in '0 rN co m~ 0 H c uuuu u uut u o u u u u u uu U U UUU UUU UUU UUU UUU UUU UUU UU u Ft u UUUUUUUUUU ~u uUU UU UU UU UU UU D~~~I ID DQ D u~~~~~~0 u 0uu u 0 uuu1 in in Dn in jin in in) a) in i n in i n a i n ) 0 D 0 E 0 0S 0 0 0 Co ta) B) :Z, 0) CO in CO in in in :D in t:) t:) CO in ::C:i n in ) in in in t:) in in u uuuu uuuu uuuu iu Iu !D D UDI U u~ p OF U D~ NFX OH i N Cr n ~ i . n ( N l~ n 0 u' N . C )~'H 'o~ in in un i n i n i n i 0 0 0 0 H H H H : H H H: HBN ( ( N ( N~~ ~ ~ ~ m H H- H H H H1 H H Hz HO H1 Hl Ho H H H H Hnlpm\Dr WO 01/57206 PCT/USO1/03504 87 mn Ln kl El CN 0) 0 H cq mo 1* in wo El 0 ~0 D H Nci rq ;V m n W r- m n 0 HD ci N M mn mn 0) mn mn m 0 00 0 000 00 H H H H H H H lH H N N'~ N N mn mc mn mn mn mn mn mn mn mn mn i mn mn 0) mn mn a', mn mn mn m m m m m m i m m uu iu u uu u uu uuou uu uu uu u u u u uu u u uu cu u u u u uu u u u o cuu uuuu H H H H H H H H (N uN (N (N (N (N (N (N N ( ui c ui ui i ui i c i c uu c~u cnu u u u u uu u r uoc ooonoo Uoooocc oooc DE N in Qn EI Un 0 Hr n0N Nc N Ni 0 in U in0 in H (NK4i n H c i ci ~ i n N i Lli n i n H ( (NF: (N c i c i c i D. n Il i n i n n i n I 0 i n i H4 HD H HHHHHHHHHH WO 01/57206 PCT/USO1/03504 88 ,;,L c m 0 N cn P OH wN r, co) m No -i 0 q H n ;v~ Ln .D r- co m H om o N N~ cq i N c q ( m m m f m m m m m m ;v ,J -v zi, ;v ;, ; v p 4 n n u) n In 0) m )m am m m 0 ) m m m m~ a% a) ON 0)0 c m 0) 0) m W )a N CN (N N N (N (N N N N N N N (Ni (N (N (N (N (N (N (N (N (N (N (N (N (N (N (N un~ uuuu uuuu uuu ~ ut u uu u u u u u CJUUU 0UU U U U U U U U u u tuU4 ottD D D 08 8n00000 0 0 0 0 0 0 0 0 0 0 0 00 cm~~~~~~~~~~~~~~ I ux 1j 03~c~~c~ ~ c~~H HHHH HHH HHHH HH( N( N( U ~ ~ ~ H HO H H H H H H H H H H H H H H H H D ~ ~ ~ ~ \ 0: 0: ND (N c) i) 0D HD (N) !Z 0: 0 HD cm in D ~ ~~~~~~~~~~~~ (N) (N cm cm In tIn In in Bn in in : DB ) D : D )t):)B WO 01/57206 PCT/USO1/03504 89 LO w- L- CO M 0 H1 (N M "z In ', L- 00 0) 0 H (N M ' In ND E- 00 0 H Cq M ;I L (N (N (N (N (N (N (N (N (N (N (N (N (N N N N (N (N (N (N (N (N (N (N N N N N N N u : 8D B 5 g8 28 8 8 2 a D BUBB BB 8 8 82BBB R8 R D8 88B B 68 88 8 88888888 88u88888u u88u88888u 888 :8)8t:888 8 00000000000000000000000000U0000 000 0000000000000000000000000 80 0000000000000000000000000000000 B B B D BBB BBB DBB BB D BD BB D B 0000000000000000000000000000000 000 0 0 :00 0 0 000 :00 00 0 B 00 B00 000 0 00 00 000 0 0 0 00000000000 B) B 6 84 Ro B6 UB8 88l B8 In I N n O (N ~ n I N n I n H N l N IN IN N IN n OH N N IN H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H In In H I In In m N m N -I N IN In N N 0 N IN N n 0 MN m In M I In ~ ~ ~ ~ ~ ~ ~ InH (uNm ~ I nN I nI n( nI nI nI nI 0 H H H H H (gN ( N ( N (N ( N ( D WO 01/57206 PCT/USO1/03504 90 in r- co C ) , H cq1 m zp4 Lo in - co mi 0 i IN m zv in in L- 00 M 0 H IN (n V in w 00 CO 00 O m~ oi a% o) ml 8) m i o) o) 0) o 0 0 0 0 0 0 0 0 H_ H H H H H H mi C ', m~ 0) C'l m~ m~ ml Mi m~ ON C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 IN N N N N I I I I INININININm mq mq m m m m m m m m mo m m m m co ~u u U I:D U~~~~~ UU U U UU U U UU U U UU U U U .UU UU U U U U U UU U U U U U UD U u uu u uuu u uu uuuu uu u uu uu uu uu uu uu u u uu uuuu uu uu uu u uu Uu uu u u u u uuuuuuuuuuu UUU UUUU UUUUUUUQ UUUUUUUUUUUUt U U~ ~ ~~~ U U U U U U U U U U U U U U U U Uu uUuUUuuu UuUUu uUUU ~ l~fl fl UUUU ~ Ug u uu u u uu uu u u u u Uu u uUu uU (f lDO D CD ) : :) ) : D D Z Z l : D D D D D : l D Z u U CD U CD u uuuuuuu JuC uU D u ID D RD U 0D F UCU B I C U UU w l in co 0 CO N l m m in CO- H N C OH IN -li CO C IN mn N CO H I N H in in IN) IN m ( n i N 11 Cl CO CO CO 0n 0n 0n IN I N m n in in in N w CO 10 w IN mm mmD mm mm mm mm Bi u4 iD~i~ i~i i~l~i~ ~ ii n i WO 01/57206 PCT/USO1/03504 91 N' 0 0) 0 H CV M 4 Lfl W [N Co 0 0 H ('1 M ;I in ko r, 00 0 0 Hq N~ m, ;j n 10 N_ 0 0 0 0 0D 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0) 0 0 0 0 0 0 0 0 0 0D U U oU t oU U U U U UcJu Uu U U U U 0 Du BIt ED 4D BD BD EDDII ED 0I:4IDIDIDI4DB, In I 00 NW u OH CN u u fl z.0 NW 4u OH IN m 0 in 1. NW u OH I 1.0 10 . 0 00 20 2 CO OC 2 0 00 0 00 01 0 00 0 IN - IN IN IN I I N CN I I N IN I I N I I I I IN (N IN IN N N N N I N HD H: HD H H D H Z HD HD HD HD HD HD HD H: HD HD HD HD H HHHHH D :) B D IDO) fl 8 0 tl 0 :: D 0 B ID0IDD :DD in i n i n i n n10 1. 1. 1. 1.0 1. 1. .0 1 0 1. 1. 1. 1.0. . .

WO 01/57206 PCT/USOI/03504 92 CO MC 0 H- cq m~ ;V in inD L, co CC) 0 - j C o v n n N CC CC 0 H iN CC tj Ul Wn LN 0 " zi u n in in in Lo in u) in in in ,o in in Co wn in i wn w r- P N - r- N , N , N N N N o 0 0 C) 0 CD 0 0 0 0 0 0 0 0 0 0 C) C) C 0 0 0 0 0 0 0 C) 0 0 0 0 MC MC MC MC MC cC MC MC CC MC MC mC mC C Cq mC mC C C C C mC mC mC C mC C C m U UU U U U O U U U U U U U U U D D CDDDIDCDCDD D D DDCD D t:) DD CD 1. CDDCDD CDCD ,n CDD CDD CD CDCD CDCDCDJC8DDBDCD tD C) :. D CDD CD DDCDD :DD CD CD) CDD CDCD DCD CD CD n CD CD :DD :DD t: D D CD B D :: D CDCD CD) B DDC CD :) u~0 0 0 0 u 00D 0 : OO O O O O OO O O O O o 000 00 u OO u OCD 0 D CD 0C CDCDM CDCMD9 9U 00 UO mC m 0 0 C) C) C 0 00 00 H H H 'A H- H H H H H Nl Nl Nl Nl Nl N N N N C ~DCCDDu 0D u CD BDD 00 6 UCDOCDCDOCDCDQ s~o~0C u uo 0C0 u CD BC ~ C D CD CD C CD g CD CD 4 4 F:4 4 UI CDDDCCC CDDDDDCCCCCDDDDDCCC co i n C a% in w -;v CC m CC- (1 in CC N CC 0 CC CC CC c) 0)~ N C C C O CC n I CC) H Nl Nl l -; in in in0 N, N- CC M a N iN n N CC 0 H' H H ;I v in in in N C C CC C C CC CC CC CC CC CC CC m CC CC CC CC CC CC) CC CC 0 0 a 0 0 0 C) 0 WO 01/57206 PCT/USO1/03504 93 0 H (N l ro i -- , n ,o r, OH o(o N ml v Lo ,o r, co o o H j m di En En co ) UUUU UUU UUU UUU uUU UO U U U U:j u R ON U . UU UU uU O U U U U U U UC U uU U BD UUU UU UR4UU UBUUBDUUU U B D g::U 6UD:l U fl 4tD E tD fl u u u U u u En En En u En En Cl En ClH Eu n N C lN E n E n E n E n 0 H C En E H ( N l~ n En E N E n n H N N Cl C ~ n EnEFn n E 00 Hr Hgo ( N ( N ( N ( N N ( N ( N ( N ( H ~ ~ C H H H H H H H H H H H H WO 01/57206 PCT/US01/03504 94 0 H CN M '4 Ln W rN 02 0) 0 H C\1 M 'I un o N" OD ON 0) H Cl M2 IV U ', N' OD M CD H H H H H H H H H HI C) C") c') N' c') C C') C) C') c') M2 02 m2 02 02 02 02 02 2 02 H H H H H H H H H H H H H H H H H H H H H H H H H HH H H H H 8 u U82D 86e5DDU 088O8" 02 < 020 20 20 20 20 20 20 20 20 20 20 0 28 U2260B8 202 02 02 00 O UUUUUUU U U U UD U U UUU 8880000888888888808880000BBBBBBBB 11111111111111111111||111111111 68 8u U20 a3 8 o s 1 0OO<OO O OO OOOOO OOO OU o 0000 0 0oi O OO O O 0 00 00 00 0 0 0 000000000000000002000uu uu uu uu uu 00000000000000000000000000 u u u u u0000 00 00 00 000R00B00B0000a00B008B B 8B BB B8 000B u0000000u 000000000000000000000000 u u u u 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0~~ ~~~~~~ 9 0 0 0 ~ 0 0 0 0 0 0 0 0 0 0000 000 0000 000 0000 000 000 0000 000 0000 000 0000 000 004 0000000000000000000000000000000 000 000000000000000000000000000 D D D D D D : :D0000) 00000000 0 00t 00000000000:0 Z) 000 l : r 0 SCD o 0o oo 0 0 0 0 0 0 Z) U000~ 0Du 0000 U 02 02 02 0 2 0 0 2 0 2 2 0 0 0 0 2 0 U 02 2 0 2 0 2 0 2 0 02 0 0 H H- H H H H Hi H H- H H H H H- H Hi H- H H H H H H H HHHHHH u~ 00g 02 0 2 N 0 2 2D0 ' C)C) I " ~ 0 C" H 0 0 ' 02 2 C")~~~~~~~~~ ~ ~ ~~~ 02 L2 02u1 n1 20 20 0 0 H H H C)C)0 '1 0 02U 02 02 0 2 0 2 0 2 0 2 0 2 0 2 0 2 H ': H H H H H H H H H H H H H WO 01/57206 PCT/USO1/03504 95 H N M '; in W r- CO 0) C) H rCV M In WO N 00~ C 0 C> 4CV m -4 tO to , N co o o 0 H '4' inz ' 1 n Lo n in t n n n L n Lo n t0 wo to wo 6o o 6oo t t H HH HH H HH HH H H Hi H H HHHHH CD u ul) UU4 00 D~ Du~ u~~~ 00 g) 000u CD CDDDDDDDDDDCCCCCCCCC CDCDCECDuCBCDC CD CDDDDDDDDDDDDCCCCCCCC CCC 6 B CDDDDDDDDDDDDDCCCCCCCCCCCCC u D 0uci 00000 0000 00000000000000000000u CDDD tC D!)Q Z : D Q CD ED 0 C) OO O O OO OoDo o o :OOOOOOOOC)D Ol 0 0 0 0 0 0 0 0 0!)0 0 0t 0 0 0 0 00D0 0-0 0 0 u 0 0 0 0 00l-I!Z l D D D Zlt u In u In u nnnn~~~~ unnnnI Innnnu~ ~ Innu uIn uuuuuuu 000 C) 00000000000000000000000000 uu uu uu uu uu CDDDCCC CDCDCDCDCDCDCDCDCDCDCDCDu u u u u uCu u uCu C uCDC!JCD D C: D C D ::) DDCCDDCCDC:DD C DCD : D D : : D DCDCDC)D ::) B CD D 0 1 D U U B H u CN m B nt OO 0 H CRm~ i t O0 '] B D U ntoN C 0 0)g 0B 0) 0)0 )0 )0 )C )0 0 0 C 0 Hg H HKr H H H H ' ' m~ ~ mm mm m m H H H) H H) H Hn H H H) H H H H H H H H H H H H H H H- H H H H H H 00 CD D CDCDCDCDCDC4D:D U D u ED CDF CD nO CDCD 44BDn 0~C to~~~~~~ ~ ~~ Q' n Ci i n H m t ' O H t o i ' n t ' N O O CO 0, 0 0 m m C] N N N N O O 0, C'] m O O O tOtO OC U M O On tO U4) i into ot ot ot otot U H H H H H H H H H H WO 01/57206 PCT/USO1/03504 96 (N H u U U U3 u PU U CD u , u U) u C CZ CD z4 0 uE(1 D~ WCO (N m S 41 LL ca <

Claims (59)

1. A nucleic acid molecule which down regulates expression of a Chk1 gene.

2. The nucleic acid of claim 1, wherein said nucleic acid molecule is used to treat cancer. 5

3. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule.

4. The nucleic acid of claim 3, wherein a binding arm of said enzymatic nucleic acid molecule comprise sequences complementary to any of sequences defined as Sequence ID Nos. 1-1422. D

5. The nucleic acid molecule of claim 3, wherein said enzymatic nucleic acid molecule comprises any of sequences defined as sequence ID Nos. 1423-3172.

6. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is an antisense nucleic acid molecule.

7. The nucleic acid molecule of claim 6, wherein said antisense nucleic acid molecule 5 comprises sequence complementary to any of sequence defined as Sequence ID Nos. 1 1422 and 3173-3180.

8. The nucleic acid molecule of claim 6, wherein said antisense nucleic acid molecule comprise any of sequences defined as sequence ID Nos. 3181-3188.

9. The nucleic acid molecule of claim 3, wherein said enzymatic nucleic acid molecule is in D a hammerhead (HH) motif.

10. The nucleic acid molecule of claim 3, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, VS nucleic acid, amberzyme, zinzyme or RNAse P nucleic acid motif.

11. The nucleic acid molecule of claim 3, wherein said enzymatic nucleic acid molecule is in 5 a NCH motif.

12. The nucleic acid molecule of claim 3, wherein said enzymatic nucleic acid molecule is in a G-cleaver motif. WO 01/57206 PCT/USO1/03504 98

13. The nucleic acid molecule of claim 3, wherein said enzymatic nucleic acid molecule is a DNAzyme.

14. The nucleic acid molecule of claim 3, wherein said enzymatic nucleic acid molecule comprises between 12 and 100 bases complementary to the RNA of Chkl gene. 5

15. The nucleic acid of claim 3, wherein said enzymatic nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA of Chk1 gene.

16. The nucleic acid molecule of claim 1, wherein said nucleic acid is chemically synthesized.

17. The nucleic acid molecule of claim 1, wherein said nucleic acid comprises at least one 2' 10 sugar modification.

18. The nucleic acid molecule of claim 1, wherein said nucleic acid comprises at least one nucleic acid base modification.

19. The nucleic acid molecule of claim 1, wherein said nucleic acid comprises at least one phosphate backbone modification. 15

20. A mammalian cell including the nucleic acid molecule of claim 1.

21. The mammalian cell of claim 20, wherein said mammalian cell is a human cell.

22. A method of reducing Chkl activity in a cell, comprising the step of contacting said cell with the nucleic acid molecule of claim 1, under conditions suitable for said reduction of Chkl activity. 20

23. A method of treatment of a patient having a condition associated with the level of Chkl, comprising contacting cells of said patient with the nucleic acid molecule of claim 1, under conditions suitable for said treatment.

24. The method of claim 23 further comprising the use of one or more therapies under conditions suitable for said treatment.

25 25. A method of cleaving RNA of Chk1 gene, comprising, contacting the nucleic acid molecule of claim 1, with said RNA under conditions suitable for the cleavage of said RNA. WO 01/57206 PCT/USO1/03504 99

26. The method of claim 25, wherein said cleavage is carried out in the presence of a divalent cation.

27. The method of claim 26, wherein said divalent cation is Mg 2 +.

28. The nucleic acid molecule of claim 1, wherein said nucleic acid comprises a cap 5 structure, wherein the cap structure is at the 5'-end or 3'-end or both the 5'-end and the 3'-end.

29. The enzymatic nucleic acid molecule of claim 9, wherein said hammerhead motif comprises sequences complementary to any of sequences shown as Seq ID Nos 1-358.

30. The enzymatic nucleic acid molecule of claim 11, wherein said NCH motif comprises 10 sequences complementary to any of sequences shown as Seq ID Nos 359-680.

31. The enzymatic nucleic acid molecule of claim 12, wherein said G-cleaver motif comprises sequences complementary to any of sequences shown as Seq ID Nos 681-790.

32. The enzymatic nucleic acid molecule of claim 13, wherein said DNAzyme comprises sequences complementary to any of substrate sequences shown as Seq. ID Nos 791-1185. 15

33. The enzymatic nucleic acid molecule of claim 10, wherein said zinzyme comprises sequences complementary to any of substrate sequences shown as Seq. ID Nos 791-954.

34. The enzymatic nucleic acid molecule of claim 10, wherein said amberzyme comprises sequences complementary to any of substrate sequences shown as Seq. ID Nos 791-1422.

35. An expression vector comprising nucleic acid sequence encoding at least one nucleic acid 20 molecule of claim 1, in a manner which allows expression of that nucleic acid molecule.

36. A mammalian cell including an expression vector of claim 35.

37. The mammalian cell of claim 36, wherein said mannalian cell is a human cell.

38. The expression vector of claim 35, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule. 25

39. The expression vector of claim 35, wherein said expression vector further comprises a sequence for an antisense nucleic acid molecule complementary to the RNA of Chk1 gene. WO 01/57206 PCT/USO1/03504 100

40. The expression vector of claim 35, wherein said expression vector comprises sequence encoding at least two said nucleic acid molecules, which may be same or different.

41. The expression vector of claim 40, wherein one said expression vector further comprises sequence encoding antisense nucleic acid molecule complementary to the RNA of Chkl 5 gene.

42. The expression vector of claim 40, wherein one said expression vector further comprises sequence encoding enzymatic nucleic acid molecule complementary to the RNA of Chkl gene.

43. A method for treatment of cancer comprising the step of administering to a patient the 10 nucleic acid molecule of claim 1 under conditions suitable for said treatment.

44. The method of claim 43, wherein said cancer is colorectal cancer.

45. The method of claim 43, wherein said cancer is lung cancer.

46. The method of claim 43, wherein said cancer is breast cancer.

47. The method of claim 43, wherein said cancer is prostate cancer. 15

48. A method for treatment of cancer comprising the step of administering to a patient the antisense nucleic acid molecule of claim 7 under conditions suitable for said treatment.

49. The method of claim 45, wherein said method further comprises administering to said patient the nucleic acid molecule of claim 1 in conjunction with one or more of other therapies. 20

50. The method of claim 49, wherein said "other therapies" are therapies selected from the group consisting of radiation and chemotherapy treatment.

51. The nucleic acid molecule of claim 7, wherein said nucleic acid molecule comprises at least five ribose residues; at least ten 2'-O-methyl modifications, and a 3'- end modification. 25

52. The nucleic acid molecule of claim 51, wherein said nucleic acid molecule further comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides.

53. The nucleic acid molecule of claim 51, wherein said 3'- end modification is 3'-3' inverted abasic moiety. WO 01/57206 PCT/USO1/03504 101

54. The nucleic acid molecule of claim 3, wherein said nucleic acid molecule comprises at least five ribose residues; at least ten 2'-O-methyl modifications, and a 3'- end modification.

55. The nucleic acid molecule of claim 54, wherein said nucleic acid molecule further 5 comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides.

56. The nucleic acid molecule of claim 54, wherein said 3'- end modification is 3'-3' inverted abasic moiety.

57. The enzymatic nucleic acid molecule of claim 13, wherein said DNAzyme comprises at least ten 2'-O-methyl modifications and a 3'-end modification. 10

58. The enzymatic nucleic acid molecule of claim 57, wherein said DNAzyme further comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides.

59. The enzymatic nucleic acid molecule of claim 57, wherein said 3'- end modification is 3'-3' inverted abasic moiety.